

The Role of Discoidin Domain Receptor 2 in Bone Regeneration

by

Abdulaziz Binrayes

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
(Oral Health Sciences)
in the University of Michigan
2019

Doctoral Committee:

Professor Renny T. Franceschi, Chair
Associate Professor Kenneth Kozloff
Associate Professor Fei Liu
Professor Yuji Mishina

Abdulaziz Binrayes

binrayes@umich.edu

ORCID ID: 0000-0003-1601-4901

© Abdulaziz Binrayes 2019

DEDICATION

To my father and mother, brothers and sisters, my wife and my daughter who have shown their support, love, and encouragement throughout my life and education. Without your inspiration, support and motivation this dream would not have been possible to achieve.

{ هذا من فضل رَبِّي }

الحمد لله الذي بنعمته تتم الصالحات والصلاة والسلام على نبينا محمدٍ سيد المكرمات وبعد:
فيشرفني أن اهدي هذا العملَ لوالديّ العزيزين ولأسرتي الكريمة أخوة وأخوات ولزوجتي الحبيبة ولكل
غالي افتقدنا طيلة أيام هذه الغربة وافتقدناه وأسأل الله تعالى أن يوفقنا لما يحبه ويرضاه وأن يجعلَ هذا
العمل خالصاً لوجهه الكريم.

{ وَقَلِ رَبِّ زِدْنِي عِلْمًا }

ACKNOWLEDGEMENTS

Over the course of my doctoral training journey, I have met several wonderful individuals who supported me and made a positive impact on my life. For that I must thank them.

I would like to start by thanking Dr. Fei Liu for allowing me to volunteer in his lab and opening my eyes to the molecular biology research world during my prosthodontics residency program.

I extend tremendous gratitude to my mentor and dissertation advisor Dr. Renny Franceschi. He was my precandidate advisor which allowed me to meet and interact with him. From that, I knew how great person and scientist you are. I was having difficulty in transition from clinic to research, and you were there whenever I need an advice. I knew that I was in a special place at the University of Michigan and that was where I needed to be. Your gentle pushes, support, advice, and direction over the years has been crucial to my growth and success as a scientist. I will always heed your advice to “work smart.” Whatever I said it wouldn’t express my gratitude to you.

I must also thank the members of my dissertation committee: Dr. Yuji Mishina, Dr. Kenneth Kozloff and Dr. Fei Liu. The insightful discussions and advice at our meetings helped to direct my dissertation research. I always left our meetings excited to try out the new suggestions, which often came from each individual’s unique perspective of the research problem.

In my training, I had the pleasure of working with many influential members of the Franceschi lab. I would like to extend special thanks to Dr. Chunxi Ge for his help, guidance, and sharing some of his work to support my dissertation. I would like to thank Dr Fatma Mohamed for

her continued help in my research experiments and being as a sister for me. Also, I want to thank Dr Yan Li for his help. Lastly, I want to thank Dr Hanshi Sun for teaching me how to take care of my animals and show me how to genotype them. Thank you all Franceschi lab members for contributing your time and insights on the work in this dissertation.

I must thank Dr. Kenneth Kozloff, Chris Stephan, and Bonnie Nolan for providing all support I needed and help in the fracture surgery and guided me in the fracture analysis.

I would also like to thank Michelle Lynch, Andrea Clark, Rob Goulet, Carol Whiting and Christophe Merceron for their assistance with histology, micro-CT components and histology imaging of this work.

The past and present staff members OHS PhD Program have been the most kind and supportive group. I would like to thank Patricia Schultz, Manette London, Kimberly Smith, Sarah Ellerholz, Amy Watson, Tao Jin and Sarah Gawne. I would like to thank the past and present directors of the program, Dr. Jan Hu and Dr. Vesa Kaartinen for their constant support, enthusiasm and encouragement to all students in the program.

Thank you to the past and present students from the Oral Health Sciences PhD program for the much-needed laughs and support. You helped keep me sane. Thanks for the great time and the great memories.

To all at the Saudi Arabian Cultural Mission (SACM) in the USA for their continuous support and help, and to King Saud University for providing the higher education scholarship for me.

TABLE OF CONTENTS

DEDICATION	ii
ACKNOWLEDGEMENTS	iii
LIST OF FIGURES	vii
LIST OF TABLES	viii
ABSTRACT	ix
CHAPTER 1: Introduction	1
The Extracellular Matrix.....	1
Role of the Extracellular Matrix in Bone Remodeling.....	3
Role of the Extracellular Matrix in Skeletal Stem Cell Differentiation.....	5
MAPKs Mediate Bone Cell Responses to ECM.....	10
Mechanical Stimulation of SSCs.....	13
ECM Receptors.....	18
Integrins.....	19
Discoidin Domain Receptors.....	24
Bone Regeneration.....	26
Calvarial Subcritical Size Defect.....	26
Tibial Fracture Model.....	28
Role of ECM in Bone Regeneration.....	29

Summary and Statement of Experimental Goals.....	31
References	33
CHAPTER 2: The Role of Discoidin Domain Receptor 2 in Calvarial Bone Regeneration	57
Abstract	57
Introduction.....	58
Material and Methods.....	60
Results.....	62
Discussion.....	66
References.....	74
CHAPTER 3: Role of Discoidin Domain Receptor 2 in Tibial Fracture Healing	80
Abstract	80
Introduction.....	81
Material and Methods.....	83
Results.....	87
Discussion.....	90
References.....	98
CHAPTER 4: Summary and Conclusion	105
Summary.....	105
Conclusion.....	109
References.....	112

LIST OF FIGURES

Figure 2.1 <i>Ddr2</i> ^{slie/slie} mice fail to heal a calvarial SSD.....	69
Figure 2.2 Localization and expression of DDR2 during calvarial bone regeneration.....	70
Figure 2.3 <i>Ddr2</i> positive cells migrate to the calvarial defect.....	71
Figure 2.4 DDR2 is required for cell proliferation during SSD healing.....	72
Figure 2.5 <i>Ddr2</i> deficiency results in decrease osteogenic differentiation markers during bone regeneration.....	73
Figure 3.1 Expansion of DDR2 expression after bone fracture.....	93
Figure 3.2 <i>Ddr2</i> positive cells expanded during fracture healing.....	94
Figure 3.3 DDR2 is necessary for normal fracture healing.....	95
Figure 3.4 Loss of <i>Ddr2</i> in purified SPCs inhibits osteoblast lineage and stimulate adipogenesis.	96
Figure 3.5 DDR2 stimulates osteoblast differentiation.....	97

LIST OF TABLES

Table 1.1 Characteristics of collagen-related genes and proteins found in bone matrix	3
Table 1.2 Integrin deficiency in mouse and the functional consequence in development or bone formation.....	22

ABSTRACT

Bone is a dynamic tissue with self-healing capabilities that allow repair of most fractures with restoration of original architecture. However, large bone defects, such as those caused by tumor resections or severe trauma, do not regenerate spontaneously and represent a major clinical challenge for craniomaxillofacial and orthopedic surgeons. Bone grafts are usually used to manage such conditions. Bone autografts consist mainly of bone extracellular matrix (ECM) and associated cells. Recent research has unveiled many unique characteristics of ECM that play a key role in tissue regeneration. ECM enhances cell recruitment through cell surface receptors, which determine cell-ECM interactions and trigger specific cellular functions such as adhesion, proliferation, and differentiation. Discoidin domain receptor 2 (DDR2) is a collagen-activated receptor tyrosine kinase shown to be essential for skeletal development in humans and mice. *Ddr2*-deficient mice exhibit dwarfism and defective bone formation in the axial, appendicular and cranial skeletons. However, the role of DDR2 in bone regeneration has not yet been investigated. Here we evaluated the requirement for DDR2 in bone regeneration by using two well-established regeneration models; a calvarial subcritical-defect and tibial fracture.

In a calvarial subcritical defect model, we showed that DDR2 is essential for regeneration of a subcritical-size defect. Smallie mice (*Ddr2^{slie/slie}*), which contain a nonfunctional *Ddr2* allele, are unable to heal a subcritical-size (0.5 mm) calvarial defect that, in WT mice, can spontaneously heal within 4 weeks. Also, *Ddr2* expression during calvarial bone regeneration was defined using *Ddr2*-LacZ knock-in mice and β -galactosidase staining. *Ddr2* expression, which was restricted to

periosteal surfaces of uninjured calvarial bone, greatly expanded with injury. Similar results were seen when the lineage of *Ddr2*-expressing cells was examined using *Ddr2cre^{ERT}*, *Ail4 TdTomato* mice. *Ddr2*⁺ cells and their progeny expanded within the defect three days and two weeks post-surgery. Furthermore, three days post-surgery, *Ddr2^{slie/slie}* mice showed a significant decrease in cell proliferation in the calvarial defect when compared with WT littermates. Lastly, levels of the preosteoblast markers, Osterix and phosphorylated RUNX2 (S319-P) decreased in *Ddr2^{slie/slie}* mice, which suggests that osteoblast differentiation was arrested.

In the tibial fracture model, we first defined the expression pattern of DDR2 during fracture healing using *Ddr2-LacZ* knock-in mice and *Ddr2-Cre^{ERT}*; *Tdtomato* mice. LacZ expression was first detected in select regions of the fracture site 2- and 5-days post fracture and expanded throughout the fracture callus after 1.5 and 3 weeks. Similar results were observed in *Ddr2-Cre^{ERT}*; *Tdtomato* mice. *Ddr2*⁺ cells and their progeny began to expand in the developing fracture callus 1.5-weeks post-fracture and continued to expand after 3 weeks. *Ddr2^{slie/slie}* mice exhibited significantly less fracture union than WT mice, and this defect was related to a decrease in cartilage formation as measured by safranin O staining. In addition, mutant mice developed significantly less callus tissue at 6-weeks post-fracture. To examine the role of DDR2 in skeletal progenitor cells (SPCs), we purified PDGFR α ⁺ CD51⁺ SPCs from bone marrow of *Ddr2^{fl/fl}* mice using FACS followed by treatment with AdCre. *Ddr2* deletion resulted in defective osteoblast differentiation and accelerated adipogenesis. On the other hand, DDR2 overexpression in a mesenchymal cell line (ST2 cells) increased osteoblast differentiation

Together, our study demonstrates that DDR2 is necessary for normal calvarial bone regeneration as well as for optimal fracture healing. This requirement may be explained in part by effects of DDR2 on proliferation, SPC function and osteoblast differentiation.

CHAPTER 1

Introduction

The Extracellular Matrix

Tissues are typically comprised of extracellular matrix (ECM), cells, blood-filled vascular space, in addition to a collection of other proteins used for signaling between cells, but the proportions differ depending on anatomical location. The ECM is “the non-cellular component present within all tissues and organs and provides not only essential physical scaffolding for the cellular constituents but also initiates crucial biochemical and biomechanical cues that are required for tissue morphogenesis, differentiation and homeostasis”¹. Each tissue has a unique ECM structure and topography created during embryonic development via dynamic and mutual biochemical and biophysical interactions between the different cellular components. In general, ECM consists of water, proteins and polysaccharides¹.

Polysaccharides, which are usually linked to protein in the form of proteoglycans, form chains called glycosaminoglycans (GAGs). The fibrous proteins, which have both structural and adhesive functions, include collagen, elastin, fibronectin, and laminin². The proteoglycans, in which fibrous proteins are embedded, fill most of the extracellular interstitial space of the organ or tissue and have a variety of functions such as hydration, binding force resistance, and buffering³. Indeed, the ECM topological, physical, and biochemical composition is not only tissue-specific, but is also markedly heterogeneous.

Collagens are the most abundant class of proteins in the body making up to 30% of the total protein mass². Collagens provide tensile strength, regulate cell adhesion, support chemotaxis and migration, and direct tissue development². Collagens contain three polypeptide chains (α -chains) that interact to form a triple-helix structure. To date, more than 28 types of collagen have been identified in vertebrates². Some of them (types I, II, III, V, and XI) are arranged in fibrils and are found in tissues that must be able to resist tensile, shear, or compression forces, including tendon, bone, cartilage, and skin⁴. These collagen fibrils are strengthened by covalent crosslinking between lysine residues of the constituent collagen molecules mediated by lysyl oxidases (LOX)¹.

Type I collagen is by far the most abundant protein in all vertebrates². It provides the structure and mechanical matrix for skin, tendons, bone, cornea, blood vessel walls and other connective tissues⁴. Approximately 90% of the entire collagen content of bone is type I collagen (Table 1)^{5,6}. Type I collagen molecules are essential for the mechanical strength of bone, especially for bone toughness (capacity to absorb energy)⁵. Any abnormalities in the collagen structure, which can be induced by genetic mutations (osteogenesis imperfecta) or pharmacologic agents (lathyric agents), affect bone quality⁵.

TABLE 1.1 Characteristics of Collagen-Related Genes and Proteins Found in Bone Matrix
Adopted from Gehron P. et al. (2008) ⁶

Collagens	Gene	Protein	Function
Type I	COL1A1 17q21.3-22 18kb, 51 exons, 7.2 and 5.9 kb mRNA COL1A2 7q21.3-22 35kb, 52 exons, 6.5 and 5.5 kb mRNA	$[\alpha 1(I)_2\alpha 2(I)] [\alpha 1(I)_3]$	Most abundant protein in bone matrix (90% of organic matrix), serves as scaffolding, binds and orients other proteins that nucleate hydroxyapatite deposition
Type X	COL10A1	$[\alpha 1(X)_3]$	Present in hypertrophic cartilage but does not appear to regulate matrix mineralization
Others	COL3A1 2q24.3-q31	$[\alpha 1(III)_3]$	Present in bone in trace amounts, may regulate collagen fibril diameter; their paucity in bone may explain the large diameter size of bone collagen fibrils
Type III	COL5A1 9q34.2	$[\alpha 1(V)_2\alpha 2(V)]$	
Type V	COL5A2 2q14	$[\alpha 1(V)\alpha 2(V)\alpha 3(V)]$	
FACITS?	COL5A3 19p13.2		

Role of the Extracellular Matrix in Bone Remodeling

The skeleton provides structural support, a reservoir of calcium and phosphate, and a niche for the hematopoietic system. Given the importance of these functions, skeletal homeostasis is crucial to maintaining systemic homeostasis ⁷. To maintain a healthy skeleton with optimal mechanical integrity, bone is constantly remodeled throughout life through the coupled activities of bone resorbing osteoclasts and bone forming osteoblasts ^{7, 8}. Therefore, any imbalance (pathological) between these cellular process leads to disease conditions of excessive bone loss or formation⁷. Osteoclasts, the bone resorbing cells, arise from hemopoietic progenitors and function to dissolve bone mineral and enzymatically degrade ECM protein. In contrast, osteoblasts arise from mesenchymal stem cells (MSC) and deposit a collagen-rich ECM that mineralizes to become bone ⁸. A fraction of total osteoblasts become entombed in the bone matrix as osteocytes. These post-mitotic cells function as mechanosensors and endocrine cells, producing factors such as

FGF23, RANKL and Sclerostin, which modulate bone activity and mineral homeostasis ⁹. The fourth cell type is the bone lining cell, whose functions are not well-understood, although it is thought to have some role in coupling bone formation to bone resorption ¹⁰.

Bone cells aren't the main components of the bone by weight. Rather, the ECM, which is produced by osteoblasts, accounts for most of the dry weight of bone⁷. The bone ECM consists of a mineralized portion containing calcium and phosphate in the form of hydroxyapatite that provides rigidity and hardness and organic components, mainly type I collagen that imparts flexibility. Therefore, it is the bone ECM that determines the mechanical properties of the skeleton⁷.

In general, the bone remodeling process is controlled by three factors; the need to couple bone formation to bone resorption, systemic factors controlling calcium and phosphate homeostasis, and mechanical force ⁸. Coupling bone formation to bone resorption requires signaling between osteoblast and osteoclast, which occurs within a basic multicellular unit (BMU). This signaling is mediated by cell-cell contact, diffusible paracrine/endocrine factors and cell-ECM interactions ⁸. An example of regulation by cell-cell contact is the receptor tyrosine kinase, ephrin B (EphB) and its ligand, EphB ¹¹. When the EphB ligand binds the EphB receptor, it activates bidirectional signaling which induces signaling in both the ligand-expressing and the receptor-expressing cells ^{8,11}. For instance, in osteoblast, when EphB 4 receptor interacts with ligand on an adjacent cell, it produces a forward signaling that activates a RhoA-dependent pathway to promote osteoblastogenesis. At the same time, in osteoclast, EphB 2 receptor interacts with its ligand resulting in reverse signaling that downregulates c-Fos and NFATc1 to inhibit osteoclast function.

The systemic/endocrine regulation of bone remodeling is controlled by four principal hormones: PTH, vitamin D₃ (1,25-dihydroxyvitamin D₃), calcitonin and oestrogen⁸. The first three hormones are involved in the regulation of serum calcium levels with bone acting as a mineral reservoir⁸. PTH plays an important role in regulating calcium-phosphate metabolism and low serum calcium levels stimulates PTH production⁸. PTH has skeletal and non-skeletal roles in controlling serum calcium levels. In bone, PTH binds to its receptor (expressed on bone stromal cells, osteoblasts and osteocytes) and activates cAMP responsive element binding protein (CREB) signaling. This results in increased secretion of MCSF and RANKL, thereby indirectly stimulating osteoclastic bone resorption⁸. In addition, PTH enhances the number and activation of osteoblasts through different pathways¹². PTH also controls serum calcium by stimulating renal reabsorption of calcium, which, together with the increased calcium released by bone resorption, restores physiological serum calcium levels⁸.

The last factor having a substantial role in bone remodeling is mechanical stimulation. Mechanical force is a key regulator of bone remodeling and bone architecture. Numerous animal studies have established the importance of mechanical stimulation on bone metabolism and bone formation or resorption. This will be discussed in greater detail later in this chapter.

Role of the Extracellular Matrix in Skeletal Stem Cell Differentiation

Skeletal stem cells (SSC), also known as stromal stem cells or mesenchymal stem cells, reside in the postnatal bone. SSCs are multipotent and have the ability to differentiate to all the major non-hematopoietic cell types associated with bone (i.e. osteoblasts, , chondrocytes, and marrow adipocytes) as well as the ability for self-renewal¹³. The first evidence for the existence of SSCs in in bone marrow stroma was provided by Friedenstein and colleagues in the late 1960s¹⁶.

SSCs, which are fibroblast-like cells, have the ability to form colonies from single cells, referred to as colony forming units-fibroblasts (CFU-Fs) ^{15, 18}. Individual CFU-Fs had the capacity to differentiate *ex-vivo* into the principal skeletal lineages (osteogenic, adipogenic, and chondrogenic) ^{15, 17}.

In addition to the *in vitro* characterization of SSCs described above, more recent work has focused on identifying SSCs *in vivo*. A number of SSC surface markers were defined including nestin (Nes), the leptin receptor (Lepr), osterix (Osx), myxovirus resistance-1 (Mx1), platelet-derived growth factor receptor α (Pdgfra), paired-related homeobox gene-1 (Prx1) homeobox gene a11 (Hoxa11), Gremlin1 (Grem1), Gli1 and Axin2¹⁴. Nestin was identified as an SSCs marker using a Nestin-GFP mouse ^{14, 19}. Fluorescence-activated cell sorting (FACS) purification of GFP+ cells identified a relatively rare stromal cell population enriched in CFU-F activity and having the ability for multipotency and self-renewal ^{14, 19}. Lineage tracing experiments suggest that this population of Nes-GFP+ cells is derived from type II collagen-expressing chondrocytes via a RUNX2 and Indian hedgehog (Ihh)-dependent mechanism ^{14, 20}.

Another SSCs surface marker that could be used to isolate stromal cells enriched in SSCs activity is PDGFR α . It is commonly used alone or in combination with standard stem cell markers ^{14, 21}. PDGFR α + CD51+ bone marrow stromal cells were shown to recapitulate the SSCs activity of Nes-GFP+ cells ^{14, 22}. Also, the leptin receptor (LepR) was shown to be an important SSC marker specifically in adult mice ^{14, 23}. Lineage tracing of LepR+ marrow cells demonstrated that these cells mainly arise postnatally and serve as precursors for osteoblasts and adipocytes ^{14, 23}. After fracture or ablation/irradiation injury, LepR+ cells are necessary for bone marrow homeostasis and tissue repair ^{14, 23, 24}.

Cranial sutures are active growth sites for intramembranous bone formation in the cranial vault and the location of a SCC population that participates in craniofacial growth and repair^{14,25,26}. Two types of mesenchymal cells are present in the cranial suture; mesenchymal cells adjacent to the osteogenic front of the calvaria bones that differentiate into osteoblasts and become incorporated into the growing bones and mid-suture mesenchymal cells that remain undifferentiated^{14,27}. Lineage tracing studies showed that mid-suture mesenchymal cells are calvaria mesenchymal stem cells^{14,26}. These mesenchymal stem cells express Gli1+ (glioma-associated oncogene 1), an intermediate in hedgehog signaling. Fate mapping of Gli1+ cells shows that they contribute to craniofacial bones during growth and injury repair, and depletion of this cell population leads to craniofacial malformations^{14,28}. Another marker for calvaria mesenchymal stem cells is Axin2, a Wnt pathway intermediate^{14,28}. Axin2+ cells are capable of long-term self-renewal and differentiation to osteoblasts during development, remodeling and regeneration^{14,28}.

SSCs interact with components of the microenvironment. Physical factors, including cell shape, external mechanical forces, ECM, among others, have been implicated in SSC fate decisions¹⁸. Within the SSC niche, environmental signals regulate stem cell behavior. One of the most important components of the SSC niche is the ECM. Many studies reported on how SSCs sense and respond to signals from the ECM at the molecular level, and how these signals regulate SSC fate^{29,30}. SSC interactions with the niche are reciprocal, since SSCs can remodel the niche in response to the signals they receive from it^{29,31}.

Native bone ECM secreted by SSCs provides an optimal biological framework that is able to maintain SSC stemness, prevent premature cell differentiation, and preserve the ability of SSCs to differentiate into osteoblasts or adipocytes³². On the other hand, SSCs lose their unique properties when they lose their ECM and are cultured on tissue culture plastic³². For example,

mice lacking Biglycan (encoded by the gene *Bgn*), which is an ECM proteoglycan that is enriched in bone, exhibit reduced growth rate and decreased bone mass resulting in age-dependent osteopenia^{32, 33}. Furthermore, when the number of osteogenic precursors measured in the bone marrow of normal and *Bgn*^{-/0} mutant mice was compared, the number of colonies (CFU-F) gradually decreased with age in mutant mice³⁴. In addition, *Bgn*-deficient SSC showed a combination of decreased proliferation and increased apoptosis³⁴.

The chemical and physical composition and structure of the ECM, which is unique to each tissue, is important for cell-ECM interactions and cellular function. Soft matrices mimicking the matrix environment of the brain promote neurogenic differentiation. Somewhat stiffer matrices promote myogenic differentiation, while rigid matrices support osteogenic differentiation³⁵. In the case of SSCs, stiffer ECM promotes osteogenesis while softer ECM promotes adipogenesis. In the stiffer ECM, cells are exposed to cytoskeletal tension resulting from mechanical interactions between SSC and ECM. This mechanical interaction is mediated by integrins, which are a family of heterodimeric cell surface molecules that regulate intracellular and extracellular signaling pathways to affect survival, migration and differentiation. Integrins activate several downstream pathways, including focal adhesion kinase (FAK), mitogen-activated protein kinase (MAPK) and Rho/Rho-associated protein kinase (ROCK)^{14, 36}. When SSCs are in a stiff loading environment, such as when integrin receptors interact with the type I collagen-rich ECM of bone, FAK is stimulated resulting in activation of the MAPK pathway, which subsequently phosphorylates both Runt-related transcription factor 2 (RUNX2) and Peroxisome proliferator-activated receptor gamma (PPAR γ). The net effect if these phosphorylations is the activation of osteogenesis and inhibition of adipogenesis^{14, 37}. On the other hand, when there is a softer matrix or in the absence of mechanical load, RUNX2 and PPAR γ are both dephosphorylated, which results in increased

adipogenesis and inhibition of osteogenesis. At least part of this switch and reciprocal control of osteogenic and adipogenic differentiation is explained by MAPK phosphorylation of RUNX2 and PPAR γ transcription factors ³⁷.

RUNX2 belongs to the Runx family of transcription factors, which consists of RUNX1, RUNX2, and RUNX3. RUNX2, which is also known as core-binding factor α -1 (Cbf α 1), polyoma virus enhancer-binding protein 2 α -A (PEBP2 α A), and acute myeloid leukemia 3 protein (AML3), is the master gene and most important factor involved in the osteogenic differentiation, and essential for chondrocyte maturation. The chromosomal location of human *RUNX2* indicates an association of the gene to cleidocranial dysplasia (CCD), an autosomal dominant bone disease ³⁸. Heterozygous (*Runx2*^{+/-}) mice showed hypoplastic clavicles and nasal bones along with retarded ossification of parietal, interparietal, and supraoccipital bones, which resembles the phenotype of patients with CCD ^{39, 40}. Mice with a homozygous mutation in *Runx2* died just after birth due to respiratory failure, and their skeleton exhibited a complete lack of ossification and chondrocyte maturation³⁹.

Runx2 is weakly expressed in uncommitted SSCs, and its expression is upregulated in preosteoblasts, reaches maximal levels in immature osteoblasts, is then down-regulated in mature osteoblasts and is undetectable during the differentiation of osteoblast into osteocytes ^{41, 42}. RUNX2 enhances the proliferation of SSCs and promotes their commitment into osteoblast lineage cells ⁴¹. Runx2 induces the expression of major bone ECM protein genes including type I collagen (*Colla1*), Osteopontin (*Spp1*), Bone sialoprotein (*Ibsp*), Osteocalcin (*Bglap2*), and Fibronectin (*Fnl*) ^{41, 42, 43, 44}. In addition, overexpression of RUNX2 accelerates osteoblast differentiation and inhibits chondrocyte differentiation ^{41, 45}. Furthermore, RUNX2 is also involved in the regulation of cell proliferation and cell cycle progression ⁴⁶. *Runx2*^{-/-} calvarial cells

proliferated faster than WT calvarial cells in vitro^{41, 47}. Galindo et al. found RUNX2 expression increased significantly during the slow cell proliferation phase (G₀), but reduced markedly during the rapid cell proliferation (G1 phase)^{46, 48}. This suggests that RUNX2 may serve as an inhibitor of cell proliferation⁴⁶.

The nuclear receptor PPAR γ is a crucial cellular and metabolic switch that regulates many physiologic processes in the bone environment. PPAR γ regulates a diverse array of physiologic processes including SSC adipogenesis, lipid metabolism, insulin sensitivity and inflammation, and is also involved in diseases such as diabetes, obesity and atherosclerosis^{49, 50}. In addition, PPAR γ is a metabolic switch for stem cell fate in both SSCs and hematopoietic lineages⁴⁹. Studies showed that activation of PPAR γ shifts the balance of SSCs fate by favoring adipocyte differentiation and inhibiting osteoblast differentiation^{49, 51}. PPAR γ -deficient embryonic stem cells fail to differentiate into adipocytes, but spontaneously differentiate into osteoblasts; moreover, PPAR $\gamma^{+/-}$ mice display a high bone mass due to increased osteoblast number and bone formation^{49, 52}. Furthermore, PPAR γ activity and adipogenesis are inhibited by activation of RUNX2 and osteoblastogenesis⁵².

MAPKs Mediate Bone Cell Responses to ECM

MAP kinase pathways function as important regulators of cell growth, differentiation and morphogenesis in most tissues including bone. The mitogen-activated protein kinases (MAPKs) include Ras, RAF, the MAP kinase kinases, MEK1 and MEK2, and the terminal MAP kinases, ERK1 and ERK2, p38 kinases, which consist of MAP kinase kinase 3 and 6 (MKK3, MKK6) and p38 α , β , γ and δ and c-Jun N-terminal kinases (JNK), which consist of MKK 4 and 7 and JNK1 and 2⁵². MAPKs have the potential to mediate the skeletal response to a wide variety of factors including growth factors, morphogens, ECM components and biomechanical signals. In skeletal

development, transgenic overexpression of a constitutively-active form of the ERK/MAPK intermediate, Mek1, in osteoblasts accelerates formation of the both cranial and appendicular skeletons while a dominant-negative Mek1 slows development^{52,53}. In addition, the hypoplastic clavicles and hypomineralized calvaria characteristic of Runx2 haploinsufficiency in mice was partially rescued when crossing mice expressing constitutively-active MEK1 with Runx2^{+/-} mice^{52,53,54}. On the other hand, crossing dominant-negative Mek1 mice with Runx2^{+/-} animals led to exacerbated clavicular hypertrophy and calvarial hypomineralization resulting in embryonic lethality^{52,53}. Furthermore, calvarial cells isolated from dominant-negative Mek1 mice exhibited decreased osteoblast differentiation compare with wild type cells while cells from constitutively-active Mek1 mice exhibited enhanced differentiation^{52,53}.

In FGF-mediated cranial suture fusion, an important role for ERK/MAPK signaling was also identified. FGF ligands are necessary for normal growth and development of craniofacial structures^{52,55}. Premature suture fusion (craniosynostosis), as is found in Apert syndrome and Crouzon syndromes, is caused by gain of function mutations in FGFR2^{52,55}. In the Apert syndrome mouse model, harboring the Fgfr2^{S252W} mutation, inhibition of ERK phosphorylation with an shRNA specific to mutant Fgfr2, or with the specific inhibitor, U0126, can block pathological suture fusion^{52,56}. Furthermore, activated FGFRs signal through the ERK/MAPK pathway leading to elevated levels of P-ERK1/2^{52,57}.

Other members of the MAPK family are p38 kinases and JNK pathway intermediates. P38 kinases are critical for skeleton development, maintenance of bone homeostasis, and osteoblast differentiation^{52,58}. They function as down-stream signals activated by the TGF- β and BMP responsive kinase, TAK1^{58,59}. *Tak1* deletion in mouse preosteoblast results in reduced cortical and trabecular bone, clavicular hypoplasia and delayed fontanelle fusion due to reduced p38

signaling and the p38 intermediates, Mkk3, Mkk6, p38 α or p38 β ^{52,58}. Interestingly, p38 β -deficient mice show defects in long bone formation without major effects on calvarial development. Lastly, several studies suggest a role for the JNK pathway in osteoblast differentiation; however, the interpretation of these studies is complicated by the known role of JNK signaling in cell survival and apoptosis^{52,60}. One example of the involvement of JNK in osteoblast differentiation is the demonstration that overexpression of a constitutively-active JNK1 increases in vitro osteoblast differentiation^{52,61}.

When SSCs become committed to osteogenic differentiation, MAPK phosphorylates RUNX2 and PPAR γ leading to activation of RUNX2 and inactivation of PPAR γ ⁵². RUNX2 phosphorylation, catalyzed by ERK1/2, occurs on multiple serine residues including S43, S301, S319 and S510⁵². However, the most important serines for MAPK phosphorylation during osteogenic differentiation are S301, S319^{37,62}. In rescue experiments using Runx2^{-/-} mouse embryo fibroblasts, transduction with a retroviral vector expressing phosphomimetic mutant Runx2 (S301E, S319E) stimulated osteoblastogenesis while suppressing adipogenesis³⁷. In contrast, when RUNX2 phosphorylation decreased or was blocked by transducing cells with a retroviral vector expressing a phosphorylation-deficient RUNX2 mutant (S301A, S319A), osteoblastogenesis was inhibited and adipogenesis was increased³⁷.

On the other hand, MAPK inhibition of PPAR γ activity is mediated by phosphorylation at serine 112 (S112) and this leads to decreased adipocyte gene expression^{62,63}. When PPAR γ ^{-/-} mouse embryo fibroblasts, which fail to differentiate into adipocytes, but spontaneously form osteoblasts, are transduced with phosphorylation-resistant PPAR γ mutant (S112A), this results in stimulation of adipogenesis and inhibition of osteoblastogenesis³⁷. Furthermore, when ST2 mesenchymal cells are transduced with dominant-negative MEK1, PPAR γ phosphorylation

decreased resulting in increased lipid droplet accumulation and adipogenesis marker expression³⁷. These results suggest a crucial role of MAPK signaling in RUNX2/PPAR γ phosphorylation and control of osteoblast and adipocyte differentiation by SSCs³⁷.

Another role of MAPK in SSC differentiation is related to its role in mechanical stimulation.

Mechanical Stimulation of SSCs

Bone is a dynamic tissue that has the remarkable ability to alter its structure in response to changes in mechanical loading. Similar to muscles, bones add mass when we exercise and atrophy if we do not. A tennis player will develop denser bones in his or her playing arm compared to the nonplaying arm⁶⁴. In addition, weight-bearing exercise increases bone mass; however, when mechanical demands are decreased, bone is lost as seen after prolonged bed rest, exposure to microgravity during space flight or spinal cord injury^{52, 65, 66, 67, 68}. The skeleton adapts to its mechanical environment throughout life, and this adaptation decreases with age^{69, 70}.

During mechanical stimulation, the bone mineral apposition rate increases. In addition, it is thought that mechanical load promotes stem cell proliferation followed by differentiation to osteoblast⁶⁹. For example, implant osseointegration is enhanced by physical stimulation, suggesting that strain promotes osteogenic differentiation of stem cells^{69, 70}. Also, during distraction osteogenesis when a fracture is created and bone segments are gradually moved apart, the zone between these bone segments where stem cells are located is associated with new bone formation. Furthermore, bone areas calculated to experience low to moderate tension are associated with sites of bone formation^{69, 72, 73}.

Due to the complexity of the mechanical environment and related responses, it is difficult to determine the specific mechanism by which SSCs respond to physical stimulation in vivo. Therefore, in vitro studies that apply controlled physical stimuli to SSCs are useful for studying potential molecular mechanisms for sensing mechanical stimulation and possible mechanotransduction pathways⁷⁴. In vitro, there are many ways researchers have stimulated cells with mechanical forces^{75,76}. These include stretching (tensile stress)^{76,77}, hydrostatic pressure or platen abutment (compressive stress), fluid flow (shear stress)^{76,78,79}, ultrasound^{76,80,81}, high frequency, low magnitude displacement (vibration)^{76,82,83}, and direct cell membrane magnetic stimuli^{76,83}. In addition, there were some in vivo studies that have been done to evaluate the consequences of loss of mechanical loading, such as the mouse tail suspension model, which induces bone loss in skeletally mature mice⁸³.

Many different bone cells including osteoblasts, SSCs and osteocytes are capable of responding to mechanical forces. However, osteocytes, which are connected through processes extending through the lacuno-canalicular network, are thought to be the primary mechanosensing cell type in bone⁶⁹. Through this network of canalicular processes, osteocytes can communicate through paracrine signaling with osteoblasts, bone lining cells, stem cells and osteoclasts to induce bone formation or resorption⁶⁹. However, some recent in vitro studies showed that stem cells could be directly stimulated by mechanical loading to promote their osteogenic differentiation⁶⁹.

For example, exposure of SSCs to 8% cyclic stretch for 1 hour each day for 3 consecutive days resulted in increased osteoblast marker gene expression, including up-regulation of Runx2, alkaline phosphatase (ALP), collagen type 1 (Col1) and bone morphogenetic protein (BMP)2 as well as reduced proliferation^{69,84,85}. Furthermore, compression induces chondrogenic differentiation of SSCs. One study showed that when SSCs seeded in a fibrin gel are subjected to

dynamic mechanical compression, increases in chondrogenic gene expression and deposition of sulfated glycosaminoglycans are observed ^{69, 86}.

Fluid flow is another method commonly used to apply shear stress in vitro, producing a gradient of stresses along the cell body ⁶⁹. This shear stress is affected by the direction of the fluid flow, with cells exposed to unidirectional flow exhibiting different characteristics from cells experiencing oscillatory fluid flow ⁶⁹. A study showed that twenty-four hours after oscillatory fluid flow, SSCs proliferation rate was increase and gene expression of *Spp1* and *Bglap* were also increased ⁸⁷. Similarly, hydrostatic pressure, both static and dynamic, can also encourage osteogenic differentiation ⁸⁸. On the contrary, the absence of mechanical stimulation also affects SSCs differentiation. A study demonstrated that unloaded bone SSCs exhibited a decrease in their osteogenic potential, as indicated by decreased ALP activity and reduced bone nodule formation, compared with loaded bones SSCs ^{69, 89}.

SSCs may sense the mechanical stimuli through different mechanosensors. These include the cytoskeleton, focal adhesions, primary cilia, membrane channels, gap junctions and mechanosomes ^{69, 90, 91}. The first three will be described. The cytoskeleton provides a structural framework for the cell and is composed primarily of actin, intermediate filaments, and microtubules. Cytoskeletal tension is generated when myosin interacts with actin, which is involved in mechanically induced osteogenesis of SSCs ^{69, 91}. The cytoskeletal dynamic is regulated by intact cytoskeleton, RhoA, a GTPase, and its effector, ROCK and they are required for fluid flow-induced osteogenic differentiation of SSCs ^{69, 92}. Any disruption to the cytoskeleton by inhibition of nonmuscle myosin II, actin polymerization, and actin depolymerization prevents fluid flow-induced osteogenic differentiation and promotes differentiation towards the adipogenic and chondrogenic lineages ^{69, 92}. Furthermore, cytoskeletal contractility, expression of E-cadherin

and distribution of focal adhesions may together influence mechanically induced differentiation of SSCs^{89,93}.

Focal adhesions, which contain adapter proteins such as talin and vinculin, link the cytoskeleton to integrins, which attach the cell to the substrate⁶⁹. There are two main components of integrin, alpha and beta, with various isotypes of each⁶⁹. Integrins $\alpha 1 \beta 1$, $\alpha 2 \beta 1$ and $\alpha 11 \beta 1$ are the main integrins responsible for the binding of bone-forming cells to type I collagen⁵². although other integrins such as $\alpha 5 \beta 1$ may also be involved in mechanotransduction⁵². Focal adhesions associate with different signaling pathways, including those mediated by focal adhesion kinase (FAK), an important mediator of signaling at these centers^{69,94}. During mechanical stimulation, integrin activates FAK and Src kinases and stimulates RhoA and Rho-associated coiled-coil containing protein kinase (ROCK)^{52,95}. FAK also activates ERK, p38 and JNK MAPK as well as phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathways⁵⁵. Liu et al showed that upon application of fluid shear stress, an increase in ALP activity and expression of osteogenic markers were observed, along with activation of FAK and ERK1/2^{69,95}. However, FAK and ERK1/2 activation were inhibited when $\beta 1$ integrins were blocked^{69,95}. Furthermore, Ward et al demonstrated that FAK phosphorylation is important for osteogenic differentiation of human SSCs in response to tension^{69,96}.

The third mechanosensor structure is primary cilium, which is a single, immotile, antenna-like structure, generated through the process of intraflagellar transport that extends from the cell into the extracellular space^{69,97}. Primary cilia are very important signaling centers in cells and have shown to be important for mechanosensation in multiple cell types. The primary cilium acts as a microdomain that facilitates biochemical signaling as a result of localization and concentration of various proteins, including ion channels and enzymes^{69,98,99}. Primary cilia are important for

normal bone development and for sensing a variety of extracellular biochemical and biophysical signals ^{69, 97, 100}. Recently, it has been demonstrated that primary cilia are involved in mechanical stimulation-induced osteogenic differentiation of SSCs ⁶⁹. For example, SSCs exposure to oscillatory fluid flow resulted in an increase in cyclooxygenase 2 and BMP2 gene expression, indicating an early osteogenic response to mechanical stimulation ^{69, 101}. In addition, a significant increase in proliferation rate was observed. In contrast, SSCs treated with siRNA to inhibit intraflagellar transport 88, an important component of the cilium, did not respond with the flow-induced increases in gene expression ^{69, 101}. These results suggest mechanosensors are important for mechanically induced osteogenic differentiation.

Multiple pathways mediate SSCs osteogenic lineage commitment during mechanical stimuli, including the MAPK/ERK, Wnt, Hippo, calcium signaling and RhoA/ROCK pathways ⁶⁹. The MAPK/ERK pathway is activated during mechanical stimulation. When strain was applied to SSCs, phosphorylation levels of ERK1/2 were elevated and this ERK activity was required for osteogenic differentiation ^{69, 102}. Also, mechanical strain-mediated increases in mineralization required activation of ERK1/2. However, inhibition of MEK blocked these increases ^{69, 103}. Lastly, mechanical stimulation of osteoblasts by exposure to fluid flow shear stress rapidly increases P-ERK-dependent phosphorylation of Runx2 at S301 and S319 ^{52, 104}.

Wnt signaling plays an important role in bone development. β -Catenin is a pivotal component of the Wnt signaling pathway and it is tightly regulated at three hierarchical levels: protein stability, subcellular localization and transcriptional activity ¹⁰⁵. β -catenin has been shown to promote osteogenic differentiation in early osteoblast progenitors ^{69, 106}. Exposure of SSCs to oscillatory fluid flow resulted in translocation of β -catenin and upregulation of Wnt5a, which is

capable of inducing both canonical and non-canonical pathways and necessary to induce activation of RhoA and increase Runx2 gene expression¹⁰⁷.

The Hippo pathway also plays an important part in regulating osteoblast differentiation. It negatively regulates the activity of transcriptional co-activators, Yes-associated protein 1 (YAP) and Transcriptional coactivator with PDZ-binding motif (TAZ). YAP and TAZ exist in an inactive phosphorylated form in the cytoplasm. During Hippo pathway activation, YAP and TAZ are dephosphorylated leading to nuclear translocation⁵². Both YAP and TAZ are additional mediators of cellular responses to static and dynamic loads that function downstream of Rho/ROCK activation^{52, 108}. The YAP/TAZ pathway is important for sensing substrate stiffness and cell shape through Rho/ROCK-mediated cytoskeletal stiffening that prevents YAP/TAZ phosphorylation and promotes nuclear translocation^{52, 69}. When YAP/TAZ are translocated to the nucleus, they interact with several transcription factors including TEA domain (TEAD) factors, T-box 5 (TBX5) and, interestingly, RUNX2 and PPAR γ ^{52, 109}. In stiff matrix, YAP/TAZ are activated and dephosphorylated resulting in increased RUNX2 gene expression and osteogenic differentiation and suppression PPAR γ activity/adipogenesis.^{52, 69}.

ECM Receptors

Since ECM binding to the cell surface is clearly involved in the response to static and dynamic stimuli, a search for ways to block these interactions was begun in a number of laboratories. One way to interrupt this interaction is by identify blocking antibodies that would inhibit cell adhesion to specific substrates. In order to find out the appropriate antibody, ECM receptors were identified and characterized. The main and most studied ECM receptors are the

integrins, which were discovered in the mid 1980s¹¹⁰. While hunting for the integrin receptors, other ECM binding proteins were also discovered. Non-integrin transmembrane receptors include discoidin domain receptors (DDRs), leukocyte-associated immunoglobulin-like receptor-1, glycoprotein VI (GPVI), laminin receptor (LamR), the proteoglycan receptors, and syndecans I-IV. Other cell adhesion molecules such as Emmprin (CD147) were also investigated^{110,111}.

Integrins

Integrins are crucially important because they are the main receptor proteins that cells use to both bind and respond to the ECM. Integrins are composed of two noncovalently associated transmembrane glycoprotein subunits (α and β) that are both transmembrane type I proteins with large extracellular domains and mostly short cytoplasmic domains capable of interact with multiple intracellular proteins¹¹². In vertebrates, the integrin family is composed of 18 α subunits and 8 β subunits that can assemble into 24 different $\alpha\beta$ heterodimers¹¹⁰. Generally, β 1-containing integrins are broadly expressed in most cells, but their α -pairing subunits are more often restricted to specific cell types¹¹³. Integrins control focal adhesion and cell adherence to the ECM through the assembly of intracellular proteins linked to the cytoskeleton¹¹³. Upon exposure to ECM stimuli, integrins undergo conformational changes that allow ECM ligand interactions together with tight connections to the inner cytoskeletal network¹¹³.

Osteoclasts and osteoblasts use a diverse range of integrins to interact with bone ECM. The osteoclast, which is a myeloid-derived polykaryon uniquely endowed with the capacity to degrade the organic and inorganic matrices of bone, organizes its actin-containing cytoskeleton to form podosomes which serve as the point of contact with the bone surface¹¹³. These podosomes contain

a dot-like core of actin filaments surrounded by a loose network of F-actin, as well as integrin receptors and adaptor proteins ¹¹⁴. In order to form a sealing zone with the bone surface to be resorbed, individual podosomes arrange collectively into superstructures forming an actin ring ¹¹³. This actin-containing sealing zone delineates the active sites of bone resorption and forms a pocket into which protons and bone-resorbing proteases are secreted ^{113, 115}. Although osteoclast adhesion to the bone surface is essential to form the bone resorption site, the complete repertoire of integrins expressed by osteoclasts has not yet been compiled. The following integrin subunits have been associated with osteoclasts: $\alpha 5$, $\alpha 2$, $\beta 1$, and $\beta 3$ ¹¹⁶. Of these osteoclast integrins, the $\alpha 5\beta 3$ integrin is the most abundantly observed and highly studied ¹¹⁶. Also, loss of $\alpha v\beta 3$ -mediated signaling, which regulates cell polarity and cytoskeletal reorganization, results in reduced resorptive activity ¹¹⁷. Furthermore, another study showed that deletion of kindlin-3, a ubiquitous activator of integrins, leads to loss of $\alpha 5$, $\beta 1$, and $\beta 3$ subunits, leading to a severe osteopetrotic phenotype ¹¹⁸.

In osteoblast, early studies indicated that integrin interactions with the major ECM components, fibronectin and collagen type I, control osteoblast differentiation and fate in vitro ¹¹⁹. The main integrins identified in osteoblast are $\alpha 1\beta 1$, $\alpha 2\beta 1$, $\alpha 4\beta 1$, $\alpha 5\beta 1$, $\alpha 5\beta 3$, $\alpha 5\beta 5$, $\alpha 8\beta 1$ and $\alpha 11\beta 1$ ^{52, 113}. Overall, both $\beta 1$ - and $\alpha 5$ -paired integrins and $\alpha 8\beta 1$ are the main integrin receptors in osteoblasts (Table 1.2) and may have prominent roles since antibody perturbation experiments blocked osteoblast differentiation and mineralization ^{113, 119, 120}. Initial investigations showed that an interaction between $\alpha 5\beta 1$ and fibronectin is required for the ability of preosteoblasts to adhere to the ECM and differentiate into mature osteoblasts ^{119, 121}. Furthermore, $\alpha 5\beta 1$ integrin is involved in osteoblast survival ^{119, 122}. Also, $\alpha 5\beta 1$ integrin is required for the anabolic effect of increased mechanical load on bone formation as mentioned before. However, other integrins have some role on osteogenesis as well. For example, $\alpha v\beta 3$ integrin is involved in the induction of osteoblast

differentiation by dexamethasone and BMP-2 in vitro ^{119, 123, 124}. Additionally, an $\alpha 2\beta 1$ integrin that induces ROCK, FAK and ERK signaling is involved in both MSC survival and osteogenic differentiation ^{119, 125, 126, 127}.

Binding of integrins to the ECM initiates clustering, cell adhesion and intracellular signaling leading to complex conformational changes that promote high-affinity extracellular ligand binding, as well as activation of signaling proteins including FAK, Rho, Rac and integrin-linked protein kinase (ILK) ^{119, 128}. FAK activation leads to phosphorylation of a variety of molecules, including Src, PI3K, RAC α serine/threonine-protein kinase (Akt), and MAPK (ERK-2 and ERK-1, respectively), among other effectors as mentioned in the section on the mechanical stimulation of SSCs. ^{119, 128}.

Mice with targeted integrin subunit deletion in bone (i.e., $\beta 1$ and αv) have an embryonic lethal phenotype, making it difficult to analyze their function during osteogenesis ^{113, 129, 130, 131}. Because of that, integrins have also been ablated during osteoblast differentiation using the Cre/LoxP conditional deletion system. However, the affected mice do not suffer from massive developmental defects ¹¹³. That suggests that other ECM receptors may be required for bone formation. Another potential class of ECM receptor are the Discoidin domain receptors, which we will discuss next.

Table 1.2 Integrin deficiency in mouse and the functional consequence in development or bone formation.

Adopted from Brunner M et al. (2013) ¹¹³

Integrin subunit	Expression in bone cells	Phenotype		References
		General	Bone	
$\alpha 1$	Yes	L/F collagen synthesis/tumor angiogenesis/callus defect	Polymorphism in the locus linked to osteoporosis	Ekholm et al., 2002 , Gardner et al., 1996 , Lee et al., 2007b , Pozzi et al., 1998 , Zemmyo et al., 2003
$\alpha 2$	Yes	L/F platelets adhesion defect on collagen/mammary ductal branching defect/mild kidney defect	No bone defect reported	Chen et al., 2002 , Girgert et al., 2010 , Grenache et al., 2007
$\alpha 3$	Yes	Perinatal lethal, kidney and lung defects	No bone defect reported	DiPersio et al., 1997 , Kreidberg et al., 1996
$\alpha 4$	Yes	Embryonic lethal E11.5–E14.5 placenta defect, cardiac development defect/hematopoietic maintenance and homing defect	No bone defect reported	Arroyo et al., 1996 , Yang et al., 1993 , Yang et al., 1995 , Yang et al., 1996
$\alpha 5$	Yes	Embryonic lethal E9.5: neural crest cell survival, mesoderm defect	No bone defect reported	Goh et al., 1997 , Yang et al., 1993
$\alpha 6$	ND	Perinatal lethalskin blistering, brain cortex organization defect	No bone defect reported	Georges-Labouesse et al., 1996 , Georges-Labouesse et al., 1998
$\alpha 7$	Yes	Partial lethality/vascular defect/dystrophy/placental defect	No bone defect reported	Mayer et al. (1997)
$\alpha 8$	Yes	Partial perinatal lethality/kidney defect/deafness	No bone defect reported	Littlewood Evans and Muller, 2000 , Muller et al., 1997
$\alpha 9$	Yes	Perinatal lethal P6–12, lymphogenesis defect, congenital chylothorax	No bone defect reported	Huang et al. (2000b)
$\alpha 10$	Yes	L/F, dwarfism, mild chondrodysplasia	Growth plate defect	Bengtsson et al. (2005)
$\alpha 11$	Yes	L/F, dwarfism and increase mortality, defective incisor	No bone defect reported	Popova et al. (2007)
αv	Yes	L, embryonic lethal at E12 and birth; defects in placenta and in CNS and GI blood cells, cleft palate	No bone defect reported	Bader et al., 1998 , van der Flier et al., 2010
αx	Yes (MSC)	L/F, T-cell defect, increased susceptibility to bacterial infection	No bone defect reported	Ren et al., 2004 , Wu et al., 2004

Integrin subunit	Expression in bone cells	Phenotype		
		General	Bone	References
αE	ND	Reduced lymphocyte	No bone defect reported	Schon et al. (1999)
αL	ND	L/F, impaired leucocyte recruitment and tumor rejection, osteoclast development defect	Osteoclast defect	Schmits et al., 1996 , Shier et al., 1996
αD	Yes (MSC)	L/F, reduced staphylococcal enterotoxin-induced T-cell response	No bone defect reported	Wu et al. (2004)
αM	ND	L/F, impaired phagocytosis and PMN apoptosis, obesity, mast cell development	No bone defect reported	Coxon et al., 1996 , Lu et al., 1997
αIIb	No	L/F, thrombastenic	No bone defect reported	Tronik-Le Roux et al. (2000)
$\beta 1$	Yes	Embryonic lethal E5.5, inner cell mass deterioration	Reduced bone formation	Fassler and Meyer, 1995 , Phillips et al., 2008 , Stephens et al., 1995
$\beta 2$	Yes (MSC)	L/F, impaired leucocyte recruitment, skin infection, osteoporosis	Defect of osteoblast differentiation	Miura et al., 2005 , Wilson et al., 1993
$\beta 3$	Yes weak in preosteoblast	L/F, thrombastenic, osteopetrotic	Defect of osteoclast resorption	Hodivala-Dilke et al., 1999 , McHugh et al., 2000
$\beta 4$	No	Perinatal lethalskin blistering	NA	Dowling et al., 1996 , van der Neut et al., 1996
$\beta 5$	Yes	L/F, no apparent phenotype	No bone defect reported	Huang et al. (2000a)
$\beta 6$	No	L/F, TGF activation defect, juvenile baldness, asthma	NA	Huang et al., 1996 , Munger et al., 1999
$\beta 7$	No	L/F, Peyer's patches defect, reduced number of intraepithelial lymphocytes	NA	Wagner et al. (1996)
$\beta 8$	No	L, embryonic lethal at E12 and birth, defects in placenta and in CNS and GI blood cells, cleft palate	NA	Zhu et al. (2002)

Discoidin Domain Receptors

Discoidin domain receptors (DDR) were discovered during the search for tyrosine kinase proteins expressed in human malignancies¹³². Receptor tyrosine kinases (RTKs) are a large family of single-pass transmembrane receptors, characterized by structurally diverse extracellular ligand-binding regions and conserved cytosolic kinase domains¹³². The discoidin domain receptors are RTKs that contain a discoidin homology domain in their extracellular regions¹³³. Ddrs are collagen receptors that differ from collagen-binding integrins in that they have intrinsic tyrosine kinase activity and selective affinity for triple-helical, native fibrillar and non-fibrillar collagens¹³³.

There are two types of DDRs, DDR1 and DDR2. Ddr1 has broad ligand specificity, which includes all known collagens, and is selectively expressed in epithelia¹³³. It is abundant in the brain and is found in the epithelial layer of the colonic mucosa, in keratinocytes, in the thyroid follicles, and in the lung epithelium¹³². In addition, DDR1 can be used as a marker for the formation of neuroectodermal cells during mouse development¹³³. In contrast, DDR2 is expressed by mesenchymal cells and principally binds collagens I, II, III and X^{133, 134}. Activation of DDR2 by collagen is surprisingly slow, and to reach maximal tyrosine kinase activity, it requires collagen treatment for up to 18 hours¹³². This activation is sustained, and no sign of down-regulation or degradation is observed after up to 4 days¹³².

Both DDR1 and DDR2 are involved in multiple physiological processes, such as development, ECM turnover, growth regulation and cancer^{133, 134}. In bone, several lines of evidence suggest an important role for DDR2. In humans, *DDR2* mutations cause spondylo-meta-epiphyseal dysplasia (SMED), a skeletal disorder associated with dwarfism, bowing of long bones, craniofacial abnormalities, short fingers, and abnormal calcifications^{133, 135}. Also, in a Han

Chinese population, polymorphisms in *DDR2* are associated with low bone mineral density (BMD) and fracture risk ¹³⁶. Consistent with the human phenotype, mice with a spontaneous *Ddr2* mutation, called smallie mice (*Ddr2^{slie/slie}*), have a SMED-like phenotype characterized by dwarfism and reduction in total bone mineral density ^{133,137}. Furthermore, detailed analysis of the bone phenotype in *Ddr2^{slie/slie}* mice revealed a dramatic reduction in mineral density of the cranial, axial, and appendicular skeleton due to reduction in osteoblast activity and bone formation in the absence of changes in resorption ¹³³. Bone changes were accompanied by a large increase in marrow fat.

When *Ddr2* is activated, several pathways are stimulated including ERK, JNK and p38 MAPKs, the PI-3 kinase/AKT and NFK β pathways ^{52,132}. In osteogenesis, *Ddr2* stimulates MAPK-dependent Runx2 phosphorylation ¹³⁸. Specifically, overexpression of a constitutively active *DDR2* stimulated ERK/MAPK signaling and phosphorylation of RUNX2 and PPAR γ leading to increased RUNX2-dependent transcriptional activity and inhibition of PPAR γ ^{133, 138}. Consistent with these results, MSCs from *Ddr2^{slie/slie}* mice showed reduced ability to differentiate into osteoblasts and increased adipogenesis ¹³³. This defective osteoblast differentiation in *Ddr2^{slie/slie}* cells was due to reduction in ERK/MAPK signaling and RUNX2 S301 S319 phosphorylation ¹³³.

In summary, *Ddr2* is a key regulator of bone growth that controls several aspects of the process. Furthermore, *DDR2* and integrins may interact during ECM stimulation with *DDR2* stimulating integrin-mediated cell adhesion ¹³⁹. Also, *DDR2* may participate in endochondrial ossification by regulating chondrocyte maturation as well as by stimulating intramembranous ossification by controlling osteoblast differentiation via phosphorylation of RUNX2. However, it is not known if *DDR2* is required for bone regeneration.

Bone Regeneration

Bone possesses an intrinsic capacity for regeneration as part of the repair process in response to injury as well as during skeletal development and during the continuous remodeling that occurs throughout adult life ¹⁴⁰. The bone regeneration process consists of a well-orchestrated series of biological events, with a definable temporal and spatial sequence, involving a number of cell types and intracellular and extracellular molecular-signaling pathways ¹⁴⁰. In order to explore these events, two different mouse models for bone regeneration will be discussed, calvarial subcritical-size defect and tibial fracture mouse models

Calvarial Subcritical Size Defect

In order to understand how the calvarial bones regenerate, first we need to understand how they develop. Calvarial bones form the dome-like superior portion of the cranium, comprising the superior portions of the frontal, parietal, and occipital bones. Calvarial bone is formed by intramembranous ossification, where a compact and spongy bone develops directly from sheets of mesenchymal (undifferentiated) connective tissue ¹⁴¹. The process begins when a group of mesenchymal cells within a highly vascularized area of the embryonic connective tissue proliferate (mesenchymal condensations) and differentiate directly into preosteoblasts and then into osteoblasts ¹⁴². Osteoid, which is secreted by the osteoblasts, is uncalcified matrix that calcifies as mineral salts are deposited on it, thereby entrapping the osteoblasts within. Once entrapped, the

osteoblasts become osteocytes¹⁴¹. The sutures, where two opposing bone fronts oppose, are the predominant sites of bone growth.

There are two calvarial defect mouse models depending on the size of the defect, critical-size calvarial defect (CSD) and subcritical-size calvarial defect (SSD). A CSD is defined as a defect that will never heal within the lifetime of the animal, which in the case of a mouse is a defect larger than 2 mm¹⁴³. Since a CSD doesn't heal spontaneously, it allows the researcher to test different kinds of grafting material, cells, or growth factors for ability to promote bone regeneration. On the other hand, SSD is defined as a calvarial defect that will heal spontaneously without any intervention, which is a mouse calvarial defect equal or less than 2mm¹⁴⁴. The SSD is used by the researchers to investigate the self-healing ability of mice after various genetic manipulations, to trace cells involved in healing, and to further understand the biological events involved in normal bone healing.

Intramembranous bone healing is a well-organized process that includes multiple biological events. After formation of SSD, clot formation is initiated followed by an acute inflammatory response^{145,146}. This inflammatory response includes cell proliferation, angiogenesis and inflammatory cell infiltration associated with peaks of growth factor secretion (BMP-2-4-7, TGF β 1, VEGFa), cytokines and chemokines (TNF α , IL-10)^{145, 146}. Subsequently, granulation tissue is formed followed by MSCs migration to the injury site^{145, 146}. MSCs then differentiate to osteoblasts and start matrix formation followed by mineral deposition until bridging of the defect is completed¹⁴⁵. During healing, no evidence of cartilage cells or tissue were observed¹³⁴. At this stage, bone formation/maturation markers (RUNX2, ALP, DMP1, PHEX, SOST) were highly expressed¹⁴⁵. Lastly, bone remodeling takes place to reinforce and strengthen the newly formed bone.

Tibial Fracture Model

Fracture healing using the tibial model has been extensively studied and reviewed. The intense interest in understanding fracture healing is consistent with the fact that fractures are the most common large-organ, traumatic injuries in humans and approximately 10% do not heal properly¹⁴⁷. The tibia is the second largest bone in the human skeleton, and it forms by endochondral ossification¹⁴⁸. The initial stage of endochondral ossification is formation of a cartilage model through condensation of mesenchymal cells, followed by chondrogenic differentiation of mesenchymal cells¹⁴⁸. Then, this cartilage model is invaded by vasculature to form a primary ossification center at the diaphysis, and later a secondary ossification center at the epiphysis¹⁴⁸. After that, the perichondrium of the cartilage model becomes the periosteum and the cartilage in the ossification center is replaced gradually with osteoblasts, which secrete osteoid that is subsequently calcified¹⁴⁸.

Fracture healing consists of a well-orchestrated series of biological events that mirror the primary morphogenetic pathways during embryonic skeletal development¹⁴⁷. There are two types of fracture healing, direct intramembranous healing (discussed above related to SSD healing) and indirect (secondary) fracture healing, which consists of both intramembranous and endochondral bone formation¹⁴⁶. Both fracture healing and endochondral bone formation are directly regulated by different growth factors and proteins, including FGF-2, BMPs, PTH and PTH-related protein, hedgehog proteins, TGF- β and Wnts^{147, 149-159}. The indirect form of fracture healing is most commonly seen in long bone fractures¹⁴⁶. Immediately following bone trauma, a hematoma is

generated, and an acute inflammatory immune response is initiated^{146, 147}. This immune response leads to secretion of multiple cytokines and chemokines including TNF- α , IL-1, IL-6, IL-11 and IL-18, and infiltration of immune cells, including T cells. Then, a fibrin-rich granulation tissue forms, which allows endochondral bone formation to occur between the fracture ends external to periosteal sites. This results in soft callus formation that stabilizes the injury site.^{146, 147} Soft callus formation depends on the recruitment of MSCs. Current data suggest that there are two key regulators for recruiting and homing specific MSCs to the site of trauma, stromal cell-derived factor-1(SDF-1) and CXCR-4¹⁴⁶. Once MSCs are recruited, several peptide signaling cascades are initiated including TGF- β 2, - β 3 and GDF-5 pathways that participate in chondrogenesis and endochondral ossification, as well as BMP-2, -5, and-6 pathways which promote both chondrogenesis and osteogenesis^{146, 147}. This soft callus is replaced by hard callus that provides biomechanical stability and replacement of cartilage by bone. This hard callus does not fully restore the biomechanical properties of normal bone. This requires an extensive bone remodeling process. This remodeling process involves a combination of hard callus resorption by osteoclasts, and lamellar bone deposition by osteoblasts and may take years to achieve a fully regenerated bone structure^{146, 147}.

Role of ECM in Bone Regeneration

Bone extracellular matrix plays important roles not only in bone development and maintenance, but also in response to bone injury and fracture. Studies of bone healing indicate that resident stem or progenitor cells interact with the ECM to orchestrate a complex signaling cascade leading to tissue regeneration and remodeling¹⁶⁰. Dysregulation of proteins mediating ECM interactions is implicated in several deformities affecting bone structure and regeneration¹⁶¹. Type

I collagen is the core structural protein in bone where collagen-mediated signaling is critical for tissue differentiation and mineralization ^{161, 162, 163}. Diseases caused by mutations in type I collagen, such as osteogenesis imperfecta, are characterized by uncoupling between bone formation and resorption, impaired osteoblast differentiation and increased osteoclasts activity, as well as defects in fracture repair ^{160, 164, 165, 166}.

ECM enhances cell recruitment during bone regeneration through cell surface receptors. Collagen binding integrins are the main ECM receptor known to be important in the crosstalk between cells and the ECM. Integrin $\alpha1\beta1$ is a collagen receptor expressed on many mesenchymal cells, but mice deficient in $\alpha1$ integrin have no gross structural defects. However, bone fractures in $\alpha1$ -knock-out mice had significantly less callus tissue than the WT mice ¹⁶⁷. Furthermore, safranin O staining revealed a defect in cartilage formation in $\alpha1$ -knockout mice as well as reduced expression of ECM related genes (*Col2a1*, *Col9a2*, *Col10a1*, *Col10a1*, *Mmp13* and *Acan*) and reduced proliferation of MSCs ¹⁶⁷.

Targeting of ECM-cell interactions represents a potential strategy to promote bone regeneration. For example, PepGen P-15, which is a combination natural inorganic bovine-derived hydroxyapatite matrix (ABM) coupled with a synthetic cell-binding peptide (P-15) comprising 15 amino acids of a cell-binding region of collagen type I, enhanced new bone formation in a critical-size tibial cortical bone defect, whereas control defects showed very little newly formed bone ^{168, 169}. Furthermore, when P-15 was added in scaffold material, it stimulated expression of ALP, BMP-2 and BMP-7 ^{169, 170}. This suggest that P-15 promotes osteogenic differentiation. Moreover, treating non-union fracture patients with a P-15 containing bone graft substitute result in a 90 % success rate ^{169, 171}.

In addition to P-15, GFOGER (glycine-phenylalanine-hydroxyproline-glycine-glutamate-arginine) is another collagen-mimetic peptide that selectively promotes $\alpha 2\beta 1$ integrin binding, which is a critical event for osteoblastic differentiation^{169,172}. Scaffolds coated with GFOGER showed significantly accelerated and increased bone formation in non-healing femoral defects compared to uncoated scaffolds and empty defects^{169,173}. Furthermore, implants coated with GFOGER were found to improve peri-implant bone regeneration and osseointegration^{169,174,175}.

Indeed, peptides containing integrin binding domains of type I collagen coupled to tissue engineered scaffolds have been successfully used to stimulate bone regeneration^{173,174,175,176}. However, the integrin-activating tissue engineered scaffolds examined to date do not approach the activity of bone autografts, the "gold standard" for bone regeneration¹⁷⁷. Also, bone-specific knockout of individual integrins in vivo only leads to modest phenotypes^{178,179,180,181}. These studies suggest that additional ECM factors/signals critical for bone regeneration remain to be discovered. As discussed in this chapter, the non-integrin collagen receptor, Ddr2, is critical for skeletal development^{133,137}. However, its role in bone regeneration has not yet been investigated.

Summary and Statement of Experimental Goals

The ECM plays a fundamental role in bone development, remodeling, regeneration and response to mechanical loading by binding to cells using specific ECM receptors. The most studied ECM receptors are the integrins, which play a crucial role in cell-matrix and intercellular interactions mediated by ECM adhesion molecules including collagen. DDR2 is a second class of

collagen receptor that differs from integrins in having a selective affinity for triple helical, fibrillar collagen and intrinsic tyrosine kinase activity. Interestingly, DDR2 and integrins may interact during ECM stimulation, and possibly DDR2 positively modulates integrin-mediated cell adhesion. Recently, our lab showed that *Ddr2* has a major role in bone development and deficiency of *Ddr2* causes craniofacial and long bone defects. In addition, *Ddr2* is important for maintenance of osteoblast activity.

Based on the known role of DDR2 in bone development and its possible interaction with integrins, which are known to be required for bone regeneration, we asked the question-Is *Ddr2* required for bone regeneration? This thesis will evaluate this requirement using 2 well-established regeneration models; a calvarial subcritical defect and tibial fracture. Studies will first determine the temporospatial expression of DDR2 during bone regeneration, examine the participation of *Ddr2*-expressing cells and their progeny in the regeneration process and use a gene knockout approach to determine the requirement for DDR2 in regeneration.

References

1. Frantz, C., Stewart, K. M., & Weaver, V. M. (2010). The extracellular matrix at a glance. *Journal of Cell Science*, 123(Pt 24), 4195-4200. doi:10.1242/jcs.023820 [doi]
2. Alberts B, Johnson A, Lewis J, et al. *Molecular Biology of the Cell*. 4th edition. New York: Garland Science; 2002. The Extracellular Matrix of Animals. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK26810/>
3. Jarvelainen, H., Sainio, A., Koulu, M., Wight, T. N., & Penttinen, R. (2009). Extracellular matrix molecules: Potential targets in pharmacotherapy. *Pharmacological Reviews*, 61(2), 198-223. doi:10.1124/pr.109.001289 [doi]
4. Kular, J. K., Basu, S., & Sharma, R. I. (2014). The extracellular matrix: Structure, composition, age-related differences, tools for analysis and applications for tissue engineering. *Journal of Tissue Engineering*. <https://doi.org/10.1177/2041731414557112>
5. Viguet-Carrin, S., Garnero, P. & Delmas, P.D. *Osteoporos Int* (2006). The role of collagen in bone strength. March, Volume 17, Issue 3, pp 319–336. <https://doi.org/10.1007/s00198-005-2035-9>
6. Gehron Robey, Pamela. 2008. *Chapter 17 - noncollagenous bone matrix proteins*. *Principles of bone biology* (third edition), eds. John P. Bilezikian, Lawrence G. Raisz and T. John Martin. San Diego: Academic Press.
7. Alford AI, Kozloff KM, Hankenson KD. (2015) Extracellular matrix networks in bone remodeling. *The International Journal of Biochemistry & Cell Biology* 65:20-31.

8. Crockett JC, Rogers MJ, Coxon FP, Hocking LJ, Helfrich MH. 2011. Bone remodeling at a glance. *J Cell Sci.* 124(7):991. doi:10.1242/jcs.063032.
9. Bonewald, L. F. and Johnson, M. L. (2008). Osteocytes, mechanosensing and Wnt signaling. *Bone* 42, 606-615.
10. Everts, V., Delaisse, J. M., Korper, W., Jansen, D. C., Tigchelaar-Gutter, W., Saftig, P. and Beertsen, W. (2002). The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. *J. Bone Miner. Res.* 17, 77-90.
11. Matsuo, K. (2010). Eph and ephrin interactions in bone. *Adv. Exp. Med. Biol.* 658, 95-103
12. Lombardi G, Di Somma C, Rubino M, Faggiano A, Vuolo L, Guerra E, Contaldi P, Savastano S, Colao A. (2011). The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. *J Endocrinol Invest.* Jul;34(7 Suppl) 18-22. PMID: 21985975.
13. Bianco P, Robey PG, Simmons PJ (2008) . Mesenchymal stem cells: revisiting history, concepts, and assays. *Cell Stem Cell.*; 2(4):313–9.
14. Mohamed, F. F., & Franceschi, R. T. (2017). Skeletal Stem Cells: Origins, Functions and Uncertainties. *Current molecular biology reports*, 3(4), 236–246. doi:10.1007/s40610 017-0075-5
15. Till JE, Mc CE (1961). A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat Res.*;14:213–22
16. Friedenstein AJ, Piatetzky S, II, Petrakova KV (1966). Osteogenesis in transplants of bone marrow cells. *J Embryol Exp Morphol.*;16(3):381–90

17. Robey PG, Kuznetsov SA, Riminucci M, Bianco P. Bone marrow stromal cell assays: in vitro and in vivo. *Methods Mol Biol.* 2014;1130:279–93. Description of methods for clonal analysis of marrow SSCs ex vivo.
18. Friedenstein AJ, Chailakhjan RK, Lalykina KS (1970). The development of fibroblast colonies in monolayer cultures of guinea-pig bone marrow and spleen cells. *Cell Tissue Kinet.* ;3(4):393–403
19. Méndez-Ferrer, S., Michurina, T. V., Ferraro, F., Mazloom, A. R., Macarthur, B. D., Lira, S. A., ... Frenette, P. S. (2010). Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature*, 466(7308), 829–834. doi:10.1038/nature09262.
20. Ono, N., Ono, W., Mizoguchi, T., Nagasawa, T., Frenette, P. S., & Kronenberg, H. M. (2014). Vasculature-associated cells expressing nestin in developing bones encompass early cells in the osteoblast and endothelial lineage. *Developmental cell*, 29(3), 330–339. doi:10.1016/j.devcel.2014.03.014.
21. Takakura, N., Yoshida, H., Ogura, Y., Kataoka, H., Nishikawa, S., & Nishikawa, S.-I. (1997). PDGFR α Expression During Mouse Embryogenesis: Immunolocalization Analyzed by Whole-mount Immunohistostaining Using the Monoclonal Anti-mouse PDGFR α Antibody APA5. *Journal of Histochemistry & Cytochemistry*, 45(6), 883–893. <https://doi.org/10.1177/002215549704500613>
22. Pinho, S., Lacombe, J., Hanoun, M., Mizoguchi, T., Bruns, I., Kunisaki, Y., & Frenette, P. S. (2013). PDGFR α and CD51 mark human nestin⁺ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. *The Journal of experimental medicine*, 210(7), 1351–1367. doi:10.1084/jem.20122252.

23. Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G., & Morrison, S. J. (2014). Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. *Cell stem cell*, 15(2), 154–168. doi:10.1016/j.stem.2014.06.008.
24. Mizoguchi, T., Pinho, S., Ahmed, J., Kunisaki, Y., Hanoun, M., Mendelson, A., ... Frenette, P. S. (2014). Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. *Developmental cell*, 29(3), 340–349. doi:10.1016/j.devcel.2014.03.013.
25. Opperman, L. A. (2000), Cranial sutures as intramembranous bone growth sites. *Dev. Dyn.*, 219: 472-485. doi:10.1002/1097-0177(2000)9999:9999<::AID-DVDY1073>3.0.CO;2-F.
26. Zhao, H., Feng, J., Ho, T. V., Grimes, W., Urata, M., & Chai, Y. (2015). The suture provides a niche for mesenchymal stem cells of craniofacial bones. *Nature cell biology*, 17(4), 386–396. doi:10.1038/ncb3139.
27. Lana-Elola E, Rice R, Grigoriadis AE, Rice DPC. (2007) Cell fate specification during calvarial bone and suture development. *Developmental Biology* 311:335-346.
28. Maruyama, T., Jeong, J., Sheu, T. J., & Hsu, W. (2016). Stem cells of the suture mesenchyme in craniofacial bone development, repair and regeneration. *Nature communications*, 7, 10526. doi:10.1038/ncomms10526
29. Assis-Ribas T, Forni MF, Winnischofer SMB, Sogayar MC, Trombetta-Lima M. (2018) Extracellular matrix dynamics during mesenchymal stem cells differentiation. *Developmental Biology* 437:63-74.
30. Jhala D, Vasita R. (2015) A Review on Extracellular Matrix Mimicking Strategies for an Artificial Stem Cell Niche. *Polymer Reviews* 55:561-595.

31. F.M. Watt, W.T. Huck (2013). Role of the extracellular matrix in regulating stem cell fate
Nat. Rev. Mol. Cell Biol., 14 (8) (2013), pp. 467-473
32. Chen, X. , Dusevich, V. , Feng, J. Q., Manolagas, S. C. and Jilka, R. L. (2007), Extracellular Matrix Made by Bone Marrow Cells Facilitates Expansion of Marrow-Derived Mesenchymal Progenitor Cells and Prevents Their Differentiation Into Osteoblasts. J Bone Miner Res, 22: 1943-1956. doi:10.1359/jbmr.070725
33. Xu T, Bianco P, Fisher LW, Longenecker G, Smith E, Goldstein S, Bonadio J, Boskey A, Heegaard AM, Sommer B, Satomura K, Dominguez P, Zhao C, Kulkarni AB, Robey PG, Young MF 1998 Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat Genet 20: 78–82
34. Chen XD, Shi S, Xu T, Robey PG, Young MF 2002 Age-related osteoporosis in biglycan-deficient mice is related to defects in bone marrow stromal cells. J Bone Miner Res 17: 331–340.
35. Q. Chen, P. Shou, C. Zheng, M. Jiang, G. Cao, Q. Yang, et al (2016). Fate decision of mesenchymal stem cells: adipocytes or osteoblasts? Cell Death Differ., 23 (7), pp. 1128-1139
36. Sun M, Chi G, Xu J, Tan Y, Xu J, Lv S, et al. (2018) Extracellular matrix stiffness controls osteogenic differentiation of mesenchymal stem cells mediated by integrin alpha5. Stem Cell Res Ther 9:52-018-0798-0.
37. Ge C, Cawthorn WP, Li Y, Zhao G, Macdougald OA, Franceschi RT (2016). Reciprocal Control of Osteogenic and Adipogenic Differentiation by ERK/MAP Kinase Phosphorylation of Runx2 and PPARgamma Transcription Factors. J Cell Physiol; 231(3):587–96.

38. Mundlos S, Mulliken JB, Abramsom DL, Warman ML, Knoll JHM, Olsen BR. (1995) Genetic mapping of cleidocranial dysplasia and evidence of a microdeletion in one family. *hmg* 4:71-75.
39. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, et al. (1997) Targeted Disruption of *Cbfa1* Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts. *Cell* 89:755-764.
40. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, et al. (1997) *Cbfa1*, a Candidate Gene for Cleidocranial Dysplasia Syndrome, Is Essential for Osteoblast Differentiation and Bone Development. *Cell* 89:765-771.
41. Komori T. (2019). Regulation of Proliferation, Differentiation and Functions of Osteoblasts by *Runx2*. *International journal of molecular sciences*, 20(7), 1694. doi:10.3390/ijms20071694.
42. Maruyama, Z. , Yoshida, C. A., Furuichi, T. , Amizuka, N. , Ito, M. , Fukuyama, R. , Miyazaki, T. , Kitaura, H. , Nakamura, K. , Fujita, T. , Kanatani, N. , Moriishi, T. , Yamana, K. , Liu, W. , Kawaguchi, H. , Nakamura, K. and Komori, T. (2007), *Runx2* determines bone maturity and turnover rate in postnatal bone development and is involved in bone loss in estrogen deficiency. *Dev. Dyn.*, 236: 1876-1890. doi:10.1002/dvdy.21187.
43. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G. (1997) *Osf2/Cbfa1*: A Transcriptional Activator of Osteoblast Differentiation. *Cell* 89:747-754. Sato M, Morii E, Komori T, Kawahata H, Sugimoto M, Terai K, et al. (1998) Transcriptional regulation of osteopontin gene in vivo by PEBP2alphaA/CBFA1 and ETS1 in the skeletal tissues. *Oncogene* 17:1517-1525.

44. Harada H, Tagashira S, Fujiwara M, Ogawa S, Katsumata T, Yamaguchi A, et al. (1999) Cbfa1 isoforms exert functional differences in osteoblast differentiation. *J Biol Chem* 274:6972-6978.
45. Maeno T, Moriishi T, Yoshida CA, Komori H, Kanatani N, Izumi S, et al. (2011) Early onset of Runx2 expression caused craniosynostosis, ectopic bone formation, and limb defects. *Bone* 49:673-682.
46. Xu, J., Li, Z., Hou, Y., & Fang, W. (2015). Potential mechanisms underlying the Runx2 induced osteogenesis of bone marrow mesenchymal stem cells. *American journal of translational research*, 7(12), 2527–2535.
47. Pratap J, Galindo M, Zaidi SK, Vradii D, Bhat BM, Robinson JA, et al. (2003) Cell Growth Regulatory Role of Runx2 during Proliferative Expansion of Preosteoblasts. *Cancer Res* 63:5357-5362.
48. Galindo, M., Kahler, R.A., Teplyuk, N.M. et al. *J Mol Hist* (2007). Cell cycle related modulations in Runx2 protein levels are independent of lymphocyte enhancer-binding factor 1 (Lef1) in proliferating osteoblasts. *J Mol Histol* 38:501-506. <https://doi.org/10.1007/s10735-007-9143-0>.
49. Wan Y. (2010) PPAR γ in bone homeostasis. *Trends in Endocrinology & Metabolism* 21:722-728.
50. Tontonoz P, Spiegelman BM. (2008) Fat and Beyond: The Diverse Biology of PPAR γ . *Annu Rev Biochem* 77:289-312.
51. Kawaguchi, Toru Akune AND Shinsuke Ohba AND Satoru Kamekura AND Masayuki Yamaguchi AND Ung-il Chung AND Naoto Kubota AND Yasuo Terauchi AND Yoshifumi Harada AND Yoshiaki Azuma AND Kozo Nakamura AND Takashi Kadowaki

- AND Hiroshi. (2004) PPAR γ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. *J Clin Invest* 113:846-855.
52. Franceschi, R. T., & Ge, C. (2017). Control of the Osteoblast Lineage by Mitogen-Activated Protein Kinase Signaling. *Current molecular biology reports*, 3(2), 122–132. doi:10.1007/s40610-017-0059-5.
53. Ge, C., Xiao, G., Jiang, D., & Franceschi, R. T. (2007). Critical role of the extracellular signal-regulated kinase-MAPK pathway in osteoblast differentiation and skeletal development. *The Journal of cell biology*, 176(5), 709–718. doi:10.1083/jcb.200610046.
54. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, et al. (1997). Mutations Involving the Transcription Factor CBFA1 Cause Cleidocranial Dysplasia. *Cell* 89:773-779.
55. Rice DP (ed) (2008). Craniofacial Sutures. Development, Disease and Treatment. *Front Oral Biol. Basel, Karger* 12, 107-143. doi: 10.1159/00011503.
56. Shukla V, Coumoul X, Wang RH, Kim HS, Deng CX. (2007) RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis. *Nat Genet* 39:1145-1150.
57. Tsang M, Dawid IB. (2004) Promotion and attenuation of FGF signaling through the Ras-MAPK pathway. *Sci STKE* 2004:pe17.
58. Greenblatt, M. B., Shim, J. H., Zou, W., Sitara, D., Schweitzer, M., Hu, D., ... Glimcher, L. H. (2010). The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. *The Journal of clinical investigation*, 120(7), 2457–2473. doi:10.1172/JCI42285.

59. Shim, J. H., Greenblatt, M. B., Xie, M., Schneider, M. D., Zou, W., Zhai, B., ... Glimcher, L. H. (2009). TAK1 is an essential regulator of BMP signaling in cartilage. *The EMBO journal*, 28(14), 2028–2041. doi:10.1038/emboj.2009.162.
60. Kuan CY, Yang DD, Samanta Roy DR, Davis RJ, Rakic P, Flavell RA. (1999) The Jnk1 and Jnk2 protein kinases are required for regional specific apoptosis during early brain development. *Neuron* 22:667-676.
61. Yamashita, M., Ying, S. X., Zhang, G. M., Li, C., Cheng, S. Y., Deng, C. X., & Zhang, Y. E. (2005). Ubiquitin ligase Smurf1 controls osteoblast activity and bone homeostasis by targeting MEKK2 for degradation. *Cell*, 121(1), 101–113 doi:10.1016/j.cell.2005.01.035.
62. Ge C, Xiao G, Jiang D, Yang Q, Hatch NE, Roca H, Franceschi RT. 2009. Identification and functional characterization of ERK/MAPK phosphorylation sites in the Runx2 transcription factor. *J Biol Chem* 284: 32533– 32543.
63. Stechschulte, L. A., & Lecka-Czernik, B. (2017). Reciprocal regulation of PPAR γ and RUNX2 activities in marrow mesenchymal stem cells: Fine balance between p38 MAPK and Protein Phosphatase 5. *Current molecular biology reports*, 3(2), 107–113. doi:10.1007/s40610-017-0056-8.
64. Jones HH, Priest JD, Hayes WC, Tichenor CC, Nagel DA. (1977) Humeral hypertrophy in response to exercise. *J Bone Joint Surg Am.* 59:204-208.
65. Gleeson PB, Protas EJ, LeBlanc AD, Schneider VS, Evans HJ (1990). Effects of weight lifting on bone mineral density in premenopausal women. *J Bone Miner Res.* 5(2):153–8.
66. Krahl H, Michaelis U, Pieper HG, Quack G, Montag M (1994). Stimulation of bone growth through sports. A radiologic investigation of the upper extremities in professional tennis players. *Am J Sports Med.* 22 (6):751–7.

67. Leblanc AD, Schneider VS, Evans HJ, Engelbretson DA, Krebs JM (1990). Bone mineral loss and recovery after 17 weeks of bed rest. *J Bone Miner Res.* 5(8):843–50.
68. Keyak JH, Koyama AK, LeBlanc A, Lu Y, Lang TF (2009). Reduction in proximal femoral strength due to long-duration spaceflight. *Bone.* 44(3):449–53.
69. Chen, J. C., & Jacobs, C. R. (2013). Mechanically induced osteogenic lineage commitment of stem cells. *Stem cell research & therapy*, 4(5), 107. doi:10.1186/scrt318
70. Leucht, P., Kim, J. B., Wazen, R., Currey, J. A., Nanci, A., Brunski, J. B., & Helms, J. A. (2007). Effect of mechanical stimuli on skeletal regeneration around implants. *Bone*, 40(4), 919–930. doi:10.1016/j.bone.2006.10.027.
71. Pedersen JA, Swartz MA. (2005) Mechanobiology in the third dimension. *Ann Biomed Eng* 33:1469-1490.
72. Tay, B. K., Le, A. X., Gould, S. E. and Helms, J. A. (1998), Histochemical and molecular analyses of distraction osteogenesis in a mouse model. *J. Orthop. Res.*, 16: 636-642. doi:10.1002/jor.1100160518
73. van Der Meulen MCH, Beaupré GS, Carter DR. (1993) Mechanobiologic influences in long bone cross-sectional growth. *Bone* 14:635-642 Brown TD. (2000) Techniques for mechanical stimulation of cells in vitro: a review. *Journal of Biomechanics* 33:3-14.
74. Delaine-Smith, R. M., & Reilly, G. C. (2012). Mesenchymal stem cell responses to mechanical stimuli. *Muscles, ligaments and tendons journal*, 2(3), 169–180.
75. Li S, Jia X, Duance VC, Blain EJ. (2011) The effects of cyclic tensile strain on the organisation and expression of cytoskeletal elements in bovine intervertebral disc cells: an in vitro study. *Eur Cell Mater* 21:508-522.

76. El Haj, A. J., & Cartmell, S. H. (2010). Bioreactors for bone tissue engineering. *Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine*, 224(12), 1523–1532. <https://doi.org/10.1243/09544119JEIM802>.
77. Jacobs, C. R., Yellowley, C. E., Davis, B. R., Zhou, Z., Cimbala, J. M., & Donahue, H. J. (1998). Differential effect of steady versus oscillating flow on bone cells. *Journal of biomechanics*, 31(11), 969–976.
78. Kobayashi Y, Sakai D, Iwashina T, Iwabuchi S, Mochida J. (2009) Low-intensity pulsed ultrasound stimulates cell proliferation, proteoglycan synthesis and expression of growth factor-related genes in human nucleus pulposus cell line. *Eur Cell Mater* 17:15-22.
79. Korstjens CM, van der Rijt RH, Albers GH, Semeins CM, Klein-Nulend J. (2008) Low-intensity pulsed ultrasound affects human articular chondrocytes in vitro. *Med Biol Eng Comput* 46:1263-1270.
80. Dumas V, Ducharme B, Perrier A, Fournier C, Guignandon A, Thomas M, et al. (2010) Extracellular matrix produced by osteoblasts cultured under low-magnitude, high-frequency stimulation is favourable to osteogenic differentiation of mesenchymal stem cells. *Calcif Tissue Int* 87:351-364.
81. Edwards JH, Reilly GC. Low magnitude, high frequency vibration modulates mesenchymal progenitor differentiation. *Trans Annu Meet Orthop Res Soc.* 2011;57.
82. Pedersen JA, Swartz MA. (2005) Mechanobiology in the third dimension. *Ann Biomed Eng* 33:1469-1490.
83. Amblard, D. , Lafage-Proust, M. , Laib, A. , Thomas, T. , Rügsegger, P. , Alexandre, C. and Vico, L. (2003), Tail Suspension Induces Bone Loss in Skeletally Mature Mice in the

C57BL/6J Strain but Not in the C3H/HeJ Strain. *J Bone Miner Res*, 18: 561-569.
doi:10.1359/jbmr.2003.18.3.561.

84. Zhang, P., Wu, Y., Jiang, Z., Jiang, L., & Fang, B. (2012). Osteogenic response of mesenchymal stem cells to continuous mechanical strain is dependent on ERK1/2-Runx2 signaling. *International Journal of Molecular Medicine*, 29, 1083-1089.
<https://doi.org/10.3892/ijmm.2012.934>.
85. Jagodzinski M, Drescher M, Zeichen J, Hankemeier S, Krettek C, Bosch U, et al. (2004) Effects of cyclic longitudinal mechanical strain and dexamethasone on osteogenic differentiation of human bone marrow stromal cells. *Eur Cell Mater* 7:35-41; discussion 41.
86. Pelaez D, Arita N, Cheung HS. (2012) Extracellular signal-regulated kinase (ERK) dictates osteogenic and/or chondrogenic lineage commitment of mesenchymal stem cells under dynamic compression. *Biochemical and Biophysical Research Communications* 417:1286-1291.
87. Li, Y. J., Batra, N. N., You, L. , Meier, S. C., Coe, I. A., Yellowley, C. E. and Jacobs, C. R. (2004), Oscillatory fluid flow affects human marrow stromal cell proliferation and differentiation. *J. Orthop. Res.*, 22: 1283-1289. doi:10.1016/j.orthres.2004.04.002.
88. Liu, J. , Zhao, Z. , Li, J. , Zou, L. , Shuler, C. , Zou, Y. , Huang, X. , Li, M. and Wang, J. (2009), Hydrostatic pressures promote initial osteodifferentiation with ERK1/2 not p38 MAPK signaling involved. *J. Cell. Biochem.*, 107: 224-232. doi:10.1002/jcb.22118.
89. Keila, S. , Pitaru, S. , Grosskopf, A. and Weinreb, M. (1994), Bone marrow from mechanically unloaded rat bones expresses reduced osteogenic capacity in vitro. *J Bone Miner Res*, 9: 321-327. doi:10.1002/jbmr.5650090306. Delaine-Smith RM, Reilly GC.

- (2011) Chapter Twenty - The Effects of Mechanical Loading on Mesenchymal Stem Cell Differentiation and Matrix Production. *Vitamins & Hormones* 87:417-480.
90. Pavalko, F. M., Norvell, S. M., Burr, D. B., Turner, C. H., Duncan, R. L. and Bidwell, J. P. (2003), A Model for mechanotransduction in bone cells: The load-bearing mechanosomes. *J. Cell. Biochem.*, 88: 104-112. doi:10.1002/jcb.10284.
91. McBeath R, Pirone DM, Nelson CM, Bhadriraju K, Chen CS. (2004) Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. *Dev Cell* 6:483-495.
92. Arnsdorf, E. J., Tummala, P., Kwon, R. Y., & Jacobs, C. R. (2009). Mechanically induced osteogenic differentiation--the role of RhoA, ROCKII and cytoskeletal dynamics. *Journal of cell science*, 122(Pt 4), 546–553. doi:10.1242/jcs.036293.
93. Sun, Y., Villa-Diaz, L. G., Lam, R. H., Chen, W., Krebsbach, P. H., & Fu, J. (2012). Mechanics regulates fate decisions of human embryonic stem cells. *PloS one*, 7(5), e37178. doi:10.1371/journal.pone.0037178.
94. Balaban NQ, Schwarz US, Riveline D, Goichberg P, Tzur G, Sabanay I, et al. (2001) Force and focal adhesion assembly: a close relationship studied using elastic micropatterned substrates. *Nat Cell Biol* 3:466-472.
95. Liu, L. , Zong, C. , Li, B. , Shen, D. , Tang, Z. , Chen, J. , Zheng, Q. , Tong, X. , Gao, C. and Wang, J. (2014), The interaction between $\beta 1$ integrins and ERK1/2 in osteogenic differentiation of human mesenchymal stem cells under fluid shear stress modelled by a perfusion system. *J Tissue Eng Regen Med*, 8: 85-96. doi:10.1002/term.1498.
96. Ward DF,Jr, Williams WA, Schapiro NE, Weber GL, Christy SR, Salt M, et al. (2007) Focal adhesion kinase signaling controls cyclic tensile strain enhanced collagen I-induced

- osteogenic differentiation of human mesenchymal stem cells. *Mol Cell Biomech* 4:177-188.
97. Serra, R. (2008), Role of Intraflagellar Transport and Primary Cilia in Skeletal Development. *Anat Rec*, 291: 1049-1061. doi:10.1002/ar.20634.
98. Köttgen, M., Buchholz, B., Garcia-Gonzalez, M. A., Kotsis, F., Fu, X., Doerken, M., ... Walz, G. (2008). TRPP2 and TRPV4 form a polymodal sensory channel complex. *The Journal of cell biology*, 182(3), 437–447. doi:10.1083/jcb.200805124.
99. Kwon, R. Y., Temiyasathit, S., Tummala, P., Quah, C. C., & Jacobs, C. R. (2010). Primary cilium-dependent mechanosensing is mediated by adenylyl cyclase 6 and cyclic AMP in bone cells. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*, 24(8), 2859–2868. doi:10.1096/fj.09-148007.
100. Haycraft CJ, Zhang Q, Song B, Jackson WS, Detloff PJ, Serra R, et al. (2007) Intraflagellar transport is essential for endochondral bone formation. *Development* 134:307-316.
101. Hoey, D. A., Tormey, S., Ramcharan, S., O'Brien, F. J., & Jacobs, C. R. (2012). Primary cilia-mediated mechanotransduction in human mesenchymal stem cells. *Stem cells (Dayton, Ohio)*, 30(11), 2561–2570. doi:10.1002/stem.1235.
102. Zhang, P., Wu, Y., Jiang, Z., Jiang, L., & Fang, B. (2012). Osteogenic response of mesenchymal stem cells to continuous mechanical strain is dependent on ERK1/2-Runx2 signaling. *International Journal of Molecular Medicine*, 29, 1083-1089. <https://doi.org/10.3892/ijmm.2012.934>.
103. Ward Jr. DF, Salaszyk RM, Klees RF, Backiel J, Agius P, Bennett K, et al. (2007) Mechanical Strain Enhances Extracellular Matrix-Induced Gene Focusing and Promotes

- Osteogenic Differentiation of Human Mesenchymal Stem Cells Through an Extracellular-Related Kinase-Dependent Pathway. *Stem Cells and Development* 16:467-480.
104. Li, Y. , Ge, C. , Long, J. P., Begun, D. L., Rodriguez, J. A., Goldstein, S. A. and Franceschi, R. T. (2012), Biomechanical stimulation of osteoblast gene expression requires phosphorylation of the RUNX2 transcription factor. *J Bone Miner Res*, 27: 1263-1274. doi:10.1002/jbmr.1574.
105. Shang S, Hua F, Hu ZW. (2017) The regulation of beta-catenin activity and function in cancer: therapeutic opportunities. *Oncotarget* 8:33972-33989.
106. Rodda SJ, McMahon AP. (2006) Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. *Development* 133:3231-3244.
107. Arnsdorf EJ, Tummala P, Jacobs CR. (2009) Non-canonical Wnt signaling and N-cadherin related beta-catenin signaling play a role in mechanically induced osteogenic cell fate. *PLoS One* 4:e5388.
108. Halder G, Dupont S, Piccolo S. (2012) Transduction of mechanical and cytoskeletal cues by YAP and TAZ. *Nat Rev Mol Cell Biol* 13:591-600.
109. Hong JH, Hwang ES, McManus MT, Amsterdam A, Tian Y, Kalmukova R, et al. (2005) TAZ, a transcriptional modulator of mesenchymal stem cell differentiation. *Science* 309:1074-1078.
110. Liu X, Qu T, Sachar A, Svoboda KKH. (2015) Chapter 4 - Cell-Matrix Interactions and Signal Transduction. 47-60.

111. Guo H, Zucker S, Gordon MK, Toole BP, Biswas C. (1997) Stimulation of matrix metalloproteinase production by recombinant extracellular matrix metalloproteinase inducer from transfected Chinese hamster ovary cells. *J Biol Chem* 272:24-27.
112. Wilson J, Hunt T. (2002) *Molecular biology of the cell: a problems approach*. 4th ed. New York: Garland Science.
113. Brunner M, Jurdic P, Tuckerman JP, Block MR, Bouvard D. (2013) Chapter One - New Insights into Adhesion Signaling in Bone Formation. *International Review of Cell and Molecular Biology* 305:1-68.
114. Albiges-Rizo C, Destaing O, Fourcade B, Planus E, Block MR. (2009) Actin machinery and mechanosensitivity in invadopodia, podosomes and focal adhesions. *J Cell Sci* 122:3037-3049.
115. Saltel F, Chabadel A, Bonnelye E, Jurdic P. (2008) Actin cytoskeletal organisation in osteoclasts: A model to decipher transmigration and matrix degradation. *European Journal of Cell Biology* 87:459-468.
116. Nesbitt S, Nesbit A, Helfrich M, Horton M. (1993) Biochemical characterization of human osteoclast integrins. Osteoclasts express alpha v beta 3, alpha 2 beta 1, and alpha v beta 1 integrins. *J Biol Chem* 268:16737-16745.
117. Faccio R, Novack DV, Zallone A, Ross FP, Teitelbaum SL. (2003) Dynamic changes in the osteoclast cytoskeleton in response to growth factors and cell attachment are controlled by $\beta 3$ integrin. *J Cell Biol* 162:499-509.
118. Schmidt S, Nakchbandi I, Ruppert R, Kawelke N, Hess MW, Pfaller K, et al. (2011) Kindlin-3-mediated signaling from multiple integrin classes is required for osteoclast-mediated bone resorption. *J Cell Biol* 192:883-897.

119. Marie PJ. (2013) Targeting integrins to promote bone formation and repair. *Nat Rev Endocrinol* 9:288-295.
120. Moursi AM, Globus RK, Damsky CH. (1997) Interactions between integrin receptors and fibronectin are required for calvarial osteoblast differentiation in vitro. *J Cell Sci* 110:2187-2196.
121. Damsky CH. (1999) Extracellular matrix–integrin interactions in osteoblast function and tissue remodeling. *Bone* 25:95-96.
122. Kaabeche K, Guenou H, Bouvard D, Didelot N, Listrat A, Marie PJ. (2005) Cbl-mediated ubiquitination of $\alpha 5$ integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation. *J Cell Sci* 118:1223-1232.
123. Cheng, S. , Lai, C. , Fausto, A. , Chellaiah, M. , Feng, X. , McHugh, K. P., Teitelbaum, S. L., Civitelli, R. , Hruska, K. A., Ross, F. P. and Avioli, L. V. (2000), Regulation of $\alpha V\beta 3$ and $\alpha V\beta 5$ integrins by dexamethasone in normal human osteoblastic cells. *J. Cell. Biochem.*, 77: 265-276. doi:10.1002/(SICI)1097-4644(20000501)77:2.
124. Su JL, Chiou J, Tang CH, Zhao M, Tsai CH, Chen PS, et al. (2010) CYR61 regulates BMP-2-dependent osteoblast differentiation through the $\alpha v\beta 3$ integrin/integrin-linked kinase/ERK pathway. *J Biol Chem* 285:31325-31336.
125. Franceschi, R. T., Xiao, G., Jiang, D., Gopalakrishnan, R., Yang, S., & Reith, E. (2003). Multiple signaling pathways converge on the Cbfa1/Runx2 transcription factor to regulate osteoblast differentiation. *Connective tissue research*, 44 Suppl 1(Suppl 1), 109–116.
126. Shih, Y. V., Tseng, K. , Lai, H. , Lin, C. and Lee, O. K. (2011), Matrix stiffness regulation of integrin-mediated mechanotransduction during osteogenic differentiation of human mesenchymal stem cells. *J Bone Miner Res*, 26: 730-738. doi:10.1002/jbmr.278.

127. Popov, C., Radic, T., Haasters, F., Prall, W. C., Aszodi, A., Gullberg, D., ... Docheva, D. (2011). Integrins $\alpha 2\beta 1$ and $\alpha 11\beta 1$ regulate the survival of mesenchymal stem cells on collagen I. *Cell death & disease*, 2(7), e186. doi:10.1038/cddis.2011.71.
128. Mitra SK, Schlaepfer DD. (2006) Integrin-regulated FAK–Src signaling in normal and cancer cells. *Current Opinion in Cell Biology* 18:516-523.
129. Bader BL, Rayburn H, Crowley D, Hynes RO. (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. *Cell* 95:507-519.
130. Fassler R, Meyer M. (1995) Consequences of lack of beta 1 integrin gene expression in mice. *Genes Dev* 9:1896-1908.
131. Stephens LE, Sutherland AE, Klimanskaya IV, Andrieux A, Meneses J, Pedersen RA, et al. (1995) Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. *Genes Dev* 9:1883-1895.
132. Vogel W. (1999) Discoidin domain receptors: structural relations and functional implications. *The FASEB Journal* 13:S77-S82.
133. Ge, C., Wang, Z., Zhao, G., Li, B., Liao, J., Sun, H., & Franceschi, R. T. (2016). Discoidin Receptor 2 Controls Bone Formation and Marrow Adipogenesis. *Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research*, 31(12), 2193–2203. doi:10.1002/jbmr.2893.
134. Fu, H. L., Valiathan, R. R., Arkwright, R., Sohail, A., Mihai, C., Kumarasiri, M., ... Fridman, R. (2013). Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. *The Journal of biological chemistry*, 288(11), 7430–7437. doi:10.1074/jbc.R112.444158.

135. Bargal, R., Cormier-Daire, V., Ben-Neriah, Z., Le Merrer, M., Sosna, J., Melki, J., ... Raas-Rothschild, A. (2009). Mutations in *DDR2* gene cause SMED with short limbs and abnormal calcifications. *American journal of human genetics*, 84(1), 80–84. doi: 10.1016/j.ajhg.2008.12.004.
136. Guo, Y., Yang, T. L., Dong, S. S., Yan, H., Hao, R. H., Chen, X. F., ... Deng, H. W. (2015). Genetic analysis identifies *DDR2* as a novel gene affecting bone mineral density and osteoporotic fractures in Chinese population. *PloS one*, 10(2), e0117102. doi: 10.1371/journal.pone.0117102.
137. Kano, K., Marín de Evsikova, C., Young, J., Wnek, C., Maddatu, T. P., Nishina, P. M., & Naggert, J. K. (2008). A novel dwarfism with gonadal dysfunction due to loss-of-function allele of the collagen receptor gene, *Ddr2*, in the mouse. *Molecular endocrinology* (Baltimore, Md.), 22(8), 1866–1880. doi:10.1210/me.2007-0310.
138. Zhang, Y., Su, J., Yu, J., Bu, X., Ren, T., Liu, X. and Yao, L. (2011), An essential role of discoidin domain receptor 2 (*DDR2*) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation. *J Bone Miner Res*, 26: 604-617. doi:10.1002/jbmr.225.
139. Xu, H., Bihan, D., Chang, F., Huang, P. H., Farndale, R. W., & Leiting, B. (2012). Discoidin domain receptors promote $\alpha 1\beta 1$ - and $\alpha 2\beta 1$ -integrin mediated cell adhesion to collagen by enhancing integrin activation. *PloS one*, 7(12), e52209. doi:10.1371/journal.pone.0052209
140. Dimitriou R, Jones E, McGonagle D, Giannoudis PV. (2011) Bone regeneration: current concepts and future directions. *BMC Med* 9:66-7015-9-66.
141. Evans WF. (1976) *Anatomy and physiology*. 2d ed. Englewood Cliffs, N.J.: Prentice-Hall.
142. Cashman KD, Ginty F. (2003) *BONE*. 557-565.

143. Samsonraj, R. M., Dudakovic, A., Zan, P., Pichurin, O., Cool, S. M., & van Wijnen, A. J. (2017). A Versatile Protocol for Studying Calvarial Bone Defect Healing in a Mouse Model. *Tissue engineering. Part C, Methods*, 23(11), 686–693. doi: 10.1089/ten.TEC.2017.0205.
144. Park, S., Zhao, H., Urata, M., & Chai, Y. (2016). Sutures Possess Strong Regenerative Capacity for Calvarial Bone Injury. *Stem cells and development*, 25(23), 1801–1807. doi:10.1089/scd.2016.0211.
145. Vieira, A. E., Repeke, C. E., Ferreira Junior, S., Colavite, P. M., Biguetti, C. C., Oliveira, R. C., ... Garlet, G. P. (2015). Intramembranous bone healing process subsequent to tooth extraction in mice: micro-computed tomography, histomorphometric and molecular characterization. *PloS one*, 10(5), e0128021. doi:10.1371/journal.pone.0128021.
146. Marsell, R., & Einhorn, T. A. (2011). The biology of fracture healing. *Injury*, 42(6), 551–555. doi:10.1016/j.injury.2011.03.031.
147. Einhorn TA, Gerstenfeld LC. (2015) Fracture healing: mechanisms and interventions. *Nat Rev Rheumatol* 11:45-54.
148. Mackie EJ, Ahmed YA, Tatarczuch L, Chen K-, Mirams M. (2008) Endochondral ossification: How cartilage is converted into bone in the developing skeleton. *The International Journal of Biochemistry & Cell Biology* 40:46-62.
149. Axelrad, T. W. & Einhorn, T. A. (2009) Bone morphogenetic proteins in orthopaedic surgery. *Cytokine Growth Factor Rev.* 20, 481–488.
150. Khosla, S., Westendorf, J. J. & Oursler, M. J. (2008) Building bone to reverse osteoporosis and repair fractures. *J. Clin. Invest.* 118, 421–428.
151. Du, X., Xie, Y., Xian, C. J. & Chen, L. (2012) Role of FGFs/FGFRs in skeletal development and bone regeneration. *J. Cell Physiol.* 227, 3731–3734.

152. Fei, Y., Gronowicz, G. & Hurley, M. M. (2013) Fibroblast growth factor-2, bone homeostasis and fracture repair. *Curr. Pharm. Des.* 19, 3354–3363.
153. Edwards, P. C. et al. (2005) Sonic hedgehog gene-enhanced tissue engineering for bone regeneration. *Gene Ther.* 12, 75–86.
154. Song, K., Rao, N. J., Chen, M. L., Huang, Z. J. & Cao, Y. G. (2011) Enhanced bone regeneration with sequential delivery of basic fibroblast growth factor and sonic hedgehog. *Injury* 42, 796–802.
155. Barnes, G. L. et al. (2008) Stimulation of fracture-healing with systemic intermittent parathyroid hormone treatment. *J. Bone Joint Surg. Am.* 90 (Suppl. 1), 120–127.
156. Jørgensen, N. R. & Schwarz, P. (2011) Effects of anti-osteoporosis medications on fracture healing. *Curr. Osteoporos. Rep.* 9, 149–145.
157. Patil, A. S., Sable, R. B. & Kothari, R. M. (2011) An update on transforming growth factor- β (TGF- β): sources, types, functions and clinical applicability for cartilage/bone healing. *J. Cell. Physiol.* 226, 3094–3103
158. Virk, M. S. et al. (2013) Systemic administration of sclerostin antibody enhances bone repair in a critical-sized femoral defect in a rat model. *J. Bone Joint Surg. Am.* 95, 694–701.
159. Ke, H. Z., Richards, W. G. Li, X. & Ominsky, M. S. (2012) Sclerostin and Dickkopf-1 as therapeutic targets in bone diseases. *Endocr. Rev.* 33, 747–783.
160. Park, S., Zhao, H., Urata, M., & Chai, Y. (2016). Sutures Possess Strong Regenerative Capacity for Calvarial Bone Injury. *Stem cells and development*, 25(23), 1801–1807. doi:10.1089/scd.2016.0211.

161. Nijhuis WH, Eastwood DM, Allgrove J, Hvid I, Weinans HH, Bank RA, et al. (2019) Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management. *J Child Orthop* 13:1-11.
162. Kular, J. K., Basu, S., & Sharma, R. I. (2014). The extracellular matrix: Structure, composition, age-related differences, tools for analysis and applications for tissue engineering. *Journal of Tissue Engineering*. <https://doi.org/10.1177/2041731414557112>
163. Viguet-Carrin, S., Garnero, P. & Delmas, P.D. *Osteoporos Int* (2006). The role of collagen in bone strength. March, Volume 17, Issue 3, pp 319–336. <https://doi.org/10.1007/s00198-005-2035-9>.
164. Rauch F, Travers R, Parfitt AM, Glorieux FH (2000) Static and dynamic bone histomorphometry in children with osteogenesis imperfecta. *Bone* 26:581–589.
165. Uveges TE, Collin-Osdoby P, Cabral WA, Ledgard F, Goldberg L, Bergwitz C, Forlino A, Osdoby P, Gronowicz GA, Marini JC (2008) Cellular mechanism of decreased bone in Brl mouse model of OI: imbalance of decreased osteoblast function and increased osteoclasts and their precursors. *J Bone Miner Res* 23:1983–1994.
166. Li H, Jiang X, Delaney J, Franceschetti T, Bilic-Curcic I, Kalinovsky J, Lorenzo JA, Grcevic D, Rowe DW, Kalajzic I (2010) Immature osteoblast lineage cells increase osteoclastogenesis in osteogenesis imperfecta murine. *Am J Pathol* 176:2405–2413.
167. Ekholm, E., Hankenson, K. D., Uusitalo, H., Hiltunen, A., Gardner, H., Heino, J., & Penttinen, R. (2002). Diminished callus size and cartilage synthesis in alpha 1 beta 1 integrin-deficient mice during bone fracture healing. *The American journal of pathology*, 160(5), 1779–1785. [doi:10.1016/s0002-9440\(10\)61124-8](https://doi.org/10.1016/s0002-9440(10)61124-8).

168. Scarano A, Iezzi G, Petrone G, Orsini G, Degidi M, Strocchi R, et al. (2003) Cortical bone regeneration with a synthetic cell-binding peptide: a histologic and histomorphometric pilot study. *Implant Dent* 12:318-324.
169. Pountos, I., Panteli, M., Lampropoulos, A., Jones, E., Calori, G. M., & Giannoudis, P. V. (2016). The role of peptides in bone healing and regeneration: a systematic review. *BMC medicine*, 14, 103. doi:10.1186/s12916-016-0646-y.
170. Nguyen H, Qian JJ, Bhatnagar RS, Li S. (2003) Enhanced cell attachment and osteoblastic activity by P-15 peptide-coated matrix in hydrogels. *Biochem Biophys Res Commun.*;311(1):179–86. doi: 10.1016/j.bbrc.2003.09.192. 236.
171. Gomar F, Orozco R, Villar JL, Arrizabalaga F. P-15 small peptide bone graft substitute in the treatment of non-unions and delayed union. A pilot clinical trial. *Int Orthop*. 2007;31(1):93–9. doi: 10.1007/s00264-006-0087-x.
172. Reyes, C. D., Petrie, T. A., Burns, K. L., Schwartz, Z., & García, A. J. (2007). Biomolecular surface coating to enhance orthopaedic tissue healing and integration. *Biomaterials*, 28(21), 3228–3235. doi:10.1016/j.biomaterials.2007.04.003.
173. Shekaran, A., García, J. R., Clark, A. Y., Kavanaugh, T. E., Lin, A. S., Guldberg, R. E., & García, A. J. (2014). Bone regeneration using an alpha 2 beta 1 integrin-specific hydrogel as a BMP-2 delivery vehicle. *Biomaterials*, 35(21), 5453–5461. doi:10.1016/j.biomaterials.2014.03.055.
174. Reyes, C. D., Petrie, T. A., Burns, K. L., Schwartz, Z., & García, A. J. (2007). Biomolecular surface coating to enhance orthopaedic tissue healing and integration. *Biomaterials*, 28(21), 3228–3235. doi:10.1016/j.biomaterials.2007.04.003.

175. Reyes, C. D. and García, A. J. (2004), $\alpha 2\beta 1$ integrin-specific collagen-mimetic surfaces supporting osteoblastic differentiation. *J. Biomed. Mater. Res.*, 69A: 591-600. doi:10.1002/jbm.a.30034.
176. García, J. R., Clark, A. Y., & García, A. J. (2016). Integrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects. *Journal of biomedical materials research. Part A*, 104(4), 889–900. doi:10.1002/jbm.a.35626.
177. Amini, A. R., Laurencin, C. T., & Nukavarapu, S. P. (2012). Bone tissue engineering: recent advances and challenges. *Critical reviews in biomedical engineering*, 40(5), 363–408.
178. Zimmerman D, Jin F, Leboy P, Hardy S, Damsky C. (2000) Impaired Bone Formation in Transgenic Mice Resulting from Altered Integrin Function in Osteoblasts. *Developmental Biology* 220:2-15.
179. Shekaran, A., Shoemaker, J. T., Kavanaugh, T. E., Lin, A. S., LaPlaca, M. C., Fan, Y., ... García, A. J. (2014). The effect of conditional inactivation of beta 1 integrins using twist 2 Cre, Osterix Cre and osteocalcin Cre lines on skeletal phenotype. *Bone*, 68, 131–141. doi:10.1016/j.bone.2014.08.008.
180. Blumbach, K., Niehoff, A., Belgardt, B. F., Ehlen, H. W., Schmitz, M., Hallinger, R., ... Eckes, B. (2012). Dwarfism in mice lacking collagen-binding integrins $\alpha 2\beta 1$ and $\alpha 11\beta 1$ is caused by severely diminished IGF-1 levels. *The Journal of biological chemistry*, 287(9), 6431–6440. doi:10.1074/jbc.M111.283119.
181. Phillips JA, Almeida EAC, Hill EL, Aguirre JI, Rivera MF, Nachbandi I, et al. (2008) Role for $\beta 1$ integrins in cortical osteocytes during acute musculoskeletal disuse. *Matrix Biology* 27:609-618.

Chapter 2

The Role of Discoidin Domain Receptor 2 in Calvarial Bone Regeneration

Abstract

Bone is an archetypical example of an organ that can completely heal itself by activating an intrinsic regeneration program. However, large bone defects caused by trauma, tumor resection or pathological bone resorption cannot spontaneously heal. Their treatment is a major clinical orthopedic challenge and global health problem. Cranial bone regeneration requires differentiation of mesenchymal stem cells to osteoblasts and remodeling of the bone extracellular matrix (ECM). Discoidin domain receptor 2 (DDR2) is a collagen-activated receptor tyrosine kinase shown to be essential for skeletal development in humans and mice. *Ddr2*-deficient mice exhibit dwarfism and defective bone formation in the axial, appendicular and cranial skeletons. However, the role of DDR2 in bone regeneration has not yet been investigated. Here we show that Smallie mice (*Ddr2^{slie/slie}*), which contain a nonfunctional *Ddr2* allele, are unable to heal a subcritical-size (0.5 mm) calvarial defect that, in wild type mice, can spontaneously heal within 4 weeks. Also, *Ddr2* expression during calvarial bone regeneration was defined using *Ddr2*-LacZ knock-in mice and β -galactosidase staining. *Ddr2* expression, which was restricted to periosteal surfaces of uninjured calvarial bone, greatly expanded with injury. Similar results were seen when the lineage of *Ddr2*-expressing cells was examined using *Ddr2cre^{ERT}*, *Ai14 TdTomato* mice. *Ddr2* positive cells and their progeny expanded within the defect three days and two weeks post-surgery. Furthermore,

three days post-surgery, *Ddr2^{slie/slie}* mice showed a significant decrease in cell proliferation in the calvarial defect when compared with WT littermates. Lastly, levels of the preosteoblast markers, Osterix and phosphorylated RUNX2 (S319-P) decreased in *Ddr2^{slie/slie}* mice consistent with there being a defect in osteoblast differentiation. Together, our study demonstrates that DDR2 is necessary for normal calvarial bone regeneration and this requirement may be explained in part by effects of DDR2 on proliferation and osteoblast differentiation.

Introduction

Bone is a dynamic tissue with self-healing capabilities that allow repair of most fractures with restoration of original architecture. However, large bone defects, such as those caused by tumor resections or severe trauma, do not regenerate spontaneously and represent a major clinical challenge for craniomaxillofacial and orthopedic surgeons.¹ Bone grafts are usually used to manage such conditions. Bone autografts consist mainly of bone ECM and associated cells.² Recent research has unveiled many unique characteristics of ECM that play a key role in tissue regeneration. ECM enhances cell recruitment through cell surface receptors, which determine cell-ECM interactions and trigger specific cellular functions such as adhesion, migration, proliferation, and differentiation³⁻⁵. Therefore, a clear understanding of these ECM receptors will facilitate the development of new bone regeneration strategies.

Specific cell surface receptors mediate interactions between the collagenous ECM and cells. Collagen binding integrins are the main ECM receptors known to be important in the crosstalk between bone cells and the ECM. Integrin $\alpha2\beta1$ is a collagen receptor expressed on many mesenchymal cells. Studies showed that stimulation of this integrin, using scaffolds that selectively promote $\alpha2\beta1$ integrin binding, significantly accelerated and increased bone formation in non-healing femoral defects^{7,8}. Integrins have clear roles in bone formation and regeneration,

but they don't explain the entire response of bone cells to ECM since bone-specific knockout of individual integrins only partially prevents bone formation⁸⁻¹¹. The discoidin domain receptors 1 and 2 (DDR1 and DDR2) are another important class of ECM receptor¹². Unlike integrins, DDRs have intrinsic tyrosine kinase activity and are selectively activated by triple-helical collagens^{13,14}.

Both DDR1 and DDR2 are involved in multiple physiological processes, such as development, ECM turnover, growth regulation and cancer¹⁵⁻¹⁷. In bone, several lines of evidence suggest an important role for DDR2. In humans, *Ddr2* mutations cause spondylo-meta-epiphyseal dysplasia (SMED), a skeletal disorder associated with dwarfism, bowing of long bones, craniofacial abnormalities, short fingers, and abnormal calcifications^{16,18}. Also, in a Han Chinese population, polymorphisms in *Ddr2* are associated with low bone mineral density (BMD) and fracture risk¹⁹. Consistent with the human phenotype, mice with a spontaneous *Ddr2* mutation, called smallie mice (*Ddr2^{slie/slie}*), have a SMED-like phenotype characterized by dwarfism and reduction in total bone mineral density^{16,17}. Furthermore, detailed analysis of the bone phenotype in *Ddr2^{slie/slie}* mice revealed a dramatic reduction in bone volume of the cranial, axial, and appendicular skeleton due to reduction in osteoblast activity and bone formation in the absence of changes in resorption¹⁶. Bone changes were accompanied by a large increase in marrow fat¹⁶.

DDR2 is a key regulator of bone formation that controls several aspects of the process. However, it is not known if DDR2 is required for bone regeneration. In this study, we investigated the functional importance of *Ddr2* in the calvarial bone subcritical size defect regeneration using a *Ddr2*-deficient mouse model and defined the expression of *Ddr2* during calvarial bone regeneration. These findings provide new insights into the role of cell-ECM interactions in bone regeneration and may have important implications for understanding and enhancing bone regeneration.

Materials and Methods

Mice

Generation and genotyping of *Ddr2^{slie/slie}* mice, which contain a spontaneous 150 kb deletion in the *Ddr2* locus to produce an effective null, and *Ddr2-LacZ* (*Ddr2^{+LacZ}*) knock-in mice, where the bacterial LacZ gene is knocked into the *Ddr2* locus, were previously described^{16, 17, 21}. Studies also used *Ddr2Cre^{ERT}* mice recently developed by Dr. Barry Greenberg (UC San Diego). These mice contain *Cre^{ERT}* knocked in-frame into exon 2 of *Ddr2*. *Ddr2Cre^{ERT}* mice were crossed with *Ai14 TdTomato* mice provided by Dr. Noriaki Ono (University of Michigan, Ann Arbor)²². *TdTomato* mice harbor a targeted mutation of the Gt (ROSA) 26Sor locus with a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato); TdTomato is expressed following Cre-mediated recombination.

Calvarial Subcritical-Size Surgery

All mouse experimental procedures conformed to standards for the use of laboratory animals and were approved by the institutional Animal Care and Use Committee (IACUC) of the University of Michigan. Eight-week-old mice were maintained with general anesthesia (2% isoflurane/100% O₂) during the procedure and received Buprenorphine (0.02mg/kg ip) for analgesia. Under sterile conditions, a sagittal incision was made, parietal bones were exposed, and a 0.5 mm subcritical size defect (SSD) was created with a carbide bur at low speed in wild-type (WT), *Ddr2^{slie/slie}*, *Ddr2^{+LacZ}* and *Ddr2cre^{ERT}*; *Ai14 TdTomato* mice. Incisions were closed using 4-0 black silk interrupted sutures. The day after surgery, another buprenorphine injection was given to the mice. Bone regeneration of the SSD was measured 2, 4, 6, and 12 weeks post-surgery. For *Ddr2cre^{ERT}*; *Ai14 TdTomato* mice, three daily intraperitoneal injections with tamoxifen

(75mg/kg) were given. One day after the last injection, SSD surgery was performed, and mice were sacrificed 3 days and 2 weeks post-surgery.

Micro-computed tomography analysis of bone regeneration

After fixation with 10% neutral buffered formalin for 24 hours, SSD bone regeneration were measured by micro-computed tomography using a Scanco Model 100 (Scanco Medical, Bassersdorf, Switzerland). Scan settings were: voxel size 12 μm , 70 kVp, 114 μA , 0.5 mm AL filter, and integration time 500 ms. All scans were analyzed using fixed thresholds (180 for trabecular bone and 280 for cortical bone). For bone volume quantification of the SSD, a circular region of interest (ROI) of 0.5mm diameter was defined for the assessment of newly formed bone at the defect area. To avoid examiner bias, the genotype of mice was not specifically highlighted during quantification analysis.

Detection of β -gal (LacZ) expression

Samples dissected from heterozygous *Ddr2-LacZ* (*Ddr2*^{+/*LacZ*}) mice were processed for X-gal staining using standard procedures. Briefly, 10 μm frozen sections were stained with freshly prepared X-gal solution and counterstained with Vector® Nuclear Fast Red.

Cell Proliferation

Three days post-surgery, mice were intraperitoneally injected with 5-ethynyl-2'-deoxyuridine (EdU, 100 mg/kg) and sacrificed after 4h²⁵. Calvarial samples were fixed with 4% PFA (paraformaldehyde) overnight and decalcified in 10% EDTA for 1–2 weeks. Decalcified bone tissues were embedded in paraffin and sectioned at 5 μm thickness. EdU⁺ signals were detected with a Click-iT® EdU Alexa Fluor® 488 Imaging Kit (C10337; Invitrogen) following the recommended protocol. Cell nuclei were stained with DAPI. For quantification, we counted the number of EdU⁺/total nuclei in each section.

Tissue Preparation and Histological Analysis

One week post-surgery SSD calvarial bones were fixed in 4% paraformaldehyde and processed for paraffin sections. For immunofluorescence, histological sections were incubated with primary antibodies to Osterix (Osx) (Abcam, ab 22552), P-RUNX2 (specifically detects RUNX2 phosphorylated at S319 ⁽²⁶⁾) or Gli1 (Novus Biologicals, NBP1-78259) overnight at 4°C (1:100 dilution), and then with Alexa Fluor 555-conjugated donkey anti-rabbit IgG (Invitrogen A-31572). Fluorescence detection was accomplished using an Olympus BX51-P microscope and imaging system.

Statistical Analysis

All data was analyzed using the GraphPad Prism software version 7.0e, La Jolla California USA. Values were reported as mean \pm SD. Student's t test was used for statistical comparison between the two experimental groups. Differences were considered significant at $P < 0.05$. A sample size of five to eight mice (including both sexes) was used for experiments unless indicated otherwise.

Results

Ddr2 Signaling is Necessary for Optimal SSD Bone Regeneration

To investigate the functional role of Ddr2 in bone regeneration, we created a subcritical-size calvarial defect in both WT and *Ddr2^{slie/slie}* mice. To show that we were able to create similar defects in both WT and *Ddr2^{slie/slie}* mice, samples were harvested three days and one-week post-surgery and evaluated with Hematoxylin and Eosin (H&E) staining. Our results showed that the calvarial defects were initially identical in both groups (Figure 2.1 A). Reduced bone regeneration

in *Ddr2^{slie/slie}* mice relative to WT animals was seen as early as two weeks post-surgery (Figure 1B). This delay in bone regeneration continued to be seen four- and six-weeks post-surgery. In contrast, defects in WT mice were completely healed after four weeks (Figure 2.1 C and D), which is in agreement with previous reports^{23, 24}. Surprisingly, even after twelve weeks, the calvarial defect in *Ddr2^{slie/slie}* mice still had not completely healed (Figure 2.1 E). Results were quantified by micro-CT, which showed a significant reduction in bone volume/total volume in *Ddr2^{slie/slie}* defects two, four, six, and twelve weeks post-surgery (Figure 2.1 F). Interestingly, no further healing of defects was seen in *Ddr2^{slie/slie}* mice after the six week time point. This suggests that the healing process had already arrested by this time, making it unlikely the defect would heal even after extended times.

Ddr2 is Expressed During Calvarial Bone Regeneration

We next examined *Ddr2* expression during calvarial bone regeneration using a *Ddr2-lacZ* reporter mouse line (*Ddr2^{+ /lacZ}* mice). Prior to injury, LacZ was expressed in periosteum and select marrow cells (Figure 2.2A). At 3 days post-surgery, LacZ positive cells were observed at the defect margin (Figure 2.2 B) and, by 1 week, were present throughout the defect area (Figure 2.2 C). As the defect continued to heal and new bone formation was initiated (2 weeks post-surgery), strong *Ddr2* expression continued to be observed throughout the defect area, and some of the LacZ+ cells were lining the newly formed bone in the defect margin as well as center (Figure 2.2 D arrowhead). This expression continued in areas still actively forming new bone at 4 and 6 weeks (Fig 2.2 D-F). Note that, unlike wildtype mice that had totally healed the defect after 4-6 weeks, healing was still incomplete in *Ddr2^{+ /lacZ}* mice at these later times probably due to *Ddr2* haploinsufficiency. Note that no X-gal staining was seen in calvarial defects from WT littermates,

confirming the specificity of the X-gal staining (Figure 2.2 G). From these results, we conclude that *Ddr2* is expressed throughout the period of calvarial defect healing where it is necessary to support injury repair, and its expression varies depending on the healing stage.

Fate Mapping of *Ddr2*⁺ Cells

To determine the fate of *DDR2*⁺ cells and their progeny during calvarial defect healing, an SSD was generated in *Ddr2-Cre^{ERT}; Tdtomato* mice treated with tamoxifen for 3 consecutive days prior to surgery. TdTomato⁺ cells were then followed for up to 2 weeks (Figure 2.3). Similar to the localization of LacZ-positive cells in Figure 2.2, in unoperated control calvaria, TdTomato⁺ cells were located mainly in the periosteum and marrow of calvaria (Figure 2.3 B). As early as 3 days post-surgery, TdTomato⁺ cells had migrated into the defect area presumably from the adjacent periosteum (Figure 2.3 C). These cells or their progeny persisted in the defect site at two weeks post-surgery where they were associated with the surface of newly formed bone and in the middle of the defect (Figure 2.3 D). Thus, our results indicate that *Ddr2* positive cells can rapidly respond to injury by migrating into the defect site where they support injury repair.

Deletion of *Ddr2* Decreases Cell Proliferation

To investigate the cellular response to injury, we analyzed cell proliferation in the calvarial SSD region. We performed EdU incorporation analysis, which utilizes EdU to label newly synthesized DNA and applies a “click” chemistry reaction to detect the thymidine analog in native tissues using fluorescence²⁵. Three days post-surgery, *Ddr2^{slie/slie}* and WT mice were injected with EdU and sacrificed 4 hours after injection. As shown in Figure 2.4, DNA synthesis and, by inference, cell proliferation was reduced in defects from *Ddr2^{slie/slie}* mice by approximately 65

percent. These results suggest that Ddr2 is required for proliferation of cells at the injury site involved in regeneration of the calvarial defect.

Preosteoblast Markers are Reduced During Bone Regeneration.

Bone regeneration requires differentiation of mesenchymal stem cells to osteoblasts. To determine if Ddr2 status affected osteoblast differentiation during SSD healing, we measured osteoblast differentiation markers by immunofluorescence in 1-week post-surgery SSDs. Osterix/Sp7 (Osx), which is critical for osteoblast differentiation and bone formation ²⁷, was significantly decreased in Ddr2- deficient mice (Figure 2.5 A and B). In addition, phosphorylation of RUNX2, which is associated with osteoblast activity) and bone formation ^{26, 27}, trended toward a decrease in Ddr2- deficient mice ($p = 0.074$, Figure 2.5 C and D). Gli1, which is a skeletal stem cell marker, did not significantly decrease in this study. Together, these results suggest that DDR2 is required for osteogenic differentiation during bone regeneration, but may not control levels of skeletal stem cells in the defect site.

Discussion

Bone ECM plays important roles not only in bone development and maintenance, but also in the healing of bone injuries. Type I collagen is the core structural protein in the bone where collagen-mediated signaling is critical for tissue differentiation and mineralization²⁸⁻³⁰. Previous studies have been largely focused on collagen-binding integrins as mediators of the response to this ECM component. Knockout of individual collagen-binding integrins in mice resulted in relatively mild phenotypes³¹⁻³³ suggesting the involvement of other receptors in mediating collagen signaling

DDR2, a non-integrin collagen activated receptor tyrosine kinase, is critical for skeletal bone growth and development. However, its role in calvarial bone regeneration has not been previously explored. Our analysis of *Ddr2*-deficient mice indicates that proper DDR2 signaling is required for optimal calvarial bone regeneration. Whether measured by μ CT or histology, bone regeneration was clearly reduced in *Ddr2*^{slie/slie} mice. Complete bridging occurred in WT controls after as little as 4 weeks while in *Ddr2*^{slie/slie} mice some bone formation was seen on the margins of the defect, but complete bridging was never observed, even after 12 weeks (Figure 2.1 B-E). Quantitation of defect bone area by μ CT revealed that, as early as 2 weeks post-surgery, there is a significant decrease of bone formation in the *Ddr2*^{slie/slie} mice when compared with WT (Figure 2.1 F). Four weeks post-surgery, there was a 50% reduction in new bone volume in *Ddr2*^{slie/slie} mice versus controls and bone formation appeared to plateau after 6 weeks with no additional bone being present in 12 week samples.

Using LacZ staining, we localized *Ddr2* expression during calvarial bone regeneration. LacZ positive cells, which were present mainly in the periosteum of calvaria before surgery, were

expanded during the calvarial bone regeneration at the defect site (Figure 2.2). Also, LacZ positive cells were lining the new formed bone in the defect margin as well as center (Figure 2.2 D). To determine the fate of DDR2+ cells and their progeny during bone regeneration, we generated calvarial defects in *Ddr2-Cre^{ERT}; Tdtomato* mice and followed TdTomato+ cells for up to 2 weeks. Consistent with the *Ddr2-lacZ* studies, in calvaria without defects, TdTomato+ cells were mainly found in the periosteum with some additional positive cells in the bone marrow (Figure 2.3 B). However, 3 days post-surgery, TdTomato+ cells were detected in the defect area (Figure 2.3 C). The TdTomato+ area further expanded at the 2-week time point (Figure 2.3 D). Our result indicate that Ddr2 positive cells can respond to injury rapidly and expand to support injury repair. It has been reported that skeletal progenitor cells involved in cranial repair mainly resided in the periosteum, dura and the sutural mesenchyme³⁴, the same areas where we see DDR2 expression. In addition to skeletal progenitor cells, it is possible that DDR2 is expressed in other skeletal cells, such as in preosteoblast and osteoblast. These cells were present in the defect area 2 weeks post-surgery when active bone formation started and positive cells were detected lining newly formed bone in the middle of the defect as well as defect margins.

We demonstrated that Ddr2 is required for normal cell proliferation during calvarial defect regeneration. We showed that *Ddr2^{slie/slie}* mice have less EdU positive cells when compared to WT (Figure 2.4). This result is consistent with other studies that showed the *Ddr2*-deficient mice exhibited shortening of long bones and defective wound healing caused by a reduced proliferative response of chondrocytes and skin fibroblasts, respectively³⁵⁻³⁸. This could be one of the explanations for the defective bone regeneration seen in *Ddr2*-deficient mice.

Similar to bone injury healing, *Ddr2*-deficient mice exhibit delayed dermal wound healing, indicating that this receptor is also necessary for regeneration of skin³⁷. A possible cause of

impaired calvarial bone regeneration is a defect in osteoblast differentiation and/or function¹⁶. Our group and others showed that DDR2 plays an essential role in osteoblast differentiation^{16,39}. Bone changes in *Ddr2^{slie/slie}* mice were attributed to decreased bone formation due to defective osteoblast function¹⁶. Also, calvarial cells from *Ddr2^{slie/slie}* mice showed defective osteoblast differentiation in cell culture¹⁶. Consistent with our previous finding, we showed that preosteoblastic markers, *Osx* and p-RUNX2, were decrease during calvarial defect regeneration in *Ddr2^{slie/slie}* mice. These findings support the hypothesis that DDR2 is required for osteoblast differentiation and function. Bone healing is a well-organized process that includes multiple biological events and factors. More investigations are required to further understand DDR2 functions in bone regeneration.




Figure 2.1 *Ddr2^{slie/slie}* mice fail to heal a calvarial SSD. **(A)** H&E staining 3 days and 1 week post-surgery of SSD for WT and *Ddr2^{slie/slie}* mice. **(B-E)** Representative micro-CT and histological images of the defect area showing amount of bone regeneration. **(F)** Measurements are shown for regenerated bone volume/total volume. n = 6-8. dps= day post-surgery, wps = weeks post-surgery *P<0.05, ****P<0.0001. Scale bar 50um. Dash lines are estimated defect margin. P: periosteum. D: Dura




Figure 2.2 Localization and expression of DDR2 during calvarial bone regeneration. X-Gal staining of *Ddr2^{+/LacZ}* mouse calvaria. **(A)** No defect. **(B)** At 3dps, *Ddr2* expression is observed in the dura and the margin of the defect (arrowhead). **(C-F)** X-gal staining found in the defect at 1wps, markedly increase at 2wps, and continue to exist at 4wps and 6wps. Notice the arrowhead in **(D)** pointed to a LacZ⁺ cell lining the newly formed bone. **(G)** No X-Gal staining in the *Ddr2*^{+/+} control. Scale bar 25um. P: periosteum. D: Dura




Figure 2.3 Ddr2 positive cells migrate to the calvarial defect. (A) Time scheme for *Ddr2cre^{ERT}, Ai14 TdTomato* mice tamoxifen injections and calvarial SSD surgery. **(B)** A 10um thickness frozen section of mouse calvaria shows the distribution of Ddr2 positive cells without defect. **(C)** Three days post-surgery calvarial SSD shows that Ddr2 positive cells have migrated into the defect site. **(D)** Two weeks post-surgery of calvarial defect shows expansion of DDr2 positive cells or their progeny at the defect site, with some of them lining the newly formed bone in the defect. White arrowhead points to Ddr2 positive




Figure 2.4 DDR2 is required for cell proliferation during SSD healing. (A and B) Paraffin sections of calvarial defects from *Ddr2*^{-/-} and WT mice calvarial defect showed EdU+ cells in green and cell nuclei in blue (DAPI). **(C)** Quantification of EdU+ cells in both and WT mouse calvarial defect sections. * P<0.05. n = 4. Scale bar 50um




Figure 2.5 *Ddr2* deficiency results in decrease osteogenic differentiation markers during bone regeneration. Immunofluorescence staining (IF) 1-week post-surgery. **(A, C, and E)** IF for Osterix, p-RUNX2 and Gli1. **(B, D and F)** Percentage of positive cells over total cells. * $P < 0.05$. Scale bar 50 μ m. ns= not statistically significant, n = 4

References

1. Mansour A, Mezour MA, Badran Z, Tamimi F. Extracellular Matrices for Bone Regeneration: A Literature Review. *Tissue Engineering Part A* [Internet]. 2017 May 31 [cited 2017 Jul 31]; Available from: <https://doi.org/10.1089/ten.tea.2017.0026>
2. Polo-Corrales, M. Latorre-Esteves, and J.E. Ramirez-Vick Scaffold design for bone regeneration. *J Nanosci Nanotechnol* 14, 15, 2014.
3. S. Zeitouni, U. Krause, B.H. Clough, H. Halderman, A. Falster, D.T. Blalock, C.D. Chaput, H.W. Sampson, and C.A. Gregory Human mesenchymal stem cell-derived matrices for enhanced osteoregeneration. *Sci Transl Med* 4,132ra55, 2012.
4. Y. Loo, M. Goktas, A.B. Tekinay, M.O. Guler, C.A. Hauser, and A. Mitraki Self-assembled proteins and peptides as scaffolds for tissue regeneration. *Adv Healthcare Mater* 4, 2557, 2015.
5. K.R. Legate, S.A. Wickstrom, and R. Fassler Genetic and cell biological analysis of integrin outside-in signaling. *Genes Dev* 23, 397, 2009.
6. Pountos, I., Panteli, M., Lampropoulos, A., Jones, E., Calori, G. M., & Giannoudis, P. V. (2016). The role of peptides in bone healing and regeneration: a systematic review. *BMC medicine*, 14, 103. doi:10.1186/s12916-016-0646-y.
7. Reyes, C. D., Petrie, T. A., Burns, K. L., Schwartz, Z., & García, A. J. (2007). Biomolecular surface coating to enhance orthopaedic tissue healing and integration. *Biomaterials*, 28(21), 3228–3235. doi:10.1016/j.biomaterials.2007.04.003.
8. Ekholm, E., Hankenson, K. D., Uusitalo, H., Hiltunen, A., Gardner, H., Heino, J., & Penttinen, R. (2002), Diminished callus size and cartilage synthesis in alpha 1 beta 1

- integrin-deficient mice during bone fracture healing. *The American journal of pathology*, 160(5), 1779–1785.
9. Brunner M, Jurdic P, Tuckerman JP, Block MR, Bouvard D. (2013) Chapter One - New Insights into Adhesion Signaling in Bone Formation. *International Review of Cell and Molecular Biology* 305:1-68.
 10. Horton MA, Helfrich MH. Integrins and Development: Integrins in Skeletal Cell Function and Development. In: *Madame Curie Bioscience Database* [Internet]. Austin (TX): Landes Bioscience; 2000-2013. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK6331/>
 11. Docheva, D. , Popov, C. , Alberton, P. and Aszodi, A. (2014), Integrin signaling in skeletal development and function. *Birth Defect Res C*, 102: 13-36. doi:10.1002/bdrc.21059.
 12. Leitinger B. 2011. Transmembrane collagen receptors. *Annu Rev Cell Dev Biol*. 27:265-290.
 13. Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE, Davis S, Goldfarb MP, Glass DJ, Lemke G et al. 1997. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. *Mol Cell*. 1(1):25-34.
 14. Vogel W, Gish GD, Alves F, Pawson T. 1997. The discoidin domain receptor tyrosine kinases are activated by collagen. *Mol Cell*. 1(1):13-23.
 15. Fu, H. L., Valiathan, R. R., Arkwright, R., Sohail, A., Mihai, C., Kumarasiri, M., ... Fridman, R. (2013). Discoidin domain receptors: unique receptor tyrosine kinases in

- collagen-mediated signaling. *The Journal of biological chemistry*, 288(11), 7430–7437. doi:10.1074/jbc.R112.444158.
16. Ge, C. , Wang, Z. , Zhao, G. , Li, B. , Liao, J. , Sun, H. and Franceschi, R. T. (2016), Discoidin Receptor 2 Controls Bone Formation and Marrow Adipogenesis. *J Bone Miner Res*, 31: 2193-2203.
17. Kano, K., Marín de Evsikova, C., Young, J., Wnek, C., Maddatu, T. P., Nishina, P. M., & Naggert, J. K. (2008). A novel dwarfism with gonadal dysfunction due to loss-of-function allele of the collagen receptor gene, *Ddr2*, in the mouse. *Molecular endocrinology (Baltimore, Md.)*, 22(8),1866–1880.
18. Bargal, R., Cormier-Daire, V., Ben-Neriah, Z., Le Merrer, M., Sosna, J., Melki, J., ... Raas-Rothschild, A. (2009). Mutations in *DDR2* gene cause SMED with short limbs and abnormal calcifications. *American journal of human genetics*, 84(1), 80–84. doi: 10.1016/j.ajhg.2008.12.004.
19. Guo, Y., Yang, T. L., Dong, S. S., Yan, H., Hao, R. H., Chen, X. F., ... Deng, H. W. (2015). Genetic analysis identifies *DDR2* as a novel gene affecting bone mineral density and osteoporotic fractures in Chinese population. *PloS one*, 10(2), e0117102. doi: 10.1371/journal.pone.0117102.
20. Zhang, Y. , Su, J. , Yu, J. , Bu, X. , Ren, T. , Liu, X. and Yao, L. (2011), An essential role of discoidin domain receptor 2 (*DDR2*) in osteoblast differentiation and chondrocyte maturation via modulation of *Runx2* activation. *J Bone Miner Res*, 26: 604-617. doi:10.1002/jbmr.225.

21. Ge, C., Mohamed, F., Binrayes, A., Kapila, S., & Franceschi, R. T. (2018). Selective Role of Discoidin Domain Receptor 2 in Murine Temporomandibular Joint Development and Aging. *Journal of dental research*, 97(3), 321–328. doi:10.1177/0022034517738190.
22. Mizuhashi K, Ono W, Matsushita Y, Sakagami N, Takahashi A, Saunders TL, et al. (2018) Resting zone of the growth plate houses a unique class of skeletal stem cells. *Nature* 563:254-258.
23. Wilk, K., Yeh, S. A., Mortensen, L. J., Ghaffarigarakani, S., Lombardo, C. M., Bassir, S. H., ... Intini, G. (2017). Postnatal Calvarial Skeletal Stem Cells Expressing PRX1 Reside Exclusively in the Calvarial Sutures and Are Required for Bone Regeneration. *Stem cell reports*, 8(4), 933–946. doi:10.1016/j.stemcr.2017.03.002.
24. Park, S., Zhao, H., Urata, M., & Chai, Y. (2016). Sutures Possess Strong Regenerative Capacity for Calvarial Bone Injury. *Stem cells and development*, 25(23), 1801–1807. doi:10.1089/scd.2016.021.
25. Mead, T. J., & Lefebvre, V. (2014). Proliferation assays (BrdU and EdU) on skeletal tissue sections. *Methods in molecular biology (Clifton, N.J.)*, 1130, 233–243. doi:10.1007/978-1-62703-989-5_17.
26. Ge, C., Yang, Q., Zhao, G., Yu, H., Kirkwood, K. L., & Franceschi, R. T. (2012). Interactions between extracellular signal-regulated kinase 1/2 and p38 MAP kinase pathways in the control of RUNX2 phosphorylation and transcriptional activity. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, 27(3), 538–551. doi:10.1002/jbmr.561.

27. Yoshida, C. A., Komori, H., Maruyama, Z., Miyazaki, T., Kawasaki, K., Furuichi, T., ... Komori, T. (2012). SP7 inhibits osteoblast differentiation at a late stage in mice. *PloS one*, 7(3), e32364. doi:10.1371/journal.pone.0032364
28. Nijhuis WH, Eastwood DM, Allgrove J, Hvid I, Weinans HH, Bank RA, et al. (2019) Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management. *J Child Orthop* 13:1-11.
29. Kular, J. K., Basu, S., & Sharma, R. I. (2014). The extracellular matrix: Structure, composition, age-related differences, tools for analysis and applications for tissue engineering. *Journal of Tissue Engineering*. <https://doi.org/10.1177/2041731414557112>
30. Viguet-Carrin, S., Garnero, P. & Delmas, P.D. *Osteoporos Int* (2006). The role of collagen in bone strength. March, Volume 17, Issue 3, pp 319–336. <https://doi.org/10.1007/s00198-005-2035-9>.
31. Bengtsson T, Aszodi A, Nicolae C, Hunziker EB, Lundgren-Akerlund E, Fassler R. 2005. Loss of alpha10beta1 integrin expression leads to moderate dysfunction of growth plate chondrocytes. *J Cell Sci*. 118(Pt 5):929-936.
32. Gardner H, Kreidberg J, Koteliansky V, Jaenisch R. 1996. Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. *Dev Biol*. 175(2):301-313.
33. Holtkotter O, Nieswandt B, Smyth N, Muller W, Hafner M, Schulte V, Krieg T, Eckes B. 2002. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. *J Biol Chem*. 277(13):10789-10794.

34. Doro, D. H., Grigoriadis, A. E., & Liu, K. J. (2017). Calvarial Suture-Derived Stem Cells and Their Contribution to Cranial Bone Repair. *Frontiers in physiology*, 8, 956. doi:10.3389/fphys.2017.00956
35. Leiting B. (2014). Discoidin domain receptor functions in physiological and pathological conditions. *International review of cell and molecular biology*, 310, 39–87. doi:10.1016/B978-0-12-800180-6.00002-5.
36. Saby, C., Buache, E., Brassart-Pasco, S., El Btaouri, H., Courageot, M. P., Van Gulick, L., ... Morjani, H. (2016). Type I collagen aging impairs discoidin domain receptor 2-mediated tumor cell growth suppression. *Oncotarget*, 7(18), 24908–24927. doi:10.18632/oncotarget.8795.
37. Olaso, E., Lin, H. C., Wang, L. H., & Friedman, S. L. (2011). Impaired dermal wound healing in discoidin domain receptor 2-deficient mice associated with defective extracellular matrix remodeling. *Fibrogenesis & tissue repair*, 4(1), 5. doi:10.1186/1755-1536-4-5.
38. Labrador, J. P., Azcoitia, V., Tuckermann, J., Lin, C., Olaso, E., Mañes, S., ... Klein, R. (2001). The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. *EMBO reports*, 2(5), 446–452. doi:10.1093/embo-reports/kve094.
39. Zhang, Y. , Su, J. , Yu, J. , Bu, X. , Ren, T. , Liu, X. and Yao, L. (2011), An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation. *J Bone Miner Res*, 26: 604-617. doi:10.1002/jbmr.225

Chapter 3

Role of Discoidin Domain Receptor 2 in Tibial Fracture Healing

Abstract

Skeletal fractures are the most common large-organ, traumatic injuries in humans. Defective fracture healing is a major public health problem with approximately 10% of all fractures failing to heal properly. The fracture healing process requires extracellular matrix (ECM)-cell interactions mediated by cell surface receptors. Discoidin domain receptor 2 (DDR2), a non-integrin collagen-activated receptor tyrosine kinase, is an important ECM receptor in bone that is essential for normal skeletal growth and development. Here, we examine whether DDR2 is also required for fracture healing using *Ddr2^{slie/slie}* mice, which contain a spontaneous 150 kb deletion in the *Ddr2* locus to produce an effective null. We first defined the expression pattern of *Ddr2* during fracture healing using *Ddr2*-LacZ knock-in mice and *Ddr2*-*Cre^{ERT}*; *Tdtomato* mice. LacZ expression was first detected in select regions of the fracture site 2- and 5-days post fracture and expanded throughout the fracture callus after 1.5 and 3 weeks. Similar results were observed in *Ddr2*-*Cre^{ERT}*; *Tdtomato* mice. *Ddr2*⁺ cells and their progeny began to expand in the developing fracture callus 1.5-weeks post-fracture and continued to expand after 3 weeks. *Ddr2^{slie/slie}* mice exhibited significantly less fracture union than wild-type (WT) mice, and this defect was related to a decrease in cartilage formation as measured by safranin O staining. In addition, mutant mice developed significantly less callus tissue at 6 weeks post-fracture. To examine the role of DDR2 in skeletal progenitor cells (SPCs), we purified PDGFR α ⁺ CD51⁺ SPCs from bone marrow of

Ddr2^{fl/fl} mice using FACS followed by treatment with AdCre. *Ddr2* deletion resulted in defective osteoblast differentiation and accelerated adipogenesis. On the other hand, overexpression of DDR2 in a mesenchymal cell line (ST2 cells) increased osteoblast differentiation. Together, these results indicate that DDR2 is necessary for optimal fracture healing and this requirement may be explained in part by effects of DDR2 on SPC function.

Introduction

Bone loss due to trauma, neoplasia, congenital defects or periodontal disease is a major cause of disability and human suffering. For example, delayed healing or non-union, which occurs in 5-10% of all fractures and 20% of high impact fractures, prolongs patient morbidity, causes substantial pain and is associated with a significantly higher rate of healthcare resource use and per patient cost^{1,2}. The repair of a fractured long bone in adults recapitulates many of the steps of endochondral ossification, which occurs during embryonic bone development³. This fracture healing process, where sequential cellular and molecular events take place to generate new bone, has been thoroughly studied in humans as well as rodent models^{4, 5, 6, 7}. There is increasing evidence that during bone development and regeneration the extracellular matrix (ECM) profoundly influences major cellular programs, such as adhesion, migration, proliferation, and differentiation, via activation of cell surface ECM receptors^{8,9}. A clear understanding of these ECM receptors will facilitate the development of new bone regeneration strategies.

Bone and cartilage ECM are organized around type I and type II collagen fibers, respectively³. ECM enhances cell recruitment during bone regeneration through cell surface receptors. Collagen binding integrins are the main ECM receptor known to be important in the crosstalk between cells and the ECM. Integrin $\alpha1\beta1$ is a collagen receptor expressed on many mesenchymal cells^{3,4}. Integrins have clear roles in bone formation and regeneration, but they

don't explain the entire response of bone cells to ECM since bone-specific knockout of individual integrins only partially prevents bone formation and fracture healing^{3, 10, 11, 12}. Mice deficient in $\alpha 1$ integrin have no gross structural defects as well as show similar fracture union to WT mice³. The discoidin domain receptors 1 and 2 (DDR1 and DDR2) are another important class of ECM receptors¹³. Unlike integrins, DDRs have intrinsic tyrosine kinase activity and are selectively activated by triple-helical collagens^{14, 15}.

Both DDR1 and DDR2 are involved in multiple physiological processes, such as development, ECM turnover, growth regulation and cancer^{16, 17}. In bone, several lines of evidence suggest an important role for DDR2. In humans, *DDR2* mutations cause spondylo-meta-epiphyseal dysplasia (SMED), a skeletal disorder associated with dwarfism, bowing of long bones, craniofacial abnormalities, short fingers, and abnormal calcifications^{16, 18}. Also, in a Han Chinese population, polymorphisms in *DDR2* are associated with low bone mineral density (BMD) and fracture risk¹⁹. Consistent with the human phenotype, mice with a spontaneous *Ddr2* mutation, called smallie mice (*Ddr2^{slie/slie}*), have a SMED-like phenotype characterized by dwarfism and reduction in total bone mineral density^{16, 20}. Furthermore, detailed analysis of the bone phenotype in *Ddr2^{slie/slie}* mice revealed a dramatic reduction in mineral density of the cranial, axial, and appendicular skeleton due to reduction in osteoblast activity and bone formation in the absence of changes in resorption¹⁶. Bone changes were accompanied by a large increase in marrow fat¹⁶.

DDR2 is a key regulator of bone growth that controls several aspects of the process. However, it is not known if DDR2 is required for bone regeneration. Here, we investigate the functional importance of DDR2 in tibial fracture healing using a *Ddr2*-deficient mouse model and also define the expression and distribution of DDR2 during the fracture healing process. These

findings provide new insights into the role of cell-ECM interactions during fracture healing and may have important implications for understanding and enhancing bone regeneration.

Materials and Methods

Mice

Generation and genotyping of *Ddr2*^{slie/slie} mice and *Ddr2*-LacZ (*Ddr2*^{+/LacZ}) knock-in mice, where the bacterial LacZ gene is knocked into the *Ddr2* locus, was previously described^{16, 20, 21}. Studies also used *Ddr2*Cre^{ERT} mice recently developed by Dr. Barry Greenberg (UC San Diego). These mice contain Cre^{ERT} knocked in-frame into exon 2 of *Ddr2*. *Ddr2*Cre^{ERT} mice were crossed with Ai14 TdTomato mice provided by Dr. Noriaki Ono (University of Michigan, Ann Arbor)²². TdTomato mice harbor a targeted mutation of the Gt (ROSA) 26Sor locus with a loxP-flanked STOP cassette preventing transcription of a CAG promoter-driven red fluorescent protein variant (tdTomato); TdTomato is expressed following Cre-mediated recombination. *Ddr2*^{fl/fl} mice in which exon 8 of the *Ddr2* gene is flanked by two LoxP sequences were generated from a “knockout-first” ES cell clone *Ddr2*^{tm1a(EUCOMM)Wtsi}(EPD0607__B01) obtained from European Mutant Mouse Repository. To generate a *Ddr2* knockout first mouse line, ES cell transplantation was performed by the University of Michigan Transgenic Model core. To generate *Ddr2*^{fl/fl} mice, knockout first mice were crossed with FLPO mice to remove LacZ-Neo elements.

Tibia Fracture Model

All mouse experimental procedures conformed to standards for the use of laboratory animals and were approved by the Institutional Animal Care and Use Committee (IACUC) of the University of Michigan. The fracture method was previously described in detail^{23, 24}. Eight-week-old mice were maintained with general anesthesia (2% isoflurane/100% O₂) during the procedure

and received Buprenorphine (0.02mg/kg ip) and Carprofen (5mg/kg sc) for analgesia. Under sterile conditions, a small incision was made medial to the tibial tuberosity. A 26-gauge needle was used to bore a small hole into the medial-proximal cortex. The needle was withdrawn and replaced with a sterile 0.009-inch diameter stainless steel wire (McMaster-Carr) that was passed through the marrow space and compacted firmly into the distal tibial bone. The wire was trimmed flush with the femoral notch, the patella reduced, and the capsule and muscle fascia were closed using resorbable suture. Skin closure was performed using glue. While still anesthetized, mice were placed on a custom fabricated guillotine device, with the femoral mid-shaft placed on top of a two-point support surface. An anvil striker was placed on the antero-medial surface of the tibia at approximately mid-shaft. A weight of ~290 g was dropped from 8 cm to fracture the bone. Tibial “splints” were placed with surgical tape to prevent initial rotational instability to the fracture site over the first 48 hours ²⁵.

Micro-computed tomography analysis

Following euthanasia, carefully excised fracture repair constructs were scanned using an eXplore Locus SP microCT system (GE Healthcare). All specimens were scanned in water using the following parameters: voltage 80 kVp; current 80 μ A; exposure time 1600 ms; voxel size in the reconstructed image 18 μ m, isotropic. The data were processed and analyzed using MicroView (v2.1.2 Advanced Bone Application; GE Healthcare Preclinical Imaging). The fracture union was evaluated using a modified Radiographic Union Score for Tibia (mRUST) ²⁶. First, the image was reoriented in the MicroView so that the anterior-posterior and longitudinal axes were aligned with the principal image axes. Each tibial fracture on each of 4 cortices on anteroposterior (A-P) and lateral (Lat) were evaluated as follows: 1, no callus; 2, callus present; 3, bridging callus; 4,

remodeled and fracture line not visible. The minimum mRUST score is 4 and the maximum is 16. To avoid examiner bias, the genotype of mice was not known during analysis.

Safranin O staining

Fractured tibiae were fixed in 4% paraformaldehyde, decalcified in 10% ethylenediaminetetraacetic acid, embedded in paraffin, and sectioned longitudinally with a microtome. Sections were stained with 0.001% fast green and 0.1% safranin O. Images were acquired with an Eclipse E800 microscope (Nikon) and safranin O positive area were measured in a randomized and blind manner using the Bioquant Osteo software V17.2.6 (Bioquant Image Analysis Corp., Nashville, TN)

Detection of β -gal (LacZ) expression

Samples dissected from heterozygous *Ddr2-LacZ* (*Ddr2^{+LacZ}*) mice were processed for X-gal staining using standard procedures. Briefly, 10 μ m frozen sections were stained with freshly prepared X-gal solution and counterstained with Vector® Nuclear Fast Red.

Lentiviral Transduction

Full length human *DDR2* cDNA was subcloned into pLentiloxRSV-Puro using restriction sites XbaI and EcoRI. LentiDDR2 overexpression was transfected into 293T cells. Supernatant were collected 4 days after transfection. ST2 cells were plated at density 10,000 / cm² in 35 mm dishes. 1 ml Lentivirus supernatant was used to transduce ST2 overnight. 200 μ g/ ml Puromycin was used to select DDR2 stable transduced ST2 cells for 2 weeks. 50 μ g/ ml puromycin was used to maintain DDR2 stable expression ST2 cells.

Flow Cytometry

For PDGFR α CD51 sorting, bone marrow stromal cells (BMSCs) were harvested from tibia and femur of 12 weeks *Ddr2^{fl/fl}* mice by flushing the marrow cavity with digestion buffer (2mg/mL

Collagenase IV and 3mg/mL Dispase in 1xPBS) using 21G needle. Three digestion steps were carried out at 37°C with periodic agitate ion to obtain a single cell suspension. After each period of digestion, cells in suspension were collected into ice-cold staining buffer (1X PBS, 0.5% BSA, 2mM EDTA). For staining, cells were resuspended in staining buffer at a concentration of 1×10^6 cells/30ul in a solution containing the following antibodies: PDGFR α /CD140a-PECF594 (BD, clone APA5, 1:100) and CD51-PE (ebioscience, Clone RMV-7, 1:100). After staining, all samples were washed twice with staining buffer and resuspended in staining buffer with DAPI (1:10,000) for analysis and sorting. Analysis was carried out on an LSRII Fortessa flow cytometer (BD), sorting was performed on a FACSAria II (BD). Results were analyzed with FlowJo (v10.0.7) software ²⁷. The PDGFR α + CD51+ BM cells were plated at a density of 5×10^4 cells/cm² for adenovirus infection.

Cell cultures and *in vitro* differentiation

ST2 cells were obtained from Dr. Kurt Hankenson (University of Michigan, Ann Arbor) ²⁸. Osteoblast differentiation was induced in ST2 and sorted BMSCs cells from *Ddr2^{fl/fl}* mice by growth in α -MEM/10%FBS containing 50 μ g/ml ascorbic acid, 10 mM β -glycerophosphate and 3 μ M Chrion 99021 (Cayman Chemicals, Ann Arbor, MI) in ST2 only ¹⁶. For adipogenesis, cells were grown for 2 days in alpha minimal essential medium containing 10% FBS, insulin (5 μ g/ml), dexamethasone (1 μ M), IBMX (500 μ M), and troglitazone (5 μ M), followed by growth in medium containing troglitazone (5 μ M) only for up to 9 days ^{16, 29}. For gene expression analysis, total mRNA was isolated using TRIzol (Invitrogen), cDNA was synthesized, and quantitative RT-PCR was performed on the following mRNAs: *Ddr2*, *Runx2*, *Ibsp*, *Bglap*, *Paprr γ* , *Cebp* and *Fabp4* mRNA.

Statistical Analysis

All data was analyzed using the GraphPad Prism software version 7.0e, La Jolla California USA. Values were reported as mean \pm SD. Student's t test was used for statistical comparison between the two experimental groups. Differences were considered significant at $P < 0.05$. A sample size of 6 mice (including both sexes) was used for experiments.

Results

DDR2 is up-regulated after bone fracture

Fracture healing consists of a well-orchestrated series of events defined by distinct phases of anabolic (callus expansion) and catabolic (callus remodeling) responses to the injury^{27, 30, 31}. Resident MSCs in the skeleton (from the periosteum and bone marrow) provide the major source of progenitors for the repair process^{27, 32, 33, 34}. To explore a possible role for *Ddr2* genes in the repair process, the expression of DDR2 was examined following fracture injury of the tibia using *Ddr2^{+/LacZ}* knock-in mice (contain bacterial LacZ knocked into exon 8 of the *Ddr2* locus)²¹ (Figure 3.1). Prior to injury, LacZ was expressed mainly in the periosteum (Figure 3.1 A and B). As early as 2 days post-fracture, we observed LacZ staining in select condensed regions of cells within the fracture callus (Figure 3.1C-E). The LacZ-positive cell area progressively expanded as the fracture healing process progressed (5 days post-fracture, panels G-I; 1.5-weeks post-fracture, panels J-O; 3 weeks post-fracture, panels P-W). Initially, positive cells appeared to be associated with mesenchymal condensations and early chondrocytes (day 2 and 5) with subsequent association with putative osteoblasts on the bone surface after 1.5 and 3 weeks. From these results, we conclude that DDR2 is expressed throughout the fracture healing process, and its expression varied

depending on the healing stage. In addition, DDR2 may be expressed in skeletal progenitor cells, chondrocytes and osteoblast as healing proceeds.

To further trace the fate of *Ddr2* positive cells and their progeny during fracture healing, we induced *Ddr2-Cre^{ERT}; Tdtomato* mice at 2 months of age with tamoxifen and after one day performed fracture surgery (Figure 3.2 A). Numbers of animals and time points were limited in this experiment due to post-surgery mortality. However, results clearly showed that 1.5 week post-fracture, *Ddr2*⁺ cells had expanded at the fracture callus (Figure 3.2 C-E). Interestingly, 3 weeks post-fracture a dramatic increase in *Ddr2*⁺ cells was seen throughout fracture callus area (Figure 3.2 F-H). Thus, our results indicate that *Ddr2* positive cells and their progeny can respond to injury rapidly and expand to support regeneration.

***Ddr2* loss-of-function mice display defects during fracture healing**

To assess the role of *Ddr2* in fracture repair, tibial fractures were made in wild type and *Ddr2^{slie/slie}* mice (referred to as *Ddr2^{-/-}*). Histology sections, x-rays and micro-computed tomography (μ CT) scans performed at several time points following fracture injury revealed abnormal fracture healing in *Ddr2* mutants. During the early response to injury, 1.5 weeks post-fracture (WPF), there were no apparent differences in the fracture between mutants and WT (Figure 3.3 A). However, safranin O staining revealed a defect in cartilage formation in *Ddr2* mutant mice (Figure 3.3 B and C). By mid-stage healing (3 WPF) *Ddr2* mutant animals demonstrated a delay in fracture gap union. This was manifested as a reduction in mRUST score reflecting fewer bridged cortical sites in *Ddr2* mutants, but no difference in the callus volume (Figure 3.3 D-F). During remodeling stages of healing (6 WPF), two phenotypes were observed in *Ddr2* mutant animals. First, a significant number of animals exhibited non-union fractures; second,

the callus volume was significantly smaller in the *Ddr2* mutants (Figure 3.3 G-I). Thus, DDR2 is required for normal fracture healing.

Ddr2 is enriched in purified skeletal progenitor cells and is required for differentiation to osteoblasts.

We purified skeletal progenitor cells (SPCs) from whole marrow of *Ddr2^{loxp/loxp}* mice by FACS using stem cell markers, PDGFR α and CD51³⁶ (Figure 3.4 A). This population has properties of SPCs. It contains most of the colony forming activity of marrow, has high self-renewal capacity, gives rise to bone, supports hematopoiesis and exhibits multipotency (forms osteoblasts, adipocytes and chondrocytes)^{36, 37}. In addition, SPCs (from the periosteum and bone marrow) provide the major source of progenitors for the repair process^{27, 32, 33, 34}. *Ddr2* mRNA in this population was enriched approximately 10- fold versus total marrow nucleated cells (Figure 3.4 B). Cells were treated with control or Cre-expressing adenovirus and grown in osteogenic and adipogenic medium. AdCre treatment (*Ddr2* knockout) almost completely eliminated *Ddr2* mRNA, clearly reduced osteoblast differentiation markers *Runx2*, *bone sialoprotein*, *Bglap*, and increased adipogenesis markers *Paprr γ* , *Cebp* and *Fabp4* as measured by mRNA expression (Figure 3.4 C and D).

As further evidence that DDR2 promotes osteoblast differentiation of progenitor cells, we transduced a mesenchymal cell line (ST2 cells) with a lentivirus vector encoding full-length *Ddr2* cDNA. This increased DDR2 protein levels approximately 2-fold and increased osteoblast differentiation as measured by alizarin red staining and induction of the osteoblast markers, *bone*

sialoprotein, and *osteocalcin* (Figure 3.5). Together, these results provide strong evidence that DDR2 stimulates osteoblast differentiation of skeletal progenitor cells.

Discussion

Type I collagen, the core structural protein in bone, plays an important role during tissue differentiation and mineralization^{37, 38}. Previous studies have been largely focused on collagen-binding integrins as mediators of the response to this ECM component. Knockout of individual collagen-binding integrins in mice resulted in relatively mild phenotypes^{39, 40, 41}, however, suggesting the involvement of other receptors in mediating collagen signaling. DDR2, a non-integrin collagen activated receptor tyrosine kinase, is critical for skeletal bone growth and development. Our understanding of DDR2 in the skeleton is largely limited to the analysis of bone growth and development¹⁶. The aim of this study is to determine the function of DDR2 in the healing of tibial fractures.

Using LacZ staining in *Ddr2^{+LacZ}* mice, we localized DDR2 expression during fracture healing. In unfractured bones, DDR2 was expressed in the periosteum (Figure 3 A and B). As early as 2 days post-fracture, when a hematoma is present and an acute inflammatory immune response is initiated, we detected a few LacZ⁺ cells in select regions of the fracture callus (Figure 3.1 C-E). Five days post fracture, at the end of the hematoma stage and at the beginning of the soft callus stage, we see more LacZ⁺ cells in the fracture callus possibly associated with chondrocytes (Figure 3.1 G-I). In the soft callus stage 1.5-weeks post- fracture, a further expansion of LacZ⁺ cells were observed throughout the callus in apparent association with chondrocytes (Figure 3.1 J-O). At 3-weeks post fracture, which is a hard callus stage, we see strong *Ddr2* expression throughout the

callus in association with newly formed osteoblasts on the woven bone surface (Figure 3.1 P-W). These results indicate that Ddr2-expressing cells expand dramatically throughout fracture healing in progressive association with skeletal progenitor cells, chondrocytes and osteoblasts.

To determine the fate of DDR2⁺ cells and their progeny during fracture healing, we conducted fractures in *Ddr2-Cre^{ERT}; Tdtomato* mice and followed TdTomato⁺ cells for up to 3 weeks. Consistent with the Ddr2-lacZ studies, in unfractured bones, TdTomato⁺ cells were mainly found in the periosteum with some additional positive cells in the bone marrow (Figure 3.2 B). However, 1.5 weeks post-fracture, TdTomato⁺ cells were detected in the fracture callus (Figure 3.2 C-E). The TdTomato⁺ area further expanded at the 3 week time point such that the label was found throughout the callus (Figure 3.2 F-H). These results are consistent with the previous one and confirm that Ddr2⁺ cells are involved in fracture healing. They also indicate that the small number of Ddr2⁺ cells in the periosteum pre-fracture have greatly expanded during fracture healing such that their progeny are found throughout the callus at 3 weeks. This localization is consistent with Ddr2 being initially expressed in an SPC population in the periosteum that subsequently expands with bone injury to provide the chondrocytes and osteoblasts necessary for bone regeneration.

Our analysis of *Ddr2*-deficient mice indicates that proper DDR2 signaling is required for optimal fracture healing. Here, we show that Ddr2 knockout results in a decrease in fracture union 3- and 6-weeks post fracture. In addition, *Ddr2*-knockout mice have lower callus volume at 6 weeks post fracture when compared to WT littermates. Furthermore, safranin O staining revealed a defect in cartilage formation of *Ddr2*-knockout mice at 1.5 weeks post fracture compared with WT littermates. These results are similar to $\alpha 1$ integrin-deficient ($\alpha 1$ -KO) mice, where knockout mice show diminished callus size and cartilage synthesis³. Moreover, faulty matrix organization,

induced by using a lathyrogenic diet to prevent collagen cross-linking, has an effect similar to that observed in $\alpha 1$ -KO mice ⁴⁴, which suggesting that the organization of the collagenous matrix is important for integrin and DDR2 function. A previous study showed that DDR2 and integrins may interact during collagen stimulation with DDR2 enhancing integrin-mediated cell adhesion ⁴⁵.

Bone formation during adult fracture repair involves activation of SPCs, which then replicate and differentiate into osteoblasts and chondroblasts of the callus. Our results show that DDR2 is enriched in PDGFR α + and CD51+ SPCs. This is consistent with the localization of Ddr2 in unfractured tibia where LacZ+ cells were mainly seen in the periosteum, which consist mainly of SPCs ⁴⁶. This suggests that DDR2 is a SPCs marker. Furthermore, deletion of *Ddr2* in PDGFR α + and CD51+ SPCs *in vitro* reduced osteoblast differentiation and increased adipogenesis. Moreover, overexpression of *Ddr2* in the ST2 mesenchymal cell line increased osteoblast differentiation. This result indicates that DDR2 overexpression increases bone formation, and could be applied in tissue engineering and bone regeneration

Together, these results provide strong evidence that DDR2 stimulates osteoblast differentiation of skeletal progenitor cells. In addition, DDR2 is necessary for optimal fracture healing. DDR2 could be a possible target to stimulate bone formation and regeneration. However, further investigation is required to explain the mechanism of action of DDR2 in bone regeneration.




Figure 3.1 Expansion of DDR2 expression after bone fracture. X-Gal staining of *Ddr2*^{+/LacZ} mice (A and B) Unfractured control showing periosteal staining (arrowhead). (C-E) At 2dpf, Ddr2 expression is first observed next to the fracture area (G-I) At 5dps, LacZ⁺ cells observed next to the bone surface. (J-L) Beginning callus area before reaching bone surface and (M-O) fracture area of 1.5wpf, notice the expanded DDR2 expression. (P-R) Beginning callus area before reaching bone surface and (T-V) fracture area of 3wpf, DDR2 strongly expressed throughout fracture callus. (W) Scanned image shows the expansion of Ddr2 expression at 3wps. Arrowhead= LacZ⁺ cells. Scale bar 50um in (B, E, I, L, O, R, and V), 100um in (A, D, H, K, N, Q and U), 200 um (C, G, J, M, P, and T) and 300 um in (W)




Figure 3.2 Ddr2 positive cells expanded during fracture healing. (A) Time scheme for *Ddr2cre^{ERT}, Ai14 TdTomato* mice tamoxifen injections and fracture surgery. **(B)** A 10um thickness frozen section of mouse tibia shows the distribution of Ddr2 positive cells without fracture. **(C-E)** Ten days post-fracture, Ddr2+ cells expanded at fracture callus. **(F-H)** Three weeks post-fracture. Ddr2+ cells highly expanded at the fracture callus. Scale bar 3000um in (B, C, and F), 200um in (D and G), and 50um in (E and H)




Figure 3.3 DDR2 is necessary for normal fracture healing (A) Representative histological images of the fracture area 1.5-week post-fracture (WPF). **(B and C)** Quantifications of cartilage areas from Safranin O/Fast Green-stained sections at 1.5 WPF. Cartilage was designated by Safranin O. **(D and G)** Representative micro-CT and radiograph images showing amount of bone healing at 3 and 6 WPF. **(E and H)** Measurements are shown for mRUST (radiographic union scoring tibia fracture) and callus volume. **(F and I)** Representative histological images of the fracture area at 3 and 6 WPF. Scale bar 50um in (A, F and I) and 300um in (B), *P<0.05, **P<0.01, ***P<0.0001.




Figure 3.4 Loss of *Ddr2* in purified SPCs inhibits osteoblast lineage and stimulate adipogenesis. (A) A Schematic diagram of the experiment design shows nucleated marrow cells from *Ddr2^{loxp/loxp}* mice were enriched for SPCs by FACS (CD140a/PDGFR α ⁺, CD51⁺), and treated with AdLacZ or AdCre followed by osteogenic or adipogenic differentiation. (B) *Ddr2* expression in sorted SPCs. (C) *Ddr2*, *Runx2*, bone sialoprotein and osteocalcin mRNA expression. (D) *Pparg*, *Fabp*, *Cebp* mRNA expression. ** $P < 0.01$, *** $P < 0.0001$. Provided by Dr. Chunxi Ge




Figure 3.5 DDR2 stimulate osteoblast differentiation. (A) ST2 mesenchymal cells were transduced with a Ddr2 expressing lentivirus (DDR2 Western blot). (B) Mineralization at 14 days (Alizarin red stain). (C and D) Osteoblast mRNA; OCN, osteocalcin; BSP, bone sialoprotein. *P<0.05. Provided by Dr. Chunxi Ge

References

1. Bostrom MP, Saleh KJ, Einhorn TA. (1999), Osteoinductive growth factors in preclinical fracture and long bone defects models. *Orthop Clin North Am* 30 :647-58.
2. Antonova E, Le TK, Burge R, Mershon J. (2013), Tibia shaft fractures: costly burden of nonunions. *BMC Musculoskelet Disord* 14:42.
3. Ekholm, E., Hankenson, K. D., Uusitalo, H., Hiltunen, A., Gardner, H., Heino, J., & Penttinen, R. (2002), Diminished callus size and cartilage synthesis in alpha 1 beta 1 integrin-deficient mice during bone fracture healing. *The American journal of pathology*, 160(5), 1779–1785.
4. McKibbin B. (1978), The biology of fracture healing in long bones. *J Bone Joint Surg Br* 60B:150-16.
5. Jingushi, S. , Joyce, M. E. and Bolander, M. E. (1992), Genetic expression of extracellular matrix proteins correlates with histologic changes during fracture repair. *J Bone Miner Res*, 7: 1045-1055. doi:10.1002/jbmr.5650070907.
6. Hiltunen A, Aro HT, Vuorio E. (1993) Regulation of extracellular matrix genes during fracture healing in mice. *Clin Orthop Relat Res* (297):23-27.
7. Sandberg MM, Aro HT, Vuorio EI. (1993) Gene expression during bone repair. *Clin Orthop Relat Res* (289):292-312.
8. Zimmerman D, Jin F, Leboy P, Hardy S, Damsky C. (2000) Impaired bone formation in transgenic mice resulting from altered integrin function in osteoblasts. *Dev Biol* 220:2-15.
9. Damsky CH. (1999) Extracellular matrix–integrin interactions in osteoblast function and tissue remodeling. *Bone* 25:95-96.

10. Brunner M, Jurdic P, Tuckerman JP, Block MR, Bouvard D. (2013) Chapter One - New Insights into Adhesion Signaling in Bone Formation. *International Review of Cell and Molecular Biology* 305:1-68.
11. Horton MA, Helfrich MH. Integrins and Development: Integrins in Skeletal Cell Function and Development. In: *Madame Curie Bioscience Database* [Internet]. Austin (TX): Landes Bioscience; 2000-2013. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK6331/>
12. Docheva, D. , Popov, C. , Alberton, P. and Aszodi, A. (2014), Integrin signaling in skeletal development and function. *Birth Defect Res C*, 102: 13-36. doi:10.1002/bdrc.21059.
13. Leitinger B. 2011. Transmembrane collagen receptors. *Annu Rev Cell Dev Biol*. 27:265-290.
14. Shrivastava A, Radziejewski C, Campbell E, Kovac L, McGlynn M, Ryan TE, Davis S, Goldfarb MP, Glass DJ, Lemke G et al. 1997. An orphan receptor tyrosine kinase family whose members serve as nonintegrin collagen receptors. *Mol Cell*. 1(1):25-34.
15. Vogel W, Gish GD, Alves F, Pawson T. 1997. The discoidin domain receptor tyrosine kinases are activated by collagen. *Mol Cell*. 1(1):13-23.
16. Ge, C., Wang, Z., Zhao, G., Li, B., Liao, J., Sun, H., & Franceschi, R. T. (2016). Discoidin Receptor 2 Controls Bone Formation and Marrow Adipogenesis. *Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research*, 31(12), 2193–2203. doi:10.1002/jbmr.2893.
17. Fu, H. L., Valiathan, R. R., Arkwright, R., Sohail, A., Mihai, C., Kumarasiri, M., ... Fridman, R. (2013). Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. *The Journal of biological chemistry*, 288(11), 7430–7437. doi:10.1074/jbc.R112.444158.

18. Bargal, R., Cormier-Daire, V., Ben-Neriah, Z., Le Merrer, M., Sosna, J., Melki, J., ... Raas-Rothschild, A. (2009). Mutations in DDR2 gene cause SMED with short limbs and abnormal calcifications. *American journal of human genetics*, 84(1), 80–84. doi: 10.1016/j.ajhg.2008.12.004.
19. Guo, Y., Yang, T. L., Dong, S. S., Yan, H., Hao, R. H., Chen, X. F., ... Deng, H. W. (2015). Genetic analysis identifies DDR2 as a novel gene affecting bone mineral density and osteoporotic fractures in Chinese population. *PloS one*, 10(2), e0117102. doi: 10.1371/journal.pone.0117102.
20. Kano, K., Marín de Evsikova, C., Young, J., Wnek, C., Maddatu, T. P., Nishina, P. M., & Naggert, J. K. (2008). A novel dwarfism with gonadal dysfunction due to loss-of-function allele of the collagen receptor gene, *Ddr2*, in the mouse. *Molecular endocrinology (Baltimore, Md.)*, 22(8), 1866–1880. doi:10.1210/me.2007-0310.
21. Ge, C., Mohamed, F., Binrayes, A., Kapila, S., & Franceschi, R. T. (2018). Selective Role of Discoidin Domain Receptor 2 in Murine Temporomandibular Joint Development and Aging. *Journal of dental research*, 97(3), 321–328. doi:10.1177/0022034517738190.
22. Mizuhashi K, Ono W, Matsushita Y, Sakagami N, Takahashi A, Saunders TL, et al. (2018) Resting zone of the growth plate houses a unique class of skeletal stem cells. *Nature* 563:254-258.
23. Hiltunen A, Vuorio E, Aro HT. 1993 A standardized experimental fracture in the mouse tibia. *Journal of orthopaedic research: official publication of the Orthopaedic Research Society*. 11(2):305-12.
24. Taylor DK, Meganck JA, Terkhorn S, Rajani R, Naik A, O'Keefe RJ, et al. 2009 Thrombospondin-2 influences the proportion of cartilage and bone during fracture healing.

Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research.24(6):1043-54.

25. Rux, D. R., Song, J. Y., Pineault, K. M., Mandair, G. S., Swinehart, I. T., Schlientz, A. J., ... Wellik, D. M. (2017). Hox11 Function Is Required for Region-Specific Fracture Repair. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, 32(8), 1750–1760. doi:10.1002/jbmr.3166.
26. Cooke, M. E., Hussein, A. I., Lybrand, K. E., Wulff, A., Simmons, E., Choi, J. H., ... Tornetta, P., 3rd (2018). Correlation between RUST assessments of fracture healing to structural and biomechanical properties. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*, 36(3), 945–953. doi:10.1002/jor.23710.
27. Rux, D. R., Song, J. Y., Swinehart, I. T., Pineault, K. M., Schlientz, A. J., Trulik, K. G., ... Wellik, D. M. (2016). Regionally Restricted Hox Function in Adult Bone Marrow Multipotent Mesenchymal Stem/Stromal Cells. *Developmental cell*, 39(6), 653–666. doi:10.1016/j.devcel.2016.11.008.
28. Ogawa, M., Nishikawa, S., Ikuta, K., Yamamura, F., Naito, M., Takahashi, K., & Nishikawa, S. (1988). B cell ontogeny in murine embryo studied by a culture system with the monolayer of a stromal cell clone, ST2: B cell progenitor develops first in the embryonal body rather than in the yolk sac. *The EMBO journal*, 7(5), 1337–1343.
29. Cawthorn, W. P., Bree, A. J., Yao, Y., Du, B., Hemati, N., Martinez-Santibañez, G., & MacDougald, O. A. (2012). Wnt6, Wnt10a and Wnt10b inhibit adipogenesis and stimulate osteoblastogenesis through a β -catenin-dependent mechanism. *Bone*, 50(2), 477–489. doi:10.1016/j.bone.2011.08.010.

30. Schindeler A, McDonald MM, Bokko P, Little DG. (2008) Bone remodeling during fracture repair: The cellular picture. *Seminars in Cell & Developmental Biology* 19:459-466.
31. Einhorn, T. A., & Gerstenfeld, L. C. (2015). Fracture healing: mechanisms and interventions. *Nature reviews. Rheumatology*, 11(1), 45–54. doi:10.1038/nrrheum.2014.164.
32. Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G., & Morrison, S. J. (2014). Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. *Cell stem cell*, 15(2), 154–168. doi:10.1016/j.stem.2014.06.008.
33. Colnot C. (2009). Skeletal cell fate decisions within periosteum and bone marrow during bone regeneration. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research*, 24(2), 274–282. doi:10.1359/jbmr.081003.
34. Worthley, D. L., Churchill, M., Compton, J. T., Taylor, Y., Rao, M., Si, Y., ... Wang, T. C. (2015). Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. *Cell*, 160(1-2), 269–284. doi:10.1016/j.cell.2014.11.042.
35. Bouxsein, M. L., Boyd, S. K., Christiansen, B. A., Guldberg, R. E., Jepsen, K. J. and Müller, R. (2010), Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. *J Bone Miner Res*, 25: 1468-1486. doi:10.1002/jbmr.141.
36. Pinho S, Lacombe J, Hanoun M, et al. . 2013 PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. *J Exp Med* 210(7):1351-67.

37. Mendez-Ferrer S, Michurina TV, Ferraro F, et al. 2010 Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. *Nature*.;466(7308):829-34. Wilk, K., Yeh, S. A., Mortensen, L. J., Ghaffarigarakani, S., Lombardo, C. M., Bassir, S. H., ... Intini, G. (2017). Postnatal Calvarial Skeletal Stem Cells Expressing PRX1 Reside Exclusively in the Calvarial Sutures and Are Required for Bone Regeneration. *Stem cell reports*, 8(4), 933–946. doi:10.1016/j.stemcr.2017.03.002.
38. Park, S., Zhao, H., Urata, M., & Chai, Y. (2016). Sutures Possess Strong Regenerative Capacity for Calvarial Bone Injury. *Stem cells and development*, 25(23), 1801–1807. doi:10.1089/scd.2016.021.
39. Bengtsson T, Aszodi A, Nicolae C, Hunziker EB, Lundgren-Akerlund E, Fassler R. 2005. Loss of alpha10beta1 integrin expression leads to moderate dysfunction of growth plate chondrocytes. *J Cell Sci*. 118(Pt 5):929-936.
40. Gardner H, Kreidberg J, Koteliansky V, Jaenisch R. 1996. Deletion of integrin alpha 1 by homologous recombination permits normal murine development but gives rise to a specific deficit in cell adhesion. *Dev Biol*. 175(2):301-313.
41. Holtkotter O, Nieswandt B, Smyth N, Muller W, Hafner M, Schulte V, Krieg T, Eckes B. 2002. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. *J Biol Chem*. 277(13):10789-10794.
42. Marsell, R., & Einhorn, T. A. (2011). The biology of fracture healing. *Injury*, 42(6), 551–555. doi:10.1016/j.injury.2011.03.031.
43. Einhorn TA, Gerstenfeld LC. (2015) Fracture healing: mechanisms and interventions. *Nat Rev Rheumatol* 11:45-54.

44. Ekholm EC, Ravanti L, Kähäri V-, Paavolainen P, Penttinen RPK. (2000) Expression of extracellular matrix genes: transforming growth factor (TGF)- β 1 and ras in tibial fracture healing of lathyritic rats. *Bone* 27:551-557.
45. Xu, H., Bihan, D., Chang, F., Huang, P. H., Farndale, R. W., & Leitingner, B. (2012). Discoidin domain receptors promote α 1 β 1- and α 2 β 1-integrin mediated cell adhesion to collagen by enhancing integrin activation. *PloS one*, 7(12), e52209. doi:10.1371/journal.pone.0052209.
46. Bahney, C. S., Zondervan, R. L., Allison, P., Theologis, A., Ashley, J. W., Ahn, J., ... Hankenson, K. D. (2019). Cellular biology of fracture healing. *Journal of orthopaedic research : official publication of the Orthopaedic Research Society*, 37(1), 35–50. doi:10.1002/jor.24170

Chapter 4

Summary and Conclusion

Bone extracellular matrix (ECM) plays important roles not only in bone development and maintenance, but also in the healing of bone injuries. Type I collagen is the core structural protein in the bone where collagen-mediated signaling is critical for tissue differentiation and mineralization¹⁻³. ECM is formed by deposited a collagen-rich matrix by osteoblasts that mineralizes to become bone⁴. Osteoblasts arise from skeletal stem cell (SSC). The osteogenic differentiation of SSC involves SSC-ECM interactions that promote and support the SSC commitment to a certain cellular lineage. In addition, ECM is one of the most important components of SSC niche. Many studies reported on how SSCs sense and respond to signals from the ECM at the molecular level, and how these signals regulate SSC fate^{5,6}. This SSC-ECM interaction is processed by ECM surface receptors in SSC.

Integrins are the classical receptor proteins that cells use to both bind and respond to the ECM. Integrins $\alpha 1 \beta 1$, $\alpha 2 \beta 1$ and $\alpha 1 \beta 1$ are the main integrins responsible for the binding of bone-forming cells to type I collagen⁷ although other integrins such as $\alpha 5 \beta 1$ may also be involved in mechanotransduction⁷. Binding of integrins to the ECM initiates clustering, cell adhesion and intracellular signaling leading to complex conformational changes that promote high-affinity extracellular ligand binding, as well as activation of signaling proteins including FAK, Rho, Rac

and integrin-linked protein kinase (ILK) ^{8, 9}. Mice with targeted integrin subunit deletion in bone (i.e., $\beta 1$ and αv) have an embryonic lethal phenotype, making it difficult to analyze their function during osteogenesis ¹⁰⁻¹³. Because of that, integrins have also been ablated during osteoblast differentiation using the Cre/LoxP conditional deletion system. However, the affected mice do not suffer from major skeletal defects ¹⁰, which suggests that other ECM receptors may be required for bone formation.

Another class of ECM receptors are the discoidin domain receptors (DDR). DDRs are receptor tyrosine kinases (RTKs) that contain a discoidin homology domain in their extracellular regions ^{14, 15}. DDRs are collagen receptors that differ from collagen-binding integrins in that they have intrinsic tyrosine kinase activity and selective affinity for triple-helical, native fibrillar and non-fibrillar collagens ¹⁴. There are two types of DDRs, DDR1 and DDR2. Both DDR1 and DDR2 are involved in multiple physiological processes, such as development, ECM turnover, growth regulation and cancer ^{14, 16}. In bone, several lines of evidence suggest an important role for DDR2. In humans, DDR2 mutations cause spondylo-meta-epiphyseal dysplasia (SMED), a skeletal disorder associated with dwarfism, bowing of long bones, craniofacial abnormalities, short fingers, and abnormal calcifications ^{14, 17}. Also, in a Han Chinese population, polymorphisms in DDR2 are associated with low bone mineral density (BMD) and fracture risk ¹⁸. Consistent with the human phenotype, mice with a spontaneous *Ddr2* mutation, called smallie mice (*Ddr2^{slie/slie}*), have a SMED-like phenotype characterized by dwarfism and reduction in total bone mineral density ^{14, 19}. Furthermore, detailed analysis of the bone phenotype in *Ddr2^{slie/slie}* mice revealed a dramatic reduction in mineral density of the cranial, axial, and appendicular skeleton due to reduction in osteoblast activity and bone formation in the absence of changes in resorption ¹⁴. Bone changes were accompanied by a large increase in marrow fat.

Bone possesses an intrinsic capacity for regeneration as part of the repair process in response to injury as well as during skeletal development and during the continuous remodeling that occurs throughout adult life ²⁰. Bone extracellular matrix plays important roles not only in bone development and maintenance, but also in response to bone injury and fracture. Studies of bone healing indicate that resident stem or progenitor cells interact with the ECM to orchestrate a complex signaling cascade leading to tissue regeneration and remodeling ²¹. Dysregulation of proteins mediating ECM interactions is implicated in several deformities affecting bone structure and regeneration ²². Type I collagen is the core structural protein in bone where collagen-mediated signaling is critical for tissue differentiation and mineralization ²¹⁻²³. Collagen receptor, DDR2, is a key regulator of bone growth that controls several aspects of this process. However, it is not known if DDR2 is required for bone regeneration. In this thesis, we examined the functional importance of the collagen receptor, DDR2, in bone regeneration using 2 regeneration models; a calvarial subcritical defect and tibial fracture.

In calvarial bone regeneration, we show that DDR2 is essential for regeneration of a subcritical-size 0.5mm defect. *Ddr2^{slie/slie}* mice are unable to heal a defect that, in wild type mice, can spontaneously heal within 4 weeks. Also, *Ddr2* expression during calvarial bone regeneration was defined using *Ddr2-LacZ* knock-in mice and β -galactosidase staining. *Ddr2* expression, which was restricted to periosteal surfaces of uninjured calvarial bone, greatly expanded with injury. Similar results were seen when the lineage of *Ddr2*-expressing cells was examined using *Ddr2cre^{ERT}*, *Ai14 TdTomato* mice. *Ddr2* positive cells and their progeny expanded within the defect three days and two weeks post-surgery. Furthermore, three days post-surgery, *Ddr2^{slie/slie}* mice showed a significant decrease in cell proliferation in the calvarial defect when compared with

WT littermates. Lastly, levels of the preosteoblast markers, Osterix and phosphorylated RUNX2 (S319-P) decreased in *Ddr2^{slie/slie}* mice, which suggests that osteoblast differentiation was arrested.

The regeneration of a fractured long bone was also studied in *Ddr2^{slie/slie}* mice. As was done with the calvarial defect, we first defined the expression pattern of DDR2 during fracture healing using *Ddr2-LacZ* knock-in mice and *Ddr2-Cre^{ERT}; Tdtomato* mice. LacZ expression was first detected in select regions of the fracture site 2- and 5-days post fracture and expanded throughout the fracture callus after 1.5 and 3 weeks. Similar results were observed in *Ddr2-Cre^{ERT}; Tdtomato* mice. *Ddr2⁺* cells and their progeny began to expand in the developing fracture callus 1.5-weeks post-fracture and continued to expand after 3 weeks. *Ddr2^{slie/slie}* mice exhibited significantly less fracture union than wild-type (WT) mice, and this defect was related to a decrease in cartilage formation as measured by safranin O staining. In addition, mutant mice developed significantly less callus tissue at 6 weeks post-fracture. To examine the role of DDR2 in skeletal progenitor cells (SPCs), we purified PDGFR α ⁺ CD51⁺ SPCs from bone marrow of *Ddr2^{fl/fl}* mice using FACS followed by treatment with AdCre. *Ddr2* deletion resulted in defective osteoblast differentiation and accelerated adipogenesis. On the other hand, overexpression of DDR2 in a mesenchymal cell line (ST2 cells) increased osteoblast differentiation. These results suggest that DDR2 can directly act on SPCs to promote osteoblast differentiation and may at least in part explain the regenerative defects we observed.

Conclusion

The information gained from these studies has the potential to positively affect and enhance bone regeneration. Understanding the link between cell-ECM interactions mediated by cell surface receptors and bone regeneration may lead to the development of new regeneration strategies. DDR2, which binds and is activated by a triple-helical fibrillar collagen, is required for calvarial bone regeneration as well as fracture healing. This requirement may be explained in part by effects of DDR2 on proliferation, SPCs function and osteoblast differentiation. We showed that SPCs are enriched in DDR2, and DDR2 was expressed in periosteum of tibia and calvaria, which consist mainly of SPCs. In addition, unpublished data from our lab (data not shown) shows that DDR2⁺ cells are present in the calvarial suture, which has been reported to be the niche for SPCs for craniofacial bone homeostasis and repair ²¹. These results suggest that DDR2 could be a SPCs marker for a specific SPCs subpopulation, since recent study provided evidence that bone contains multiple pools of stem cells, each with distinct physiologic functions ²⁴. In addition to SPCs, we think that DDR2 is expressed in other skeletal cells, such as preosteoblast and prechondrocyte, and osteoblast according to the LacZ localization.

Cell-ECM interaction is important for multiple cellular functions including cell proliferation, cell adhesion, migration, and ECM remodeling.²⁵⁻²⁷. The decrease in cell proliferation in *Ddr2*-deficient mice we observed could be due to defective cell-ECM interaction. We speculate that one of the reasons for defective cell-ECM interaction is abnormal collagen cross-linking in *Ddr2*-deficient mice. Khosravi and colleagues showed that DDR2 mediates collagen induction of lysyl oxidase enzyme-dependent collagen cross-links ²⁸, and knockdown of DDR2 with shRNA in differentiating primary rat osteoblasts largely suppressed collagen induction of lysyl oxidase ²⁸. Also, the authors suggest that integrin signaling potentially cooperates with DDR2

in collagen induction of lysyl oxidase ²⁸. This notion is supported by a study that shows DDR2 interacts with integrins in mediating cell adhesion to collagen ²⁹. In unpublished studies, we observed abnormal organization of type II collagen in growth plates of *Ddr2*-deficient mice which could affect activation of both DDR2 and integrins. Defective cell-ECM interactions could affect multiple cellular functions, such as cell proliferation, migration, differentiation, and ECM remodeling. It is possible that in the absence of *Ddr2*, an abnormal collagen matrix is formed which reciprocally alters the ability of cells to respond to matrix either through integrins or other matrix receptors. How *Ddr2* affects matrix structure could be the focus of future studies.

Proper differentiation and functioning of osteoblast is essential for bone homeostasis and regeneration. Our group and others showed that DDR2 plays an essential role in osteoblast differentiation ^{14,30}. Bone changes in *Ddr2*^{*slie/slie*} mice were attributed to decreased bone formation due to defective osteoblast function ¹⁴. Also, calvarial cells from *Ddr2*^{*slie/slie*} mice showed defective osteoblast differentiation in cell culture ¹⁴. Consistent with our previous finding, we showed that preosteoblastic markers, *Osx* and p-RUNX2, were decrease during calvarial defect regeneration in *Ddr2*^{*slie/slie*} mice. In addition, deletion of *Ddr2* in PDGFR α ⁺ and CD51⁺ SPCs *in vitro* reduced osteoblast differentiation and increased adipogenesis. These findings support the hypothesis that DDR2 is required for osteoblast differentiation and function

There are several experiments that could be done to help us understanding the function of DDR2 in certain cell populations during bone regeneration. Our lab developed *Ddr2*^{*loxp/loxp*} mice that can be combined with tissue selective Cre mice to disrupt *Ddr2* in specific cell populations during bone regeneration. *Ddr2*^{*loxp/loxp*} mice could be crossed with the following TAM-inducible Cre mice: *Gli1CreERT* ³¹ for knockout in cranial and long bone SPCs ³², *Col2a1CreERT* for

knockout in chondrocytes³³ or *2.3Colla2CreERT* for knockout in osteoblasts³⁴. By performing these experiments, it will be possible to determine the major cellular sites of Ddr2 action.

Despite the unique capacity of bone tissue for self-repair, there are situations in which its regenerative potential is limited or associated with complications. In my field, dental practice, the bone loss that develops after tooth loss, periodontal disease, or trauma often requires extensive horizontal and/or vertical regeneration procedures. Tissue engineered scaffolds that improve cell-ECM interactions have been used and studied in order to enhance bone regeneration. For example, peptides containing integrin binding domains of type I collagen (GFOGER) coupled to tissue engineered scaffolds have been successfully used to stimulate bone regeneration³⁵⁻³⁸. However, the integrin-activating tissue engineered scaffolds examined to date do not approach the activity of bone autografts, the "gold standard" for bone regeneration³⁹. We showed that overexpression of DDR2 in the ST2 mesenchymal cell line increases osteoblast differentiation. This suggests that manipulation of DDR2 levels or activity represent potential new routes for stimulating SPC osteogenic differentiation and bone regeneration. DDR2 binds and is activated by a unique triple-helical sequence present in fibrillar collagens (core sequence GVMGF-HO-Pro)⁴⁰. Peptides containing this sequence do not bind integrins or directly stimulate integrin activity, but increase integrin-mediated collagen binding and downstream signaling^{29,40}. A possible future direction for our research would be to couple the DDR2-binding peptide sequence (GVMGF) alone or combined with integrin peptide sequence (GFOGER) to tissue engineered scaffolds to stimulate and enhance bone regeneration. In addition, dental implants could be coated with DDR2 and integrin peptides to improve peri-implant bone regeneration and osseointegration^{36,37,41}.

References

1. Nijhuis WH, Eastwood DM, Allgrove J, Hvid I, Weinans HH, Bank RA, et al. (2019) Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management. *J Child Orthop* 13:1-11.
2. Kular, J. K., Basu, S., & Sharma, R. I. (2014). The extracellular matrix: Structure, composition, age-related differences, tools for analysis and applications for tissue engineering. *Journal of Tissue Engineering*. <https://doi.org/10.1177/2041731414557112>
3. Viguet-Carrin, S., Garnero, P. & Delmas, P.D. *Osteoporos Int* (2006). The role of collagen in bone strength. March, Volume 17, Issue 3, pp 319–336. <https://doi.org/10.1007/s00198-005-2035-9>.
4. Crockett JC, Rogers MJ, Coxon FP, Hocking LJ, Helfrich MH. 2011. Bone remodeling at a glance. *J Cell Sci.* 124(7):991. doi:10.1242/jcs.063032.
5. Assis-Ribas T, Forni MF, Winnischofer SMB, Sogayar MC, Trombetta-Lima M. (2018) Extracellular matrix dynamics during mesenchymal stem cells differentiation. *Developmental Biology* 437:63-74.
6. Jhala D, Vasita R. (2015) A Review on Extracellular Matrix Mimicking Strategies for an Artificial Stem Cell Niche. *Polymer Reviews* 55:561-595.

7. Franceschi, R. T., & Ge, C. (2017). Control of the Osteoblast Lineage by Mitogen-Activated Protein Kinase Signaling. *Current molecular biology reports*, 3(2), 122–132. doi:10.1007/s40610-017-0059-5.
8. Marie PJ. (2013) Targeting integrins to promote bone formation and repair. *Nat Rev Endocrinol* 9:288-295.
9. Mitra SK, Schlaepfer DD. (2006) Integrin-regulated FAK–Src signaling in normal and cancer cells. *Current Opinion in Cell Biology* 18:516-523.
10. Brunner M, Jurdic P, Tuckerman JP, Block MR, Bouvard D. (2013) Chapter One - New Insights into Adhesion Signaling in Bone Formation. *International Review of Cell and Molecular Biology* 305:1-68.
11. Bader BL, Rayburn H, Crowley D, Hynes RO. (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. *Cell* 95:507-519.
12. Fassler R, Meyer M. (1995) Consequences of lack of beta 1 integrin gene expression in mice. *Genes Dev* 9:1896-1908.
13. Stephens LE, Sutherland AE, Klimanskaya IV, Andrieux A, Meneses J, Pedersen RA, et al. (1995) Deletion of beta 1 integrins in mice results in inner cell mass failure and peri-implantation lethality. *Genes Dev* 9:1883-1895.
14. Ge, C., Wang, Z., Zhao, G., Li, B., Liao, J., Sun, H., & Franceschi, R. T. (2016). Discoidin Receptor 2 Controls Bone Formation and Marrow Adipogenesis. *Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research*, 31(12), 2193–2203. doi:10.1002/jbmr.2893.

15. Vogel W. (1999) Discoidin domain receptors: structural relations and functional implications. *The FASEB Journal* 13:S77-S82.
16. Fu, H. L., Valiathan, R. R., Arkwright, R., Sohail, A., Mihai, C., Kumarasiri, M., ... Fridman, R. (2013). Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. *The Journal of biological chemistry*, 288(11), 7430–7437. doi:10.1074/jbc.R112.444158.
17. Bargal, R., Cormier-Daire, V., Ben-Neriah, Z., Le Merrer, M., Sosna, J., Melki, J., ... Raas-Rothschild, A. (2009). Mutations in DDR2 gene cause SMED with short limbs and abnormal calcifications. *American journal of human genetics*, 84(1), 80–84. doi:10.1016/j.ajhg.2008.12.004.
18. Guo, Y., Yang, T. L., Dong, S. S., Yan, H., Hao, R. H., Chen, X. F., ... Deng, H. W. (2015). Genetic analysis identifies DDR2 as a novel gene affecting bone mineral density and osteoporotic fractures in Chinese population. *PloS one*, 10(2), e0117102. doi:10.1371/journal.pone.0117102.
19. Kano, K., Marín de Evsikova, C., Young, J., Wnek, C., Maddatu, T. P., Nishina, P. M., & Naggert, J. K. (2008). A novel dwarfism with gonadal dysfunction due to loss-of-function allele of the collagen receptor gene, *Ddr2*, in the mouse. *Molecular endocrinology (Baltimore, Md.)*, 22(8), 1866–1880. doi:10.1210/me.2007-0310.
20. Dimitriou R, Jones E, McGonagle D, Giannoudis PV. (2011) Bone regeneration: current concepts and future directions. *BMC Med* 9:66-7015-9-66.
21. Park, S., Zhao, H., Urata, M., & Chai, Y. (2016). Sutures Possess Strong Regenerative Capacity for Calvarial Bone Injury. *Stem cells and development*, 25(23), 1801–1807. doi:10.1089/scd.2016.0211.

22. Nijhuis WH, Eastwood DM, Allgrove J, Hvid I, Weinans HH, Bank RA, et al. (2019) Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management. *J Child Orthop* 13:1-11.
23. Vignuet-Carrin, S., Garnero, P. & Delmas, P.D. *Osteoporos Int* (2006). The role of collagen in bone strength. March, Volume 17, Issue 3, pp 319–336. <https://doi.org/10.1007/s00198-005-2035-9>.
24. Debnath, S., Yallowitz, A. R., McCormick, J., Lalani, S., Zhang, T., Xu, R., ... Greenblatt, M. B. (2018). Discovery of a periosteal stem cell mediating intramembranous bone formation. *Nature*, 562(7725), 133–139. doi:10.1038/s41586-018-0554-8.
25. Kawai I, Matsumura H, Fujii W, Naito K, Kusakabe K, Kiso Y, et al. Discoidin domain receptor 2 (DDR2) regulates body size and fat metabolism in mice. *Transgenic Res* 2014; 2013;23(1):165. doi: 10.1007/s11248-013-9751-2.
26. Agarwal G, Kovac L, Radziejewski C, Samuelsson SJ (2002) Binding of discoidin domain receptor 2 to collagen I: an atomic force microscopy investigation. *Biochemistry* 41(37):11091–11098. doi:10.1021/bi020087w
27. Labrador JP, Azcoitia V, Tuckermann J, Lin C, Olaso E, Manes S, Bruckner K, Goergen JL, Lemke G, Yancopoulos G, Angel P, Martinez C, Klein R (2001) The collagen receptor DDR2 regulates proliferation and its elimination leads to dwarfism. *EMBO Rep* 2(5):446–452.
28. Khosravi, R., Sodek, K. L., Faibish, M., & Trackman, P. C. (2014). Collagen advanced glycation inhibits its Discoidin Domain Receptor 2 (DDR2)-mediated induction of lysyl oxidase in osteoblasts. *Bone*, 58, 33–41. doi:10.1016/j.bone.2013.10.001.

29. Xu, H., Bihan, D., Chang, F., Huang, P. H., Farndale, R. W., & Leiting, B. (2012). Discoidin domain receptors promote $\alpha 1\beta 1$ - and $\alpha 2\beta 1$ -integrin mediated cell adhesion to collagen by enhancing integrin activation. *PloS one*, 7(12), e52209. doi:10.1371/journal.pone.0052209.
30. Zhang, Y. , Su, J. , Yu, J. , Bu, X. , Ren, T. , Liu, X. and Yao, L. (2011), An essential role of discoidin domain receptor 2 (DDR2) in osteoblast differentiation and chondrocyte maturation via modulation of Runx2 activation. *J Bone Miner Res*, 26: 604-617. doi:10.1002/jbmr.225
31. Ahn S, Joyner AL. (2004) Dynamic Changes in the Response of Cells to Positive Hedgehog Signaling during Mouse Limb Patterning. *Cell* 118:505-516.
32. Shi Y, He G, Lee WC, McKenzie JA, Silva MJ, Long F. (2017) Gli1 identifies osteogenic progenitors for bone formation and fracture repair. *Nat Commun* 8:2043-017-02171-2.
33. Chen M, Lichtler AC, Sheu TJ, Xie C, Zhang X, O'Keefe RJ, *et al.* (2007) Generation of a transgenic mouse model with chondrocyte-specific and tamoxifen-inducible expression of Cre recombinase. *Genesis* 45:44-50.
34. Kim, J. E., Nakashima, K., & de Crombrughe, B. (2004). Transgenic mice expressing a ligand-inducible cre recombinase in osteoblasts and odontoblasts: a new tool to examine physiology and disease of postnatal bone and tooth. *The American journal of pathology*, 165(6), 1875–1882. doi:10.1016/S0002-9440(10)63240-3
35. Shekaran, A., García, J. R., Clark, A. Y., Kavanaugh, T. E., Lin, A. S., Guldberg, R. E., & García, A. J. (2014). Bone regeneration using an alpha 2 beta 1 integrin-specific hydrogel as a BMP-2 delivery vehicle. *Biomaterials*, 35(21), 5453–5461. doi:10.1016/j.biomaterials.2014.03.055.

36. Reyes, C. D., Petrie, T. A., Burns, K. L., Schwartz, Z., & García, A. J. (2007). Biomolecular surface coating to enhance orthopaedic tissue healing and integration. *Biomaterials*, 28(21), 3228–3235. doi:10.1016/j.biomaterials.2007.04.003.
37. Reyes, C. D. and García, A. J. (2004), $\alpha 2\beta 1$ integrin-specific collagen-mimetic surfaces supporting osteoblastic differentiation. *J. Biomed. Mater. Res.*, 69A: 591-600. doi:10.1002/jbm.a.30034.
38. García, J. R., Clark, A. Y., & García, A. J. (2016). Integrin-specific hydrogels functionalized with VEGF for vascularization and bone regeneration of critical-size bone defects. *Journal of biomedical materials research. Part A*, 104(4), 889–900. doi:10.1002/jbm.a.35626.
39. Amini, A. R., Laurencin, C. T., & Nukavarapu, S. P. (2012). Bone tissue engineering: recent advances and challenges. *Critical reviews in biomedical engineering*, 40(5), 363–408.
40. Carafoli, F., Bihan, D., Stathopoulos, S., Konitsiotis, A. D., Kvensakul, M., Farndale, R. W., ... Hohenester, E. (2009). Crystallographic insight into collagen recognition by discoidin domain receptor 2. *Structure (London, England : 1993)*, 17(12), 1573–1581. doi:10.1016/j.str.2009.10.012
41. Pountos, I., Panteli, M., Lampropoulos, A., Jones, E., Calori, G. M., & Giannoudis, P. V. (2016). The role of peptides in bone healing and regeneration: a systematic review. *BMC medicine*, 14, 103. doi:10.1186/s12916-016-0646-y.